var title_f15_42_16032="Tennis racquet grip size measurement";
var content_f15_42_16032=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F66638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F66638&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Determining grip size for tennis racquet",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 442px; height: 460px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The Nirschl criteria suggest that appropriate grip size is determined by the distance from the middle of the proximal palmar crease of the hand to the distal tip of the ring finger in inches.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Nirschl, RP. The etiology and treatment of tennis elbow. J Sports Med 1974; 2:308.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_42_16032=[""].join("\n");
var outline_f15_42_16032=null;
var title_f15_42_16033="CPA radiograph";
var content_f15_42_16033=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56179&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic cavitary aspergillosis transformed from ABPA",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Longstanding asthma, ABPA with chronic cavitary pulmonary aspergillosis. The patient suffered a long history of severe steroid-dependent asthma with recurrent infective exacerbations culture positive for",
"    <em>",
"     Aspergillus fumigatus",
"    </em>",
"    and",
"    <em>",
"     Pseudomonas aeruginosa",
"    </em>",
"    . An Aspergillus precipitins test was positive with an elevated total IgE level. Despite initial treatment with oral itraconazole, chest radiograph deteriorated, showing cystic cavities in both apices, and&nbsp;a CT scan showing a right upper lobe mycetoma (fungal ball). She developed respiratory failure and was established on long-term oxygen therapy of 2 L/min via an oxygen concentrator at home and oxygen conserver when mobile. Systemic steroids, nebulizers, and long-term itraconazole did not prevent disease progression of ABPA to chronic cavitary aspergillosis. She&nbsp;was treated with voriconazole for &gt;5 years with some benefit, although very slow deterioration requiring 4 L/min oxygen 24 hours a day.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: The Aspergillus Website (file://www.aspergillus.org.uk/). Copyright &copy; 2010.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_42_16033=[""].join("\n");
var outline_f15_42_16033=null;
var title_f15_42_16034="Sling placement";
var content_f15_42_16034=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F76965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F76965&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pubovaginal sling placement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 291px; height: 422px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Robinson, D, Norton, PA. Diagnosis and Management of Urinary Incontinence. In: Gynecologic Surgery. William, WM, Stovall, TG (Eds), Churchill Livingstone, New York 1996. p.722.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_42_16034=[""].join("\n");
var outline_f15_42_16034=null;
var title_f15_42_16035="Cavernous hemangioma MRI";
var content_f15_42_16035=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F77870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F77870&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Cavernous hepatic hemangioma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 319px; height: 320px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFAAT8DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5zgtGlMaIgLMMkBec/TvU0i/vcGNQRxsKgH6e3NeifA6903Q9R1fxBquq21hNp9qUsBIBI7XM2UV0iyDIqAsSO2RUfxv/ALJufHLav4dvbe6sdYjS+KwuC0Mjj94si5yjbgTg9N3tQB57wAueGQkA4HT6U2Da2FypPOOOAfoe9KTuwH+UZC4Iye/NLGhATacp8ytleV4oAsW2nXc9hcXsdrPNZ2zKJ5gh2Rl8hc46ZIwKg2L8x3BlUdzj8TXpmq2s+nfCXQdItIna+125fUrhB97y1+SMfRvvD8ah0L4L+NNWiRotIeFJFysk52AenBrkwmIeIjKdtFJpeaWl/vT+VipR5bI87jUtsIzs2nJ6Dp+lOQqSAGDKvyc8cetfRNp8AtK0e2S78b+JbWxTHKRsAT6jJxn8Aagn1b4MeGJDDZ6ff69MPvOg+TP1JUV1knzwuSCoGeMdCeOvSnssw8vKEkYySMDqK+gx8T/ComSLRvhvDI+ODM4b+QNUNX8Z+FrxHTWPAlpHGpAdrK/Eciceh4P0oA8VsZGhkZrd5zICVwOKv3jkRIZBH5oUMSPvMT/Dj2617Onwn8M+LUCeCvFFv55HnHTrxdlwAQMg4OSPcDA9awpfgP42S6Lpp9k6/dAWYYAz7mgDy8YD5D7gcjLDgHGDSu4REELhbYqRufgtj/GvcNE/Z/1lwJvE2pabYxmRWHVyOeR1Az261p6rD8KPA+oSQXthf+Ib2JQZpUXzI03HIGche3TnFAHg+l6XdxS+a0StFJGRtLD7p71FNbTeWFlt2LoQMKP4elfSMXx28EWMDLb+F54oV4ASKBck+26rFv8AHP4e6kmL/QL9Djn/AEBJhj6oTxQB8tIDHCqv5kbr03nhqgViJymABnduPH5n0r67i1X4N+M1Nqx063n4AWaNrVwe33gB+dcz4t/Z0t57c3Xg/UY3RvmFvN91h/suOOfwoA+YZ3cI/nKyOq52gA56/wCfwr9Lbf8A1Ef+6P5V+evivwZrfh2S4g1PTbmHy8gF1P5hu/1r9Crf/UR/7o/lQBznxP8A+Sa+LP8AsEXf/ol6/O63jd8IiszkcKoyTX6I/E//AJJr4s/7BF3/AOiXr4i+DF9a6f8AE7w5dahNBa20V0rSTzSBERdp5JPAH1oA5CaF4SUnjeN+u1xggfQ1FuOVODkegr2v9oDWNO1jSPDqjVLe4v7Wa7VoYL9dQIieTcjtMOhPACEnaOmK8VOME7+c9MUABzu56flScgnI47U/yzuxgM3Ud6s21jPc/wCqhZ16ZHOT7UAUznI4B57Uu3jPOMkV3vhf4X+JPEF35NtYSglQcsvAHqT90fia9T074B6bpCRy+LtdtLU4z5SuXdj7Dj+RoA+dFjJPIYZ6dF/nUht32EjoBxlutfUEPhj4daYwFlo15qr/AMTzziBD+WD+lXAvhaE5t/CWhxAjpM7zNx6GgD5VEJjG9yduQPkwfzFX0u12LHcrEWU/uwyEIc/eb69K+q28F6HrWmS3EXg7TCUiZ0NszQSfg2Tg1wupfB7SddjVvCGtyW1+AJG0vWGw/P8AclAyfyYeuKAPEILGS6iL3VyjW4YAfvenvS3U6W0ptoCJU+4HTv6fMf1r2zTvgd42hhEDTWccfK8+XKAD3BOCce4rb0v9nlLa4WbXdX8yEHJeaTaAe+EXA/8AHvwoA+enEk5EMbBlQ8CNfMI9uKmXSNWuN0iQXZXGRshY5/T9K+wfDOh+DdIt0ttIsYb1wf8AXSxbYzj0+XB6en410tvrNvCfKt10+JxyiKhUY+tAHwt9i1vTmL/6VC2ejRtg/mKr3F/dM7NcwWhfoX8spn64xX3s+swShVktbKf1xKOn0K1k6tF4X1EbdZ8No8edplFssigeuU5H5UAfClxIrnc0BjkwNoDnao9BntUF55Ztn3xLFJgFdrZB55FfXeq/BTwT4mLy+GtQNjMud6RESAH3RuRXiPxR+DWveBdKm1OQW+oaVGy77qA7DFuYKAyH1JAyPWgDymLYVBLHbz16cf5/SpokbchUkMqhjjn+ftUMWMMPlwTjkV3Xwu8B6j8QfESafpxWK0g2ve3TDIhXsB/tHsP/AK9AHNaJpOo61fpZ6XZy394x2rHGpJI+uOgr3zwT+zrdSRG78Z3X2WELuNtbMC7DHQt0H617DEPBPwX8LxpNNDZIRjc/zXF0+Ow6sfYcCue1f4ieJWk1t7zw3LpGkadaySq8zCR7uTgRoCvygEnPBJ4HY1wZhjY4SjJ3XO0+VdW9lb5tfeXThzPyOrurzwh4G022vNXlsLOeO3SKLfhpfLQHaiDrgA9vWvFfGXx/1nXrtNK8EWUtl5+USVkEk7+6jov1PT1ry/SdH1XxZqMt1qd/5WQWuLy5be6464J4FdnZ674I8J2Fxa6FpN9rF0y7HvdwCvkYZS56d+BW+Ew6w1CFFfZSX/B+YpS5m2eVa5qd7qGoPLqc82o3quVeWeUuM9OM8EA+lanhmybUJgLGzupLokdAqLEOzZbjr3qLUhHcXbSabpcFhGCQI3k8zn0U+mOlT2Ia4kT7Zd3ogkIUrBgKBn7pA9RxXQSez+E/A2u3MzfvNOMyAnyFv1cjPXIUVwnxP8Pays4urvTYJbJIjNHdWcZAZM43t1GPrzVvS/Cthezi68MXs8MkOSESVllUDkkZPX/Ct3wva+IdE1ixtn1TUVsCn2X7LcSB4ZI+TtIYdCWJ455oA6b4b6n4ZX4caJaeLbnQ0+zyTMWe7QTQxk5UowIYEk9q1bXW/Bdo6SWXjm6iXBcIuqzyRgjoMHIx7Guv10+C/CKRXWs6foNve4DIsVkhmZgP4eMj615NrPx68jUHGleFoLazkIzNJHukYjjoBjt70AegzT6Hr1tcQtLb69JLDLiWeZZUJKHYyDoB1xivmv4bxarceKF03T7Y/amiKTJ5fmZUZL5J4Uj1PSn6l4u8QTzPMJ1tLZ3aZBawohQEnHQdOelYmjXN5b3Uj6frS6ZPMDHcSo7K0qH+8ffOaAPoe8+GWrQxNPG1gEdVZzG8eyFh1Dbx8x7duteX+L/DN9pgjMOjTzPIwbz47FWjbg52tE3r6+lc7Bd3dzdm2v8AU/7XySwYzPsHvsBCjoOTV6B3s1BiikRIuAljqLwuOc8LnGaAOLvLm4ivVtrqIsxYAW8o+Yfg3auj8L+MfEXg5jfeHr64gtxIqywYMkIP914ycDPZlroo5LDXoUTUr43turhfIulVriJvQuuCfxrR0+TS9GibTrN9PNjKzZ88HcG6Yc9xzwe1AHeaB+0LoWqW32fxVpr2hIw8iRi4tifoeQDX0KhBUFehHFfD+peFNP1CC6bSJGt7p0J8m2kEqv16A844r7eg4hj/AN0fyoA534n/APJNfFn/AGCLv/0S9fnZGPuc9uor9E/if/yTXxZ/2Cbv/wBEvX5629uZAq9uAf50AQorEgKCfat3QvC+o6u260h/dBtjTO2yNW9Cx7/7IyfYV23w88BS63dWw+ym4kuNxtrQyeX54U4eSRxykCngkfMx+Re5H1NoXhPQPA9lFf6g8U15FGI1mdAiRD+5BEPljX2HPqT1oA8R8AfAWW/EVzqLYtmHM00ZVW/3Is7mHu5A9FNe0WHhXwZ4DtPOmihluEBKvc7Xk+iLgBenYCqWueOr27j26Sn2KDoZ5MMzeyivOdY1SOG5UuRealIdwa6bcqnHUigDs/EvxKuntHOnxiwtDhUlYfO3svue2Kq2fhGe5mSfWriUX06CVoh8zLnnDH15ryq81tEu0uIba91PUoysiSun7pGBzhV6ACpNd8afEXXYmiUppUMpyXt48vJ9SelAHqmoaXo+nki8XCrjy13gfVmrn7wQ6hqaWWnJbyzMA0cayDc5Pb614Vqel+JJtzaldX05brliAT9Kr2GhvK0clrcvbXsOGw5IcEehznNAH198KtUiFs1rJNEBKrSRD+8qHa2D3AOQa4DSdU8P2tx4us9cFvNoy6558UVwGLJG0Q+aJh0+foPrXkmg2Wu6S0csep39i8MRhjkimPyoTuICnghs5I9ea+gfB3i/QNH8C/2l4iNj5izGNGjgBluCAMZXGS3agDmdM1HQ7TUo5rfUb+OzmPmMnnyEIP4Rs68dferml6pZ6j460i41C5lv42uW2tMGCAEYQ4PAwea3rLxVqmsm4vbKz0jw7BIAyz30RkmlA6HaMdvWuWutY8M6YXkWK61/UjIXdp/3MYY9wB2z0oA9N8f6hZwxmzl8uS58t3ghRwHOFycKPp1rmoi0qSubyxuLi1hU3SkeXHakHBjU/wATDoa4z/hIpJppZ7OwsLCYrteaNd7sD2LHmsy51K8IRLmeB13F/LKYBYn7x9T3oA9d8Pa14du/ku54fMOFGRgZ9K6eTQ9Mv2E1nL5bD+K3fivnm5kt7uHbd2NnMMdVJhk69iKraWJ9KuXk0fVtVsFbJNtLJvAz/dNAHo+tqsfiG6sb4CXWLJRPHcWkvkXSxtkK6sPvDggqcg46VyHxd8VatdfCbXtOvri31GB/IxcFfIuI8Txkb0+63TGVx16VBmKRxfQanPNqb/697uI+YvsCOqgVx/xIvpn8GanbzyRODswQcMSJU9aAPG7CGS4migtYWmuJmSKOMdXdmwo+uTX1vNrGl/AfwNp/h3ToIL7xXeRG4nP3VMh6yyt2QH5VHcLx3ryf9lrw7DqXjW51/VNi6ZoEX2ku/CCZgQpP+6odvY4p2qeT8T/ipq+q2wkXQldN88pIM4Awqj0XAzj0+tADjptx4jUeIvEeoy393cDckkpIIQk/dU/djBzgDr3r6H1bXLPSPDUmrahJ/oyQiQ9i5I4AHqScY96+fPHHiaC8thBpIEUKHyNsfG2JPunP+0cnHoBVL4jeNZtfsdJsrNnaxsIUDsRjzZRGAzkegOQPx9a+X4hyaWa1sPDaMXLmflp+Ltb8eh0UKvslJmT4h1rU/EL3c7hI4LmTcLWJdsePTjrjjJPXFYdxHMLESeZ9+XakKjCtgf8Ajp5pjXjJGyKk5YsGCh8KBjp/U1IkjywGN4GJB81HDYKtjA+o/wAK+mhCNOKhFWS0Rzt31ZWDiPcJVaMkYz2NWZ5JbdgEuoVBiEsZjfcDk/ocdjUwEgkxqCMi9miHDjuTTrWHTY3idL23ZTnIEXzHOe3rVANsdals71biO7cskmzeePfIxXqlj8SWl0a6TUbdJ7xMPA6jhjnGAO3XJ+leQ6jJb3EcMVrGXMYCNKTgOASRx69qgjufLaRl8xmAJVc4AbqB796ALHiK+1y616W81O6le+kO4uclFB5AUnsPam3F7canFIl5KAsH8UXyjbjJP1rZOtm808xXohV8DaMegqnCqRMk8EuyZWDxqFB29ycHgj60AZzKi2ZZV3vtG0s4DEZx0/CtSI2wsoGh0lmkyPmdwPn9/Y1l6jPdiLybloHikm81XCBfnY4LewPp2NV47m5+1Om9FjQEjzEOG6Z59fSgDoLae5vWuYLKK1gKLtMaKGaRh/D7D3qB4vs9tLG1yiCDB3rHiSNyPbgjrVCyiFxdo8izPO+4xTw/KRj/AApkZt0jRjFMlwrc73yrt3J/GgBxlikw0sUjljsEinZKSf72Ox9KRzcRlFuiSpPlqjH7mPT61StppLnUWcOkblsDd0ZqtXk08ls8V1tdcjayrk5+lAGhaW9t5d41pLPb6jCgkhkQ/KTzuGO3A/Ov0Cg/1Mef7or86LadLOGS4t0YXCoVO5eCOpr9F4OYY/8AdH8qAOd+J3/JNvFn/YJu/wD0S9fEXg/Tre4ufNvCy2cCGWVkGW2KMnA9ew9yK+3fid/yTbxZ/wBgm7/9EvXzL8DNAXWvF2lWcig2sA/tC6GOCkZxEh+svzfRKAPb/DKW3w/8JDU9Vtl/t7VFRmtYhjywqgR26eiRqQD6sWbq1cHfa3fa1qD3OpTiV97COMn5IwOoUe2Rk0vxX8TrP4smFrIJnjTy4znhE6Ej6kk1D4O0wmza7uhlzmIbucgncSPqcflQBc+w3up3DpalliiJAZuCw9faruneFNOsZjLe5uJuCwJzitiOVIISsX3GXdtJ59Kz3vEmuHBGfKxnP96gC40drCTHBBEgK8kDg+nNVpvKO0JGg29scZqhJcBGbyyxGM+v5VAbzfnY24E8sPX0oAszLaTDMkasp4ORWFrXhnT9ThXYfKuFO9XA5/Grss/yvz1HBx92qxvNjAIckdhzj60Ac2xmt7S5tb8L5kaM4yOmO4NZfg8Sy3kUt05dIv8AUlhnywSSSPc119zGk4ZJOrDBPXOa5s6XNaiQWzERn5iAeh7YoA19e1UmAQRs6kcMwfkg9q5yabKMsz72HActz7VFqRnLxtMq7QCGyMZ9fxpkJgWMeY4KHlQBzmgDUtrsIhL7VcDA3d+3IqW6udsO3IlfswXtWV5sTAEja/Jx1yfWmQ3vASUfMD17CgC9Ffk43KTk85FaluqlQ0mGz6HjNZNtKzykqBt6Ajv9Ks3N4EhARcn24oAvXF9EqjyySVONwODmuV+ImpLeeEr+ORQT+7KMy8g+Yuf0qzPdNJEPlB5zg9a5vxhvPh+8HP8AAcdf41oA0JdV/wCET+CVppFqwXUfEcr3F5t+WRYVIwmfQ8D6E1v/AA+0ma4fTfDVuT/pjg3k6HbtU4aU/QJhBXnfjC6Gs+MJLSFjLa2YSxhQH70UeOB75zzXtfwUE7jX9b1AL9puLhbeMAfdAXcwX26CgBPif8JJm1mfUfDs9sbW5cCO1cFREAoACt3HBPNeR+IvC+t6LPHHfWjqjfKk4OUY9+a+rbu78yzeMtsx0XPAI71z/igxah4au4LiJSgi3AccEc8elAHy5FKBs+VXweFU4C5/rTnvmtpGVWjiaNuWb52BGcge9VryJGlcxRuoeR8Ip4C59fc5qPEgdhFGPlHDleAO/HrQBNc3D7SDMQrgExoxIXPvUcTMxdTKED8Hb958D17VOlixtTdJcqY04IPc1UK7XkaIJtP8RGCe2MduKAHeapXeVBA4yAcYz0prtGrIyMQANxGDlT7nvxUSCM/K7SRFmzuycAeuenYVPBZ3FwAsBSRsg4Dd/T6dKAHhZUwojRWHzOW5OPSp7XfZb/tAAB6c/MoPYD0Hei68yK+ka8kiN9cOB+6OVRjjPFeo+FfCNksMEkyFpApaN5z8xz169s5oA4qfTbm7tcnTnRGH3l5Dcds9jXMX1u8U0cMpMUi52nPVen4ntX0TdWun+R5TX3zKvyAdv9k1xfiDR9GunYxs3IwFC8e/PrQB5hZo0A2vHMcBgu59qAEYLe/+NQ3js8oBhWNANsaZ6nHX8v51oalaWazRw2v26R41KNCVJ29+vpnmsuWzdImOTggZLPkn2Ue3pQBFZyQW7b03eYoGFP8AL61NPdI33WY4wMrxwP4vzqoREFQo5UAt95ec+gp8NqPkCvucttC5zkjvQAlywmt5tm/IBBG7IPv/AJ9a/Se3/wBRH/uj+VfnPp+kTyRuGXYgDYjzzIOa/RiDiGP/AHR/KgDnfiYCfhv4rA6nSbsf+QWr54+EVyuh+Add1tX23epzrpluehWOJfmIPcZJOfevof4nZ/4Vt4swcH+ybvB/7YvXy1qMh0rw7pujhlxZWwVgvAMrjcx/WgCHTX+33kuoynOS0nJ6KpIUfjiu10LxbEIES8Qxyq5O5emD/hXB+asFjFHEQPMVeR6AdPzpsUmOF4OCMe1AHq6apDdK8lvIrIhyDnk+opJJgGGTjnqO9ecaTeeXdoAxweMjvkV1rXnTe2TgHPvQA/VHa4tWSK5e3YnG9eoGen41VM627Bo95jwPMH/s1NackqWxg9DVSa63fI3UHBHSgCzdSvNGNsmEHzEg9R6VH5ixn9wApbOc85rMYzQszW+DGOChphv1JxKrRN244oA2IZSwG7CnlSwNKJwFbzWGD8oJ4wRWQ92I1dhIjKO/TAx1NY+qa15FkkESefcMS4yfkUdMn8e1AG5fSRX8Du0jIic/RsdfpXIrPFFNKsykM/MUrHg/5NXLJLu4sJJ5ZI2cDluikewrBv2aYyQhUfIwpJ4U0Aay3ZX5BtDq2GHXH/1qliOS0c8jJIRlz5ZOR7VgWtiv2VHWVxNtx97G71qaNlRX3bkcEKfnLN+fvQB1EU0RjUxXQcdOVK4NR3Eju5Rdpcfw+grGiuZYmCqzKBwcHIOfY1q2WqyJytvaykghfMyhH1xQA4BihO3aCcbgaxPGUijw1egMSf3Yx6fOK07+9jMShrcKSQCEk4J9axtTt5NYsZrWCNsuQ2AeuCD1ppX0AwfBqbtUnupsb418wnHBLc9O1e9/Di5a18G2obPnTSTTnHbc3GPwwK8I8KyJG2oGbCxlVDMRxxzt/Kvf9LgS3sbSNQqkRLhR0HHSkBrtOxjEaHr1JOQvoPrXDfFL+0k8Nyy2NzILaMj7TAMAup4OG/HpXX+Zg5YFuc59K86+LfiCzOmjS7eYTXrTLI6H7oVc5z/hQB5XcELHEI8mGOM5RTgjnPT8qajIhAaO4kYqdux+/XJ/SmTTJGFKYX0fHLjPp2AqSNUkUMJPIfGcR8oT2Ge1AFma9me1S1Z0aPbtJQBcjHGf8aqZjDl2ikZu+09PrS3NpOqRGe0+SQcyocjHvUW6HEitcSxsTySv5DNAE32ltscKEpEMYjPP4k/rUkEUQYSfZTIOCRGSv4mqbs3MaRMy8fM2efU1NG0tpJv804YY2P8Aex6AfjQB0Ph6GO71+zTT7W3ikSQEB+VQd2Y9817rpttbvGraqyErkLuOA2epA9OK8a+GskNvqkt7e7So4WAnBz/j0r05TJeyK5CGPAPlg5O360AbWs3mk2Fuu5YnA5Uxckj1rldY8QyxWZS204uH+6XAXp/nNJq95YQRviMpGCVYqNzOf7q/jXI3XiOe6heN7aVth2IE+8fc+4/pQAx/EVxY3JM1vb+Uw4UN8zZ9Dj2qlNqGlX0UqS6bM05BYbV+aMk/eqaXTYryAFbW4lumAJkznb7D/Z9ar/2Xc2skjyXnllk3FQvLKOwHU4oAzPsUEzNFG+dpyN4w49sVNYaRAXYlgWLcnGBnpVq1fbudljuWwSrldpBzyM/ia2NNMULkbUMacfP1z3z9KANKw0sJb8qWTbhyOCB7V9mRf6pPoK+PrvV7PTbNZD+9Z8gKDgAepr7Bi5iT6CgDD8fx+b4E8Rx4zu064GPX901fGniC7e5vtpOXcM59OOK+zvHJ2+CfEB9NOuD/AOQ2r4funLTRYb5hHtOPQ5oA0ZZAY7RARkwrlewqTzcZAPIJzjtVO8YLMqov7tFCgD0pDJgKAw6ZxQBuaDNELtfMUs7L8jL0FdDDPuDK3VehPcetcxocMoJlK7UI69/bFbEigjcJGVh6f56UAS3MHmEsJpI8NuITofaoYftCHEsqyoDkHuKia6aPes6kHsy9CPWljnWSMMrZXGOOtAExkJY5/H3quzKx/eDI6gZ/OovtCB2QscgZ24zTlcMFZDlW68UAMuUSaN02DDqRtB7e9YWoQ24uEjjwCcZUng+5rYubyC1jHnSIpPUD73tXK6jM9zdyT/d3cKMcgUAdPJL5dmigA7VwSBxj1xXOXTRxxyTAE7OeeKWDUTFEI2ym4nkeop1rCL6433WVtEJMh6bvYUAJYx3aQymOLdE5OHk7A8jFOmsZYIVadv3hPCKPyyavXGozhPJgaIQwgPGeu4ehqiL19RVSobzlbay54YUAR28m5GIxt25Ujrk1Za5kiADkfKeQw61QjdormRG2hg+Qg+lS3E26BSTxjLhvXPJoAQSzXjBcIV5A4zjnqK6Ty7vRrQ3Kwoqx4w7e+Bj8jWP4ciSM+ZcsIosjbIe4z2q3488Q2lz4ZuLSyRpCxX96T0w4z/Khgcd4fg3mR2k2BPmYN7dDXdeE/Hf2FJrXWlkkjDkpLENzKp/hx3ArivCjOl1LA0aOZ0O0MeHwMn8cdKivIRb3jjy2VSA6Mr9Aw6j1oA9N8R/Ei0is5o9FWWW5YbVmdNqJnvt7mvKpYp7h/Oa4inkdgxOeR75+uaYGHlIyEj5tuZDjccZ+tSQQq65liQW54GzqxoASC2vWl3W6LJtzyxyGPTH9alS2nhQ/voYWH8O4AY7/AI0skkTXDRTQdfuojfKo7Z9TVcsEYhLeJUIHTkg+2aALUFyIoGSOSUEnBRQfKOPY1aiv3GfMt7BARjJOc+hIqG107VNXDR28bsEwuAPuZ9a2U8CamkX7+Nc43ZGTg5/SgDAmniPmCW4XPRvKHaooPK+3K7M21ccuDkntx+Nbd14Yu7SLzGaM/NtCqp6f41mwWySa3EbiZY1MwDyyjARAeTj1GKAOo8AaXdrGL5rfdFLIQu8ZO0Z5FdH4h8Q/2PGLaICO4mwgZFyx9FA9ScCsXXPHEzTG18MwGzsUzHvkPzFR6Dse9WdChsfD0qaxr9vcajrdwm6C0i58he7uT0Y9fagDS1TwvqBtLeeGAXcyjzJ4BMAQ57exHQD61x2rapLa7rS6AiRX2OtuvCHGcFu59a2/DF3ZpLe20Ut/Df3j74BeNtjkZQSpJ7uGPHrXDao0pupo2SVZN5aSNxjae+fcmgDrLrxH5OgpJoskhdWWF1lX5o1bJDAdwSMe1crPf3d3e+fd3DSzkgDs2BxgenFQlZIrTBXDq25WP3lBGMkentUccRR4f3R2BtztnJPbHtQB3eiyQSWZlulXzC22Nfu7sdz61FfJcS3QkmwsSZwqkDB9T69az7A7lXerSZbIGenHSrTxkgkqNpBXlvUcAigCDUJZLmGcebuTb5bY4xgdq+9oP9TH/uj+VfBs8Un2ZssqIFxgDJPy9D6EetfeUH+pj/3R/KgDF8e/8iL4i/7Btz/6Kavhx5hHfW4YAxn92w+pGD+dfcPxBcReAvEjkZC6bcnH/bJq+HtYttk0LopIOUAH94cjNAG3d6cZdslsfmKkFD/EQe360y00uZiJLoCOMdhyWq/pcon063lzu4yPr6VcwFlwqHJHU9BQAqyxhSuQMY4HaoJhJLLA8NwIlRssP7wqSby0ILgFuccdajWD5AZRkdcDtQBJPcQqWzIhI/h69e1ZsxVpVNpvxnBxWktrAVBWIc/rSSvFbltxVBjJxQBlouqOAEljiBJO4rk4qVdPuW+We+lcnugxVgXsRJ8twyr3P8qlW6Qkgc98g0AZB0lTvkcsxXJG7kk1jT4RIUWTfKwLkHqvsa626uYrG0aaQruC8Lnlj2rgBcgMWLLJcOQHPTknp+tAE+po4jiitk824lcIuP4i2AB+Jrqb7wze2ieQ1w7RxBRKqruwx4z+fSqvg+2s7a4XWNWR7qW3kAtLbOxA46ufUdqqNN5PiyK/1OS8bTWuUefyW6ruzg47A/yoA3LbQjBp7mKPZcyfIiz/AHj/ALR9Kwr63TSNOkgV3h1gId4mXh1yMvHjg49K9I1RHnvp7vIMMrGWE9Qyn7pBrifiKf8AiWlmP77cpjHdeecenGaAOQsJJGYyNIGcnDMe9bVvCl1cnIPkovJJ+/7Vy+kyuZGYylgRnB/nXZaf5YgQFQc4PFACz24uNiO+FDAKP4QKoeIbZIdDuiFwcqeD1+YZreRF4+UKB1z6VS8Sosnh66AXLFlxj/eXNAHFDz9I1EMga3ubeQPGDyBzkH34x+dbms3MV6kd1EIyJWZgg6QSMcsn+4Tkr6HisS4nSRYLkEiVEEciyNncVHBP1B/Srnh8h55LGRfMWdQAOgc9duT0z0B9aAKc0n7wFxIvoSN35fSpbW2uLyREtX3B9qL2OT/LNT3llJBMDEdySAvHIwwXGcEEdmU5BH413nw50aX7WpNsGhhORxhgx6HPt1oAboPw1JgjkvZSSwDlE/5Ze2e9dbYeCdF09ozHZ+dKrZDTncR9BXZ/ZwEGA4AGAc9R7ipVtCwJB9MuTzQBjW1ukWTHFGmTnITmrBiYgYQsx9P51qQ258wqFTpyCeae9rvBAjbceOO3pQBz91piTRSfLGHwTyOhrxHx3Y3Vl4ia38sbR0bHDZGf619KxWmVYuuAPXn8a8c+MsMSasnl4MwBUADuRmgDi/CGmi88RQNOjT21nG13cKq7lITlVY/7T7VFdC/nXLS3eoTuLu4O6UFTvdmOeAP4RnpXUfDXw3MPB97cybzLrILQqTsxHFk5x1wX2nNVI7eeW2D3E8cZQgsI/wCHjkg0Ac3cW5MDJLC8sROCHUjJ7MPQ/wAq6bwxoVt4jOy5hN5eW+2CSRPkcr1Qt6nAYZ/2ajubZn+ZxOrMAyuWG3b7+/FdP8O7mzsb2/S6MsMTIrLNngOpzjPqRke1AHlvxBtYj4glsvD9vI1rbBUklVGZp5f4mPHbAAHTArmHjaMo0iSpJGSCTGQCOxIx9a9e8YXGsaHeDWbJ3l0q6JjkMO0mGdAdyvnpu+8PXNc1qGrX0pWYajvVwDh4FKjjoQOaAMDRxNOuLbMyN1Cn7px+netbyFiPziXKn5ieScenvSWeuI8rf8SrTTONqmaImMP69Oh96m1PxDBO0PmWBikXjfvBXBHHPrQBUumjit3Afy32nJf9K+7If9Sn+6K/PbVNRgl80NlJGyiBhkEHPJz6Yr9CYP8AUR/7o/lQBz3xM/5Jx4q5x/xKrrn/ALYtXxrJB/aWjRh3aJ7mJZY3xyrY4P6V9nfEPI8AeJsdf7Muf/RTV8cabE/2MQyEnyWxER/zzPb8Dn8KAGaDdshkM6iOQnZNEOiyDjevs1dGgBXkke1ctrcTwyreRAdNkg7EGtzQ7tJ4Igr7oyvyM3VeeR+FAFzy44gZJDgk8E9vWsq71QB2jiGAvHPpV7WSNuc7V27V9658puYkhiSPzoAkk1C5lUKZAoYnAHf0qo4Z2ILMxHqetWPL2kEdW4/LpT1iyN4XPHP1oApCM/KAMHA6dqt2kpRhnJHQY7DuakERGeOSOtSRQ4+70A6GgDJ8VyPcRJs42g7VrnNMsTfarZWWdqlgWI6qucsfwANdNqqHc5fIAUk56dOtWfhnpkUt1LqF/FmG6YWduc4HHzSHPf5QB9TQBd1dmvLuQovlWyALEo4XYOBUOGdAjAmB1wQfuuKszxPHPLZn76OYxG4wBk5qS4iYoiIdoUfdxnb7igC34VE4D6JZzyJECNrHG5FboBnsCK5Tx/PZr4gl0vSDK0UJAuJpm3ySSY5yewHoPWur0u3ibXLdnbEEURMkmcAHIIJNcX4w8P3UEz6iokCeY0U0jjDCTJIdv9lgcA+1AGDBvgnUfu+eAduCwrpbK5/dghRzjP0FcwqPOY/JTkJ8xZujdyPSpYb5oCUlJBXI246CgDtRd7TlyMY7is7W76RtKmSOMsTt6dfvViyak3mfvF+7xnPX2FVNSunNmyB/3uA3BwTk0ARaLGly4t5ZDH9oUxwu5+US5yoYnt2qvMpt2kQo8bq2ByQVI65/pVqOW7t4LmxYfIZMzQug3AqD1zypGcZFJcvFexRy5ZboKVkX/nsMcEE8ZA4I/GgDuPDc6a0gmkKtd2zCWaJh94gY347qe9e36DYW5X7RZqYxKv7yFmG6Jxzx6qc8V8s6Re3mnXkd1pk0sE8bgIVGW6+/UE8EGvWtF8TzSQ2mqvH/AGe6fuxO5JgDH+An+HPON3A6UAeyx2/I3Flz3xng1LHZhueQ3Yn096yvDHjGx1Nhb3jraXx/hf7r8dVboa66P7NKWUXMRJAOFPIoAy/sDZZnhHTO4f4VaSxXBxM+AMgKKtT6jpOnRlru9VT0IY8/rXN+IviNpGm6f5tvtkPO0JyWHqP8aALGs3tro+nPNO+3jgt/OvDrHTpfiJ4xkId7TS7NvMvLxuBHETyP+ujdFUeua9N8Ba8nxAvdQtdR0b7ZpsCCUXpj2xoxI/dE8bj6Yz0NdzYaRpHhTSHTTbZbS1jlNxtQeYzStxu+bJZs4AznrgV83juJaOAxP1bEUpJvZqzT9NV/w50Qw7nHmizGFiYYrZTpUmSqrbp91rWJc7Mr6YGT9K5bQbDwHq2vSC11cPqcrstva3TFFkuME5UdMZBH4+tdFMyeIYLldJv5l1Ft4nMrFSwYgNzxtwOPaub1XRNLtk+zalLoeCCNyFpAo/315UdOfavo07q5zk81mbbw/quoeNfDtppcFpJFFAiRbDdMXwy4yd/y5O78ay/Dd/pNzdWdtplmbKzkuC8d1qDbjnoMr06YFXb3SZpGt4daETx2KfaYb3Ur957a3iI4lBJ546L1JxWTq3iTwfA6Q3Gp6nrIMW4QpaCJfZmXHyjuM880wO9tbOzvmnt5JLaxugvkyxzp+7ucDlHH05VxzXmPjH4X6npBi1HQYWe18zzPsjNuKnGdqN/EOM8+ldFNLDq+h2l1azTNbeTJHK38cZUjaozy3UDI7CuJTW9Y0Jrm40TVZUSA+Zm6uxJHcHIyjKepHPTHpQB5zqDQQSlLq3KXTOSWlDQhznJBzxk0klqqQLJOh3PJujAYMrJ6AZ9cda9y8MfFC91G2UXegyXFsoJkdbNJo2IGSEDck4P5VoJf+D73fdJ4d0NHkXLtJA8R6/3eze1AHgji0uLGY3EH2dwrFnJA+XsV56nmv0Jt/wDUR/7o/lXyhqkNmZGOk6Domkqclp/s5mdvoGOB619YRf6tO/AoAwfiGM+APEo9dMuf/RTV8kxRCCOOZ8+Qp2yhedqtwW/Dg19eeN4XuPBmvwxKXkk0+4RVHcmNgBXzTBpqxMIrqIwXBUKyS/K3fj0IoAw5bRQJbe4UFG/dvg5z7iud8ibS7w2p4B5ikPRh6/X1ruDZNCvkTBhs/wBVKRncv9xvcdjVS+sEvYWgmXG0Bkdedp9RQBzUdy00CxytuIO5WJ6/4UqI24fU596gn0yRPOnjDMyyZdouQo9SKdb3DxIiToWUjO9eRjOOlAE6RZ4wSPrUixbsE9f6VIssBUfMFycEAdxU6tGM9uMkA9PpQBCkQOCDggcVI6hQdpyfSpTKhB8vJwMnPWsfUNQJDQ2Sie54VtoyFJOOfU57UAUNTSTU7xNIttpeRh5spPyxp3z/AId69UsdAXS9AgjksmmZ4itnZsNrRoWz5nsWxn6UeF/C9p4K0Z73XyJdfm/eRW7kMUQ8h2A/lXR6ZcPrU0xeY/2yIC6yTNtHzLhWPoo6UAcBeGz1PVma5nmgu1+WePyvvEDGVP4Cs3xHbWUYs5dJup7nUWlB8pOA0Y5Yn0A5FdknhkWr5ju7a5mhbBZW3MD6+9UbDwwHla3tzDMl2zMJBz8nU5PoDnIoA5t9WhhvVEViGtrm6RZjuyLaMNwfQgDmvQIdLh1B5rDVryJpIgVW6Zcqcj5Q4/iQg8GqGpeDI4oB5Nw19ZuQuFxGHPTjvjtT9Fic2rwKFguopRbQpLz8hXIH+0QBQB5t4x+G99pW+8s4g9oT9yFw230298e1cjNay3EzSbW39RuHtjBHY17p9if+0hEhnXc4neZTjynAwPl6EGsu9sBdXLR3VtaXVxvO6baY/l6np0oA8fFopMnmI23aNpx/F/hVe8gjisbovEXYbfLJ42/Nzk/lXqDaNZTXCw+ReRMGIGJdyIccZqjr/h8XGkyW+nQyXt+2CkSyAlvmGePoCfwppNuyA1rP4g+DPHsKW/xG0ZrPU1XC6tpo8tz2ywH/ANf6VVu/hv4Y1I58M+OtPmQkEQapGYmHtvHX614vGjgE5Pp6kj0qdGZSGWQqvoOrH/IwaQHoWpfCzxRZxvKmm/b48cT6fcpOm3vxnPpWVpWt654VaaAhrdZYzFNbXdsWikUn7rKev1rE07VdT07Y1lqM9vIo4Eb7Qf8APFdda/FnxIg8u9mttSiAIb7ZAsmBnA6jJoAz7LX4NzfZUS3t5m3SWDN5lu3PJjPWI+1egeHJrW/jYaXqeo6XdDBSIv5kZI6Ybr3rl5fHPhXWJQNe8H2kK8B5LBjC5/2vSkjtPA00yNpHifVtIc8LHcxbwp9Ny/4UAdpceEp9VkkF9rer3iE7m3zKoBH93PQVlX+meFtDuxL4imtry4BwbZbgysy+hA4H0qhJ4J1XWNqWvjPSNSg/hEl4YGHPcHFLa/CHXFZvP0e71GJpQXOl6lAwK+g3HOffNAGhrnxcnu4Dp2krPpOmR4EaWAXcgAxnd6kfjVXVvi54ikttNtrAC1jtRtaW6TzZZyANrOO3HQ9SeTWSfhP4081xb+F9VSIPlDIsQYDPHRutaej/AAQ8d6vfbrzS0tFlkBknu5VXaM8nap3N9K5q+EoYiUZVYKTjtfpfQpScdEzXf4l6X4msDpXilZ7O4lcA6lpeRsIxtLL1YHkHjp27ixb6HqHhi1i1fS0g1zTfOKb9NZUha3xl0mUk4J6ZH3e/WpPEPwN1qG4itdItNTvfIyJbyaS3SGQ9jEm7coAOOe4NdD4N8E+P/CP29ND0HT8XMSRk3M64BBPzAKeW571x/UamF1wUrL+R/D8usfldf3SudS+P7ypq93BceG51itZbDTIoY44bG+AlSFjMoMhlBIaNTkgjrkV562myR6ZePaLBeXGnJ52olp12wK/CSk9WJyd3px6V7hoPgrUG0a/Pim9gs7qYlV065uI5LGNSQSyxrgjGNwBJwwBzVSS0bw3ok+maN4w8Gz21xEUdLu1RGlGMHeUY7s85zXpxbaTkrMzPn+DUJ3s0D3V1JJHE0atGjEwL6BugBHWsa908lGaW3S2ZiCIkQkkY6qvbscmvT28GQAxtqHjfwjbwM5/cJ5jhs84CjHHtW/p/h34Y6fFJL4h1SC+uWyNulRSxxRgdyCTk/jVAeFW99NDG0FkZ44JGG4M7MzsON2B9047CtPTk1d1kl+2SW9ujMzyX0/lx4xjac8k9Rx3r0q7b4NWFwxtLbV7rB+QJN5YBPB56+9ZreMvBOmzs2ieBdNM/OyXUJHuGJHGeeM96APPYLC8v98dnLeaj5mAIrXey9Om8/hX6GwgiGMHghRXxPrPxc157KWKxltNNTyseXYwLEqj8Oc/jX2xCcwxk9SooAw/iDObXwF4kuACTFptzJgNtPETHgjp0614L4Z+L3h3xBZR2HiuJHREVVkmVUnXjqH+6/wCh9jXunxP/AOSa+LP+wRd/+iXr87oHIj9R/dPI/KgD6xnstBuj5mg6/bSxtyIZsxsPbPINY1zpV3G4ZI/MU/3MSA/itfN0czwsWiZ4yO8bbSfyrb07xfrOnlTDfynb0Dndx/P9aAPX5bB4b5Lu3aSzuF4DwjIYd9yHqKpajpEN5Is08SRTEbfPhyI3HoV/hOe9c1pfxZ1GFQt/apcR4wQGDfow4P410Wm/EfQLmNBPELd1/idSnHocZWgDKm0NVnxHdXEIYZXcN4yB61A+jXbME+1RlG5dliLFR7c13VvdaFqh32dzF5hGflcZx6Daf6Vo2eh2fVJBIefkknxj8wKAPOxoYuZHj+03d53EcS+WmPfHJ/Ou30jw0LLy30y0t4yFGwSj+Mcgn3rqrTSb5IzHYi3ysZX5UUgv2YkHpXRWWkTSMu2znQ7RuRrdjhsc4PpnNAHIwaCJhNcSzPNrTtue8ddykdAig9qv+HNEvLWSa4u/s91NLF9nkMPVoif0I4rt5NIuLWyP2bT576RAcW6gQg57bmIrT0jQL2OOR76S3WSTY0EcMfFsdvzKWz84z34oA8nsdJvm1q/0+5mgF08BnsfIT51KknzPfGACPetLws6f2hLb21oY72NJpZ4YyDHIzKCMHqoOSWHY5r0VfCUP/CSaZrc0shv7JZUUwoFRkcYZWGfYH6is6HwdNF4ku7y2igtUS7+1wTK3zTM4PmRuP7h3H8QKAOHt7WaHxKkN80E39oWoGh2UTYLurFpy3ptAyM9hWrceHraPWodQMW66t93lx5+RX6byPUeld2nhGwTXIdZjd11C33qjqBhVb+HBBwMccYon0S2lkmuJVWGV8kuZcZ9TjsaAPP7m1ETkBfUkkYJNY1zax+cZm2eaQRuxjAI6H1rs5/7F04Aa74gtiithY4nVXcerk8muS1jxb4AtW3NqdzJtB+RJ06/gDQBizRWkzyIYfPmxh1hG3j3Nc14y1GbRPD19qWl/ZbK/hVFDxfNKCZFXPtlSfzq7qvxV8HWsrPY6PLe45Xz3d1z6kHaDXn3xB+Kl34k0G90mDTrewsJwgaOFFTIVwwyAOeQO9JpSVmB5ekiKQN6DHBJbvV21kt0QyF4lY/KoDg5HfPpX6U/ZLb/n3h/74FH2S2/594f++BTA/NKWdHl3F49ueuQefamC4j8s5eMrnBy4ywFfph9ktv8An3h/74FH2S2/594f++BQB+ZzTRZ4ljJyAuSPy+lOWZB8/mDJz/EOcHqa/S/7Jbf8+8P/AHwKPslt/wA+8P8A3wKAPzQNykbfLKA4/iEmP61PBqtxbkeTfyxkHqsuMEe+a/Sj7Jbf8+8P/fAo+yW3/PvD/wB8CgD88bLxxr0WHg1+/jfAJAumA4/GtJPif4uYqI/E+oDbnhr1vy619+fZLb/n3h/74FH2S2/594f++BQB8IxfFjxWd+7xTeqCRgfaCePzrTm+Iuuta+XrOq3M8hTKGS6J4z1xn3Ffbf2S2/594f8AvgUfZbc9YIv++BQB+fkviOacMTPbkvliZG3kgdT1qjqE88AQTzxtHIuQSQpZDztz/Wv0R+yW3/PvD/3wKDa256wRH/gAoA/O63ns3drjfDG2xRtkcNjnGfrQdTkt4GhF1B5ZlZOGG4Nj+Vfoj9ktv+feH/vgUfZLb/n3h/74FAH5ttMkrl/OhVGzglhyR3/PNRxyW7uzMyqUORhx0/P9K/Sj7Jbf8+8P/fAo+yW3/PvD/wB8CgD81rm4RY5IxJHsC8jI5wOOK/SyD/UR/wC6P5Uz7Jbf8+8P/fAqagDmfif/AMk18W/9gi7/APRL1+dKzJsA8xOBxyK/TsgMCGAIPBB71F9ktv8An3h/74FAH5medGP+Wie/zA5oMsYOPMjz65Ffpn9ktv8An3h/74FH2S2/594f++BQB+ZZkjwdsiYxx8wpUnTacSoG/wB4fnX6Z/ZLb/n3h/74FH2S2/594f8AvgUAfmcLiLJw6Ag5yHwfzFaFtr15aEC31K4RRzxcH9Oa/SH7Jbf8+8P/AHwKPslt/wA+8P8A3wKAPz0tvH2uW/A1qYj1Zlb+lblp8X/E9uQV1eM8bcuqnj14r7v+yW3/AD7w/wDfAo+yW3/PvD/3wKAPiRPj34zhAVNXtcZzzED/AFq8v7QXjZoyRrOmhRx/x6oT+pr7N+yW3/PvD/3wKPslt/z7w/8AfAoA+J7r46eOLrKf8JDEnGcwQRLj8axbv4seL7pSk/iq9DdMJIqDB6jgCvvL7Jbf8+8P/fAo+yW3/PvD/wB8CgD8+Ljx74jn4bxHqDjoM3ZH4daqTa3e3RButUmuAOu+7Y49+TX6JfZLb/n3h/74FH2S2/594f8AvgUAfm1eXEbsWaZG7A78kVVNxER/rE+u4c1+l/2S2/594f8AvgUfZLb/AJ94f++BQB+aZukDMyzqGxwQRzUMsgdTtZJGwOhBNfpl9ktv+feH/vgUfZLcdIIv++BTVr67ATUV+aQ8Qa3/ANBrVP8AwMl/+Kpf+Eg1vH/Ia1X/AMDJf/iqQH6WUV+af/CQa3/0GtU/8DJf/iqP+Eh1v/oNap/4GS//ABVAH6WUV+aX/CQa3n/kNar/AOBkn/xVL/wkGt4/5DWq/wDgZL/8VQB+llFfmn/wkGt/9BrVM/8AX5L/APFUo1/W++tar/4Gyf8AxVAH6V0V+aw1zXD01nVT/wBvkv8A8VSjXdbxk6zqp9cXkv8A8VQB+lFFfmyNf1gAbtZ1TB6E3kuPx+atCwudfvpTs1rUkiBxu+2yZOfT5qAP0Wor89dR1e70mfyTq2p3ZwVLC8lxn67qqHxHqv2dFXUroTO2QBeSswHofmwKAP0Vor87o9S8TTyOIdQ1mYdhHNOT+GDSrrXi+yAlOqazH22vJKw/EGgD9EKK/O9/GGpkbb0XJZeSyXk8LNn1w2Kz5/EWoy4NvqOsRMTyov5HH4c5oA/SCivzXbX9YCEHWdWVgDyb2Tr9M1+ksHMMeeu0fyoAfRXOfEqSSH4deKpYXaOVNKumV0OCpELEEHsa/PRfEOt7Qf7a1Tp/z+Sf/FUAfpdRX5pf8JBrf/Qa1T/wMl/+Kpf+Eh1r/oNar/4GSf8AxVAH6WUV+af/AAkGt99a1Qf9vkv/AMVVqG/8UT6dc38N/rcllbMiTTrcylIy33QxzxnH+c0pSUdW7AfpFRX5p/8ACQa3/wBBrVf/AAMl/wDiqP8AhINbz/yGtUx/1+S//FUwP0sor81F17W2bjWtVP0vJf8A4qpDrWvAZ/tbWMf9fUv+NAH6T0V+aq69rRYD+2tUJPb7bJ/8VUsWvasVydZ1VgDyReS5+n3qAP0lor857O/1ydPMOsaqEzjm6m/T5qt3GpX1q4VtZ1RgOCzXsuCew+9QB+htFfnTF4i1mRPLjv7/AGsSQTeSAn6fNk1r2dj471VVax/4SKaNCMmEXBAz0ySRnNAH3/RXwWdB+JNgfN8nxYp5YFjLj8txrH1HxD4jsw0Gpm/jk4O+SWeF1+vIFAH6GUhIAyTgV+cUmu6uSXXUdUVPa+lZfz3U2fXdTktXZNW1RGTBIN7KwPIHHze9J3tpuB1/wItLa71TXvJtrK78Rx6a76Nb3iqyPcZHRX+VnAztB9z24534lJr6a/EPF1lbWWrG3UukEMURZcthnWPChvwBwBXJUo5NMAH1oA/Wr2m6Vd6g7i0iLhADI+QFQerMeF/Hn0r1rwB8EtR8QYuJWUWin95cS5jgX2X+KQ/TaPegDxuKGSUkIjMR1wOldFoPgjXdbureGx0+eQzfc2oWz+XA+pNfXOn/AA68D/D+1W71RoLu6UKy/bANi46lIhx+eT71z3iP4sXtzBJFoEEdhp6ho/N2gYHYg9B+FAHnVl8B10mKK48ba9p2kRsQTE0nmSkeyjGT+JrR/sP4aaQFjtNM1PWpujSTTC1jJ/AbsVPY6Ld6vHb6rq11KUu/mgD5Z3XoG9cHFWLzSNP07YLlz5QUlhuG6Q+n0oArrqHhqFd1v4Q8PWqrwDO0tx/MitPTdC07xKAkHhjQnLNhcwmLJx0BDZFcfqU+nSSW9vb3dmkc52/PIODngE9q7z4Z6idE8SXOmXxjt5o7j7FKh+dVmwGG0jruBBoA4WT4deFdUMlqNWu/CetJK0XkX5E1pIwPASU8r+JrY8OfBLxbCHUzaRcRscrOswdlz36Vc8T6lYR/E7xbNm0FtdaasLxXab4nlVhnA/hOBWQb3w3a6ilzYSy2Vv0iiErJlSeSFHJFAG0/7O2oTSC61nWLdBjL7n2xp9MDPT3H1rf0vwr4C8J5sYLYeIL7d5cjeXsgjOO5UEn8S3XrXP8Ai/XYtRtrWF5rie3ieHaJSw8v5gXQr1IxXq3jm80eC0tIxcWsdveiJYII2VFcscDpyeKAJLbxPa6ZDHBBY6ZafKN0UUJCj05GKVfGg83Zc2OlzgjcCshQgd8hlNeZx2Jt9di0KUQW9/cAzRWs0hKRwHcBNLIPUocL24p+kavpDX0sV7eQ7MFJXQgqMcDb6igDu7nUvC2rI8Wq+D4pIydzNDFFLlu/TB965y/+E3w18TStFotz/ZuqsPkRXKOMjp5bYJ/Cut0rQtC1GNUtbrfIejRNtxx39zXOeOtHj03Ubex1V4L+O63PbPM3lzZXG5UccqwyMGgDyXxr+z34qsILifRbi21y1XIWJRsmUD69T9K+xoQRCgPUKK8K0vx1rWkRPFDef2pBH/y66kfLuVA7LMOH/wCBD8a93U7lBxjIzQBzXxP/AOSaeLf+wRd/+iXr4A8CRxz+M/D0U0aSRSahbq6MMqwMiggjuK+//if/AMk18W/9gi7/APRL1+cicqMdKAPof4w6TBb+H/Gr+I9KsNMmt9UjTw3JFaxW0s8RciRcIAXjCYIZs8nrXz1688UAbjW/4a8Lajr06JZxHazBd5UsS391VHLN7D8cUAYG098Ada9a1HRNRs/hR4c0HTbOSS91qdtVugo5CY2wqfUEfNj1Fel+DfgPpelRWt14suNk8x/dWxIMsjYzjHRfwzjua6HxB8QYdLmmtvD+nW8c8P7o386glAvHyD0A6V5mJ/fYulQ6RvN/LSP4tv8A7dNI6Rb+R4f4d+CPiTVGkN2qWaIAW8w7OvbJrrk+HngPw4yx6rqT6teqQrw2iFgCPvfMeKn1XXNV1PbNc3bLCEOJHOAc9Wx3NYcgZmjaJWWNuTLL1bPT6V6ZmdGdQ8K2DKujeGbVFXnN0xlJI9lwKsaddtqDqI7O1ihbOVW0QYHpzmuSZ55ZmWGaKIc43LkdecetbOn30VhukTUkZogZJIp49hwBksvqeOlAGnrnhTRpbyM+KNChm0y7bbJfaaPKmtXPT5ehX6Vlal+z9/akb3fgPxNp+p2ijCwXQ2TKf7pZe/1Arc1rVG1qytxpxWcSILiGNW+Z0OcSMe2MHI7Yp1tqFhbeDXtonVBcNvS6Zds0soI+UHrtHQH3oA57TfgZ45t4vIl0zTHX7okOoEY98YORWrpX7OGpvcytruoWVtaIcgwM3PTJJPOOvcV0ceolNP8As1pq8ymeJVk/0hjz0O0Z6g0/XNbOnwaZdHUzLDauiLBNcmQTr33L1JzQBsaLovgTwHNHaaRYHWNYCrIxVAxwf+WmcdPzrq/+E2aEeVFBbxsOBG0bIN3sfT3rk/Dl6ljdF2aXE6HZN5JXZGTuZBntj+VQ+Ibm4vNQEdlYyXE3mRRW9vGwAhMqFknlfsmFPHuKAO6t/HbTs4j0+KRV/iS6AyfxAqjqvjHRr63e313QbiWHOXUokwAx1ODXAaxoGq2FukV4NP2IgK/Z7g8MfvHPfmsG/a8tbUNLbtMgOQbaUNx6sBQB02ufDP4c+OLSeTwlKlrq6x71gtJfKOf9uMjPrXivxI+DWteDtFudZF3ZajpMaoZJ4W2vGWdVAK9+SBmu7jvLe6Ed0372dORISbe6hboNrDnisr4m+ItXn8BalY3WoG7spo4VCXcQ85AssbfK468jvQB4Gi7iBXV+DPC8mu3sKmOd4nkEKpAAZZ5SMrFHngMQMljwi5Y9gcXSLQ3d3HCnLuwX8TX1P8HbHSfCXhBvHWrArCY2tdLi2jcYt3zSAf8APSVhnPZAo6CgDpvBfw10HwXokGq+LFtGubf94kAObW0bsEU/6yT1kbLE9MDisvxD8ULu9hki0KAW8IYj7Q+OAT/PpXnvi3xXqXivVprjU3eK2Qgw2e75I93Cj3Y4NRWmnX2rCKC1yu5dxbGBu9B9KAK2t6oZpnu9Tnk1C6c8eax2k57j0rDu7uW5cMLO41G4RztVV2wIMdAK9S0XwNptkRJflru+I3qN3A+ta7PbQIqW0MceD91RzQB43eap46vLQW0e60iChEZEy6qOig9hXG33hvXWjL3El5M4JzuY8e4r6Ra5UDBVTtOeKpSyRSsVaJcgdQOKAPmo6MuY4bgNbzEZLTDhjWtY6Rc20kV4Xkg8uUSLcRyspD9ipB6jtXs+q6NpWoxNDcRABuMqOQa4K406bR7wWUoMlnJlVLDIAOcH2I6UAemfD7xroGheD73VPF/2O7IuBHF5tsr3UrEZK9Pm7HPvTf8AhYOt65qqahp+naP4fttvkpezWomuAmeFx2rwnTZJZtQhkmJ8iFz5Y6hcnk/WvdPh+lt9qjk8sbl+bc75B9c+5oA1NJ8H3Ws3c17Pa3Gs3Mr7nvZ0EEUxz129uO1d7D8M7K4aCbUfIinhAERtIwGjx6M2f5V2mjOgsIwGJbAZh6E9hV9RgY5/GgDi/wDhWPhZ/ONzYvcyT482SaZi0gA4BOeg7DoM1n6j8HvCd5E6C0eLP3QrZC/T/wDXXotFAHhb/AmfTJmufDPiK6tLkHKiRmKH6jmsHXPBXim2jY6rNNfasG22zyMHgZerbW4KseOor6C1DV7WyJV5AZf7g60y0t2vFE923mK/KxkcAfSgD5S1m213RbX7TqunzRW55klYFkT1z6V9fRcxJj0FUb7Sba7tJ4DGgEqFTldwOfUHg1fUYAA7cUAc18T/APkmvi3/ALBF3/6JevzniQlRgdq/Rn4n/wDJNfFv/YIu/wD0S9fnzodjJfXUMMQAZiACeijGSx9gMn8KAOi8BeEbjX9UtohA8omlEUMKnDTP1IB7KByzdAMn0r6ntf8AhG/hPp8YuPLn154hGZY4+Bn/AJZxJ1A9up6k1x3w3sJPCPg1/FVvaq2oalF9l0Zbj5Ut7UDLTv6GQ/OfYIPWpfBelHVr6XVZbv7XrU0bSRXc44AyAWRf4c54NY4ivTw1N1artFbscYuTsjQj1PUTNqXifxGzWscEXl21qzbpImkO1Wb0OD90dAawPD3g/XdYtzcWllthc5XzRwR75r1Twl4Vjk06ODXBHd3Rna5dc5QueAfU4Xj6813EzW8EWGbaiED9369OlefldSOJdTFxd1N2X+GOi+93fzNKi5bR7HhU3wg1icq1zqUQnXAGFygBB7Vz+qfB/XrwMX1G8uAgC7N4jTFfQOoXlzbxLC6KsqktuHIYAVj3WpEvieVlYdAO/ocV6xkfPtz8HNXSJWtfIinQ5ykzHPoeay7/AETUNKcNr9qkTYHlzgbo2PbJ7EV9ETX8fm5VzJEQCT02mqOo/YL61kt7uHzo2xujfvnofyoA8esI7fRGF2kyQoyHb5bfN833+Oyn0rpNV+L2iaTZWcdhocOqasFwj3EYCRjsAO2K53W/Ck9jHfW9qfNgl+YB+SNvQD8K4C1017a6B1KFnDNkS9ce1AHrOgeKvE+oyTTrDoGkWdxkiJrPe4B64Poa7Dwn4SvLfDaNaWzMfvXM0QGM85XPNcH4X1CzNxCBNlFAGAeAe1fQPhPUIpbZW80HKgY+lAFaLwtqt1CsWsa2ZYOMwxQqBgdsmp4vAWiIjKyXMgYnO6dhkehxjIHbPSuqBBJHcUtAHC6h8LvDt3GVUXsB7GO4Y7T6gHNcrcfBG3aRzb6tNEfvJMAQ4PbODgivYnkSNSXdVHua5bV/EETMYVDj/aU9B/WgDzO++HutxRrbXclpcyxkGO5x/rQP4SOoavK/izo9zpHhvUUvbS5tXfyyFY7oyfMXlT/Svp2A2pIYygSYyW9ff61wP7Rc9tc/CDXghy0Zt2XcMkE3EYOKAPlzwTpT6rqtjp0TFJb+dbYOOqI3Mjfggb/voV7v8dtcsrfUdL0TTiDaaZCIYIFPyowAGfwUAfnXlfwWuE0zWtQ16UKy6RZMY1YdZZTtH44/lUDtca5rrgvuleQRb5G4DHlmz+NAHWeCtKn1i/e+u9wtof3ikj70mMDjvgGvU7FLbT7dFhUYI2ktwTz/APqrifDnijwjptn9ilur6SRXVTOVwqgcNgfXmti+17SZzJb2WpxXL7wAwGM5HUfpQBvXF5sjSbcpY5jZehXjhhWFdXBPzx5Lr94jt6cVS+2gw5OSSDknqKoy3pUkKdrjGG9BQBoreBiQWIYLhgwwfyqKW7JJ2nBB4I/lWPqeoPezNcMSJ+gYDAcAYwarLfrNGzKSjZGR3BoA25ZXEhlcGNWGA56MTzis+9eGZCZA2719SKoSXz7PKd90YPAPrjg1As25QuQe5z/SgDAutL+zTTvEuEYk4981teG9Zm06QwysGj+UgEdqLuU/ZMHDDnOBkj2rMgk23DjZJIox8kYyfcmgD6K8L+M0m0+3ijnRLhc7QRwqnsffNdTH4ytp4JWtEZ3RvLAxkj1Jr5Jg1gadcfvJDHaSE7mz8wIPQ+lehaP4mjxCY523Yz8gwjexPrQB9A6f4nguRt2SfL95yMY96TUfE8MVjPcxqwt1VsSHjOPSvLrPXIPsu/UY5VAQlUVwPMGa5C81+bWr+RSt3GowkcIYFcZ44oA9K0nUTq2rfabgbUBztPcdgK9Vt5IzApU4UADmvBPDBuZJxgyTRg9R8pGOxrpL3xs9smxcGZGYOM4EfGAPf1oA9M1DVbe0gEhcFScZH8q0RyAa+dtR8XyPbSmVwFAOwk9PfFfQ8fMan2FAHN/E/wD5Jr4s/wCwRd/+iXr4k+GWjf23renaYAf+JjP5D46+Qg3zY/3sBM+5r7c+J3/JNfFmOv8AZN3/AOiXr42+HdwNC0fUdeaTE/lnS7IL94E8yyD05OKAPTfin4rXxBrS6RBIkXhvTgVkEfCzsmNwX/YyAgHsa9E+HmgGy0ePV71THfXq/LEeBHH1wPbhfyryL4U6RZa54jMurSJDpVk4dvMOFwFJCn+f1NfTOpT6NZaZbvcXSRW5VQkgOSVxxj25rzs2ws8Zg6mHp7yVjSlJQmpMz/Pa2YMMjK8MvJ64wKhv9QR7NVt3BMTnzB7noc+lYniLxFoqxQS2GrRyJFJ5ahDypbrn26Vjz35KR8LsYcEdG96vLsvpZdh44ejsvxfVsVSbqS5mdF9unuI/IWXICtgddqjk/hWLNcxqrNGRIcbt+euaoRajJbSl4CEJUqf9pT1FUJbqP5kSURKgAwBniu4g0YLovMm1ckfyPeoJrkxjEvzSg43dwB0FZceoywPIEQDcGG49aom7PzZdi/OCe31oA17q+V4nR1+8cD1b1NYN9p1rJbDy0CRr096SWUzBMMMDjj1pl2GMjmNj+5wuxjjnHNAGBcWKxDdbKqljnfjg1ueFPGOoWsiLcSbIYjtGP4sf/Xqa/mtreW2tA2DMA2AudnHevPvEut2tl4ga3Cs0MHOF/i9D+FAH0po/jGS5kgkZiC3VO3TrXTTeI0CbfOjDNwpU9Pc180+GfF1uEm8wvBIsedhOWz6+1F345jdY4LbezsQXdc/KaAPete8SwLZNbxMrSFsGTGR05rlo9RWR1w6iIdSD09Sa8vm8Vx24EcV5KpKgu7LnHPSnN4xtJJ1R7iJ3OMkDAI/2qAPZm1yG2twsAQjdkyPycdgK81+NesLdfD7WI1Vh5nlDnuBMh/pVH+2oijybk8kjIKNkf/rrkPiHqy3Hhe7iV/3bhSPfEi0AcxpEpsPC8AOM30huXx/dBKqDTIJvLsDJnEu5l4Pcnr+VVLyR1gtYDnKKkYHtjP8AWoWJWzQHq0jNj0oAsrKSnHPpmrVpcGGVDGoJBBGOorNdiEAU9a734YrpmoQavYXMYTUZYN1vMRnp1X2oA6HQ7TUdVtYPsNnc3Hy/fVCVz7noK6my+HmrXIMmoTwWUeORnzGA+g4/WuI8P+K9U0GXFlctHHkgwN80ZI4PB9fbFei2XxSs7rTLiLUYTa3hhcI6AtGzbTjjqMn6/Wvls6r51Sl/sUIuHdayXyen3JnTRjRfxvU8umvNqqMg9cEf1qhcmQyGSM7XHb1rrW+IWpyoy3tvYXT/AHg01qjAj3wBzUL+M7SY4vPDGiSjv5MTQnP1BPavX+s4yPxUL+kk/wA1Ey5Yd/wOUe9cFVnQjPO4etDXShTlyq4OQR1FWvEGoWF/cxS6dpkenRKm1o1maQM2T83PTjAx7Vkgbyyt0AOAT2xXfSm5wUpRcX2drr7m1+JDVmVdT1TyrfFvISzZJKc84wB+ArV8OQSXGltJcXBt4nGD5f3mrCnjhS4gA2ogBzjrirjXRhsxFvLRrlgR1B/wqxGfqlyqyxxxopi5DsRkuufvfhUlpMtpEEuZJJ1f54grYRBnjj1xzVa5I1B44dp8wrhNowT6VTtmkd2aBfNBwCOynGKAOhstRuY3zeTTNDIMqCfnb6egrZstWcTMY42B7dyue9cfMzxxZeQOTwGPb2FS2d60YkkUn7vzMT09vrQB6bpvii4htp3juHUA42IcdKik1u51DD3ATcxPKjHHoT34rhLOVpQkEW4AkKxNT6/qRgtxbwtgYwSp7DrQBf8AEGsSvbupRHUoRuQ84xjivuKD/Ux/7o/lX58WtnctEZWDN8p3sTgIMdq/QeD/AFMf+6P5UAc58T8j4a+LCOv9kXeP+/L18W6VCXs9I0wH5Yxvl/3j8zfrX2p8TOPhx4qP/UKuv/RLV8R6fcYvfM3EFkPHpkgUATX2qzR262iSlbcszyKvHmsW+UfgBS2+u61dJHp0d5LMZCEhVjkg+n0rHvXdrv5Y/kX5Uz2Pc/0q9oU0+l6hb6k9pLMsLgkKv3RQB1cng/W9EgSe/hZpJlykSNwuT1b3r0O1nJ0yEu21v7ueEHAwPxrRTV9L1nwfDfQP5qTRnGTkxyLwVP8AP8a5lsiABWVgMEKp+6fSgDUe4YrNJIcAYVQv8JrKub+6hu4mUKsJJRsclO3NRG8mjIXPGfu+o65qC7vkuBhkO7ksVGC2ehNAGk1/tyJcOOmfU+tITBOm/DKTwGz1rGa4BHA+cjaD2AqKSYtyCy/7IPT3FAHQWVnNLMqxYA6huoP/ANeo7uNLbzJblyJowzNK3Tp1xWRHfSouxJdgxjKnmsbxdqoWPasrEsh3An7x6CgDj9d8V6pq+rbhN5McQKKYeNw9zWFDK806+bIXYcgk5B78moZlaLcqMzoxy31q9oSW8Vne3E33yojgTruagC74f2yXwi3sGuCGaQc7ea6UXaW99JZ6csbZOWlYdcdcVytvDdx6crF/s8jN9zGDkUlvPsuH/e5BOGcnnPfFAHc2d6JQkbwJKo5LY5f2qJxpU07s8cUQB57ZJrBt9QMkjBrjZsAQ7OhPY0/ULvZbsPLSVT1JH3PT60AWr28sbdh9mkyqn5tjfLn1x7VzesTvcW0weQtC4BC9gdwp1s7yTq/koqLwSOgJp3iOBRpTzJlQAFAA4+8KAI79wLknssh5+govB5cEY6vnn6modSYpcOQeQ+4Vqm0ivLGBo2CSgAq3Y57GgDQ8MeGjrlpcSm4EaRodgHVpBjC1X0myubTUFlE5iVc/Oh+9g4K/nUen2V5ZT71uWiGOQh4Y1oRvEi+WJNnJ4PSgC5ORLl3+TJzwehqu0skXyyZZSPvd6fFLGGJkQPCT8yg1CZ4lHLqT05oAclysqnblSP4fenjczhApVnBxnoayp3jeTdBndjFI7X7QrGrMqjOM9fegDTdWRyrLtIPQjiqc95DCoLOC/ZfWoBY3Ui5uLyRh2GarNp2SSS3AwCec0AJOWuYXcjaMcH0NU4r5opIxP+8i24I6VqXDJDp0m7ADIAPc1jNEjWTTM4O1SRGe1AGi0zvfJLpow5xJlRnB7/hV19MuILef7JIjxuwkcofmQnnp3FWdCtpbPTEuLoSWyTIC6bckqeciu58CeFbrWLW5udCsJDYpwt1cjAfP93PUUAeSzElGWRSJVywGeoHUfWqbySCYRhWSPjaD3PXJru/GmgXHhy9MGv6cYJ55BJBcq2Ypjj7u4fdPsa4bz4ruXe8DoQcYDZIoA1NPvZICz7iGPB9s1bithcsLqSU8+q8Be+Kp6RYjUpS1rJLszgqV5PNd3DocskitIvlqAqlAOFXOKAOcuNSJ06ePT4C5VT88nQ196wf6mP8A3R/KvjyLw7b2dxPuBLEblj/hK96+xIv9Wn0FAHO/Ez/knHiv/sE3f/olq+FNMYtf2rE/KxKn3OOlfdXxN/5Jv4r/AOwTd/8Aolq+ELQGOWFuyyhgPagDsvBcOnXXjC3sL7/ULExbcP4ya9dWzs7S3PkQQLa7SmWUZcD/AOvXkTaUlxfQ36SGCRR/D/EPeumOqymzS3upWeUD5mX+FaAIbe0j0S7v0sr0paXmJTBjKhu+PSnrdtCAVXEQHLd6qoruWS3gZ/RuyrViCO4hLLs3MykHPIXr+ooAspNBcHDkpJ02+tQ3dvNF2JiPAkH8XtUQt5toDRDj+InnpSieWyUqLgOp4CNzigCIwyN5ah0VXUsD+PSo54nicjHI4BNXG1OHKr9jRmXgN2Bx1qKS9adJPLijC4xuY96AKSxM+DEPmz1rB8QQLb6TJdXBUyyyFY1zyNvFdPaSTPhQp+oGMivPtfvxOzxISY4WYAdeSeaAMNo2aNQSFDc//XrZ0uziW0a9umWBY1AtieR/n3rn7p2MRXdjjk/3RXVPYStpmn29yEMkkSCK1DgMWP3Vb04oAztOX+1dXlt7pmR3w4kU5AGOtVYreBFufMDNHG/7uY9CfQ13kfg3VLaExKqWlxICGTuM+9cl4wsbnSbmC0vLVQqRhVVJN0bY/iB9fXNAGKbxATFbINpw24nkmrMly8xjhEm4jG0Dt6k1nCYFsSQjrzt4OMVv+Hbe2e6811JYkFY26AfWgDY0TRCkQeVwTLg7T396s+ItNhi8P30J3GZQjBu331H8q2rKKMD74kX+LttqDxIx/sS4QEqu1NqEZY/MvLHsKAOb0Lw1f+LbuSHSvsxulj84RSzLGZM4+VM9Tk5/DrVmLStR0iCSy1eyuLO5jcjbKhXI9R2I9xxWDYYa0wdwRWMWemCOf6iuy8N/EbW9PtxpWteVrVlHx5V+vmF09mPIYfj9K4a7xdOfPSSlHts/k9U/RpepceVqz0IIYpXgkkjVmijALMFJCk8DJ7ZqHoAAiszfKAR1z6V9M+FPDel2uhSBNKW1XUUV7i1lcybQR9wk9hk/iTXkXxC8ByeG7try0LyaVJ91ycmA9lb+h/r18bLeKcNjsVLCtcr+ze2vdaaXvtq7o1qYaUI8xwAt1aVvPbY3QKOgpDaxoSPLXg9e2KsX6m1ESyyBGkG4L1wo7msW+1GQlVidSB/EtfTnOaYRYju2KAvUjpVY3aluvfoelYLyyupBkfB6rng01WZeATj0oA6SK5jYgbRkkmnb44lMkzBVBLfX/wCvXPJM6nJJ/wAKsalKZrEIpwq9R6mgCoXW6mG9ipeVtqHpGvatLS4Iby+RLkmLS4FDTMvWZ/7oPtWDdrLBEsaIfPmbaB3yccV111aiCztbCAny7ZNhcdGkJyx/PI/CgCj4+vF1fUxfWSTRWoiEaw5+4AMZH1r6k+GU+nar8OPDD+Hp5WsbO1FvJHnJimH3xIB3J5FfL+2TaCpwowpPXNaPhjXNS8I312fDd/PaveqPMRT8p2nkjPGcUAe2/GxLKLwTcxXiofPkVYAwzlwc7lHUdOtfK1tE4uydw3L+td14+vbi7uIBeaxeX2oFB5kl1IMQg9FRRwM9Sa4ya3khCl2BDnG8HoaAO/8ABSiKMOigODn6Gu/tGeaXLj7wwBXlPhvUfs7KhAUjhiT1zXoUGpqlqJNwHy7eO+aANWeOcmUlF89EIDE8YPTFfU0X+rT6CvjG911/slwoYZVSYwTyOOlfZsPMKf7ooA574lnHw48VH/qFXX/olq+D8iF0EpxFIfKZv7h6q35193/E7/km3iz/ALBN3/6JevhO2Rbm0Xd8ysuxvcjjj8aAO20iXzrOPccSKArDrkjv/WtByEiyz/LkEYHLGuI8N6gbW4+z3JOMdfVR3+td3b4l2YwzEZA7CgBbeKdlZnlEEI5C55apkY3AYLI6IThSP4j70nlI8ih2LeYwC4/WtHU7CG2jjCOREg3EL1BoAyvsbuP3sjbRnIU9RWXeo1ukzuoVl53Oen/162dTvEh0hXtMKcHk9a4DXtYN9FgkDHU5oA2HN5Fa+ak0ThhkkHt7iq9nfuHVWVXcnAOeDXKQXNzHkCQhTjLevtWp4fZbm+Dvkxx5Y+nFAHWeLtWTT7JBC2xnUZCnp7V5lNdLcSq7/uxycL356mtzxJmfejOXCSbBjnJPIrCmt2e4jtYeHmfYvHJ5/lQBe0azil1C3mvIybJNsojXpNhuma2NRv7aTxnZ6i9hnTradZGjUcsgYE5+mOKsXFv9ngjs4mIihTYrY7dx+eaYiM6+WvGcD6jsDQB7nfLFrLPqOnzi6tLlt8c8Z4KnnafQjp+FeP8AxevdNazh0+zcNJFLvfbyQfQntWYuoXGjyx29nNLHBcZR7cOQiOejD/Cuf8RCFdYeztVJhtiQWY/NLIRksx788UAZlqhdsjhsZw39K6PSyiJtEeW6HmueC+WyhzgEA59D6CtSCYwoplBCtyD3oA7SKaJEXLbztByvRfb3qhr1840W82SAFtpPct869fpWJNqh+TYvlxgYBI7VRuL1bhGXJUEdO3UUAXLTc0knmciUbx6bgP6j+VF9C7QpKmRJHhg2Kt2sB8gFAS64IA747VaKDEciZaKRd6j1U9vw6UAWvC/iXU4IdtvqF7CwYBljnYbD6jB6Hmu/07xLrV0streX809rJG25JwsisMHIO4H1ryOeB9PvFmhz5bcqfb0rutAv7nXtLk0+zs4xIEw14rcqPQj1rmqYPD1HedOLfmkylOS2Zy2s3gluJG3DKgL65rFC4JP8q0NSsprK9kguU2SIxwfX3qvswSFHPv0rpJINvOSMf1pyxZIx0HXNTiPIPrwCKcqZzxz3oAgEOWIHSp4oXecYU4AHHrk1ZigIC5+UeveluZ1sLV1hQvdXAK26Z5yerH0GKAKdgfM8Rz3jxGWy0hTK3PBkJ2xrn3Yjj2NberW40+doIiXidVdRnO445OfrmtLwxoccHh+SaTL2EMiTTbhhbydQQdvqibuD3NV9RuFdLa1nR7W5hyIUKZATqFJ9TzQBnJbOlsVJ2MTlhnrnmqupRYktI4FMjtKN3HRe/wClaWs2ttDYtKt9KLxOIowOWYn7pFQ2pMtot9fW7TXohMa26HAJxgtx3JoAy/GNjLNq1zcQovlLGjRAfdMIUKCp7nOSazFiedIY2R5LrcVJz8hUjjHv1r1ODTbeOCxt5pA+lXkCzRhh88C8Bgh/vK3UVgat4TntpJXgdLm0XJE8ByVHrjrQBxo+0WMhjuI2DqRtGMk/jVhtRukVHkDeQw3jDZP/AOutmPSmvbS0gjlWcRR+Um5vnDbskt+dJb6BP9rgtrqzm2EES7f4R/CR9P60AYd1PNLaMTIURlOM9elfovb/AOoj/wB0fyr8/wC30NpJ3S/trtrQQu7eUuGJC5VR9TgGv0Ag/wBRHxj5Rx+FAHO/E3j4b+Kz/wBQm7/9EtXw3Zj5DCQAijzIlHYE/MB+PNfcvxN/5Jv4r/7BN3/6Javim0t3EKyQoGliHyxk4yfT8RQBnXsDApKnykMCrej/AOBrrPCepCWLy3GJR8pHv/hWXLDG8a4G6GRcjPBHsfcVUiMtpfp5LbbjoyEcTr2I9DQB7j4dsoZDIRAlzIMk4H3B7Guc8W6hZxagyIpEcZ2sM87qs+AvE9uGWC4JgU4DEfWovinbaU8ha2Z08wfuzj5vegDgNdeN42e2nARvmZM1x7xhX+4MZyQO9W51EcpVZDKO7AYP41HsTOVOG60AQGN2BXGGP5Cu+8BaVZJZT/aXQM0J69zXGLAGbbnI6nB71egdoUBeQrxyAe1ABfpEl9P9mb5F+Z3PRe2P50z4e2seoeO1knXMMMMrxgjjcIyFGfXnNOvA8enC0VALq+dfs8THGB3dz/d6V0yadFo/gS0IaRbm6u3tbeEriaZwMSSHvtJIA9hQBlujTOxILLyVw3H/ANepltjbneyrv4yWOBmrMLxaUkmn38BbUbeFIwyIdsJDAN9SFJPvWdrUi2iRPpd095qkshihgkTIl65JHbHXmgCPUrR7qGKJMSTpKtxgcfuwcnn86xPE+nvJdzagu9oWkEcz4xtcklT9MY5rsdaH9nX093otsZVjRN0UpyMbRuUkcfe3Gui8R6KbC9TU9Ih+16FqKJJe2LfOyIRxInqvWgDxiWPzYIysRckEyMpzvIPDD04pweS1dUvQRK4GYyOQD93I7V2er+D4orVNR0W5kl00uNskWXkQ+jj09KreIrS71zWpbwRq9xNGrhtoAbgDHseKAOWupNsrR3gZNpKqMccVFEglWQSLtAUY9TzziuibTDLp8iyQTRjfmJ2GcMPvA+xzxTJLGP8AsmMNDOk1u7EPt4IYgc0AdHb6bLZCH7bC9u5UhWkGAcjBwaSSyMLyRsrfZ5PmVhz5T9z9DWn4K+K1jHpsWj+ILKK607PzJdclR6Ry9V9cN+db1/H4Pv8A/SPDWueUScfZrxCCM/7akg0AcK9uGQxSoHjbrjsfaqmkTXGia2bqxO6ZU5ROko9CPWupudLuFLPEUlXPWJ1kH+NZN9pzMyGRGhkQhllj+VgevegClrV4NWnN1CDIWPzoOHU+mKy1VT1yGHOMfrW3e2pvGSSdQ0q/cuol8t8/7S9DVUwyRlMsZVJwzEZHP05oAqRoWLlQcgZx6irdnYvMyjawBPzAjlvYUEXIYyR2sE7spUbg2COnSrEgv2jgh+3GEpkIlvCA2Tz1OSKAIrh7fTmaS+O65cEpbR8sT1GfRcd6veFtAWaJ/EHifEVpMgNrADj7QR/Ao6hR3PerGi+HYkgD+QRJJnzXl+Zmz2JPaugj0VLllfVWaS4SMR2qp9y3X2HrxQAlpqceqNbW2ph/JaQJbqvyokakEoo9+Oah1HQ92pXEl3cWj3EhMjRCXOMngA+uK0tG0a//ALRhuZpbaZrRzLb4XBzjoV9DUd3pdwnii0S7EP8AZ167RRw7f3jsQP3fs2elAGBLo8Mty1ypSeYkRMn8SuMDAHY4rVh0ddPtnt1nR54yFkjRQoj77dx6mtTSLVrTW47W8ilXUxcRRCZAMyIjsDuU8h8AAeuavatbomqWN9qAS10oXssN1COZnuiMQJjqQSQD6E0AcriOMT2ixPbxwj7QomO5Q5OCc9s5BrNv7SRbr51keaVPKl8rKYXOd3vivRda8NR30kNtrFqbSZGV5oI35Pfy2P8AWk1CzRp5pfLCluhAxj2HqMUAebalbu0kyypFcyBVWMquxuPlBJHrnmqbtcxiWKCXUEBAV0in3Hg89e2a7u7tYAVZidy4K7gOB35+tZNzBbm4jRgrSt9wRqQxz1OewoA5eaK+FtOJdSuMbSP9dtIGOmBzX3bB/qY/90fyr4lnigC7RawRumRulfc5XBzwO9fbcP8Aqk/3RQBhfEGMTeAfEsTOsavplypdui5ibk18mHQ7rToozfW7LHgbJgN0b+4PvX1d8S3Mfw48VOMErpV2RkZH+pbqK+RPA/xgOl2S2Gp2qvYtgNE2ZIcewPzJx6EigB9za4ZmUb0f5nCHIz/eFUbu2DQNnJKjIZR8wrs5tT8Da1J5uk6jLYSMciNysi59OxFUZtDmlO6wvLS8I/55yBWxjOdrUAcrp5nS3adE86KI5fb99Pw9BWjqGoya7p6tHJiSJvkdOcjuCKdNp1zbT+bNbTwynpIg2nH8iKzLuxBRikvkyk582IELn1IHSgDKuLW4kbzHUbSOeMYPpTbe2VwcEll74/z3rXGm6mJIJSTPEcZIw/Ppkdqsiw1MXASHTUjkKCMmTJUr9PWgCnplmqt5qwi5K4xEQQJMnoSCDzg9K9k0j4a+FPEOnR6lppuLeVwC8LSiVYpMD5WB5OMjuOK80gsLh7RUnmuGeI5EcMflhjngFuvXNdt8NLiXwzdoXjWK1n4ukGSSezk9yOfwzXiZ5hsXVoe0wM3GpHVJbPyttft93U2oyipWmtGVdT+HVp4T1Ftd8QaqNVWPEsduI/LkmZeigZICLwcD8an0+a21TxVb+J5ftF6UjP2RGXACgc4HbDHJNdZqk2l+IrmQ6pbSwksRb3aj50VTxweqnGT9TWd4d8KX2g6rf3zyxXtlJbyQW8lscBQ4GSU7EEdqnK8bWhThRzFtVX1aST8k1pddVo/KwVIJtunscLelBqEl7fMNzsXMqISu7HOfcGrSaRbaBHqmpz3AeLVIN6JbqHe5diAY4z/CSSM1saL4fvrLxGLDUbyCae6VpbWYJ+5ZwuQjZ43NjGPetLwRppj8UXOlTQOtlaahHqaB1z9mMsRVkPou7aw9CK90xMWy0F7XSorbW1x8gaTSoPlWMnosjdSfaq9ld6haa/bQSiKwgUpDahlIRYnONq56gN2967S1hvh4t0wukE1tqEc32C0djulvQcySTN/dWMMy/Sr+s6Fa3muQahdySXDWakRRY/cM4OQ/6DigDyq4sJIdZuJ9OaWG4icZntjs3DPG5OhqC9tjLLO0sMUjlsoYwYpOeTyODXpN7Ys8kk0kQj8zJLbcE55/KuevbKQyK6jaUbKsTjkDGP1oA4hisapuurwDfjCgSAAdP8Ki1KCS60uZInmDHHDnqNwPSty9jgSZsASyjjZFwSR2JrnfFU72eh3M0UcKyoFVsuXON6+nuaAPJgcUoO05U4PqKbS0AX7TV7+0/wBRdyqB2JyP1rodP8fapb4WYLMnpnj8jkVx9HFAHpVp4402cObu0EcjHdnaRtPfBX+orXi1DRNS5imRZG5HzD+mDXjvvSnnqOaAPcLfTbd/nE7EHkxtNgHP1FbNhpM0DxBQmCxJ8sLIxXHTOfWvn2G6uLc5hnmj/wB1yKvweItXh/1eo3I+rZ/nQB9H6dpN1IsCy28/2kE7zHbsyvycYx7da6SDwzeiAn+z76Vs5WJLYr/482AK+YbXx/4ktgoj1OQhem5QcVrW/wAXvGVsgSDV2UAYxt7fnQB9O6N4Q1iO3S81OyS1tZI2QadCBLPE+75JDIMgjHUD1pb/AMBTaq9oL2S4We1uYri3mt7YqUdGDAktge1fOEHxw8eKgjTWQB6mEEj8c0T/ABg8d30EqHxBMGByQiKtAH0l4v8ABd1rPiqS7MUVnb3luhuNQ3rHLbyRnKMgyctxz9a1L3wDa63d219rF1BFfxPHdKtoo2CQAEuNwwSWAOcV8e3Hj7xXclvtOvagWUcjzAuT7YFZt14t8RXKILnXdVcAYVTcsoHbAGaAPtPVtHXUr1ri+MRuAcebI4iD4GBkAVyN7p+m2N1OdV8R20FivIRGDT7u6AtwBXyXcanf3QC3F/eTEngS3DNj8CapTMXPzFmx/eOTmgD6U1zXvAluSItSvXG4kKJYz8vbkVx2peOPCcbKLWyu7zYNpE0zEP6dMce1eNwgFx8wH41MZSD83QcAfSgDv9T+Jd3sYaTptppyqSQ8MYVs4555JH4195QEmGMnqVH8q/Mm5lYo2TkFe1fptB/qI/8AdH8qAOc+J/8AyTXxb/2CLv8A9EvX5yIeBj0r9G/if/yTTxb/ANgi7/8ARL1+ci/dAzzigB3XtV2z1W+syPs11KntnI/I1R6YooA7LTPiDq9oQJGDqP7rFc/hyK6CHx3pV4VF1arbOeuE2gn6r/hXltL29KAPY7a70e8AksrwQSZOEjkH/wBY/pW5BBK5Ui7MoIyN8+Mn8RXgGR7VZhvrqEAQ3VwgHQLIcD8KAPouxtbsARLCHn2NsxhlLYG0nB+tdBpdmzxx7rW4WYIvnDymbMmPm24HTPIr5ltvE+tW5Bi1KcEdN2D/ADratPiV4otSpj1LkHglOf0oA+q4NGkktjK9rd3G0EmKOB9546AkYFbnhjSNU/e3tzY/2ZpbWxEemtiW4Eobh2YZHzLkbe3FfKdv8bvHECgR6ohA/vIT/Wrsfx/8fLEY11K0APc2wJH4k1nVo060HTqxTT6MabTuj6b1Hw7Hq81hJdW91ElndxXgXyWVWMbbgDkDqcVmXfhzVp9b1rUrE21ibhorq1nlkxvuUb7rgZzHgnj1r5qvvjb4+ulw/iBlPTEUCpxWPc/ErxhexlJ/EV9zwNhCkn8BXLhsLUw8uWM26fRPVr0lvbyd35lSkpLbU+y7nwoG8T2Gu22po0tjNKyW7xZjVpF2nGDkcMRn3qbU9FuVtpTaC3gvN5MLzOBGCc8lfavh+fxx4snz5niPViB94C5YAfkay7vWdTvMfatSvpgP+etw7D9TXcQfamrw6JZaYg1rxEH1RVLSTKybXPoFJ6V5dr3iPwbasC2tXc8gP3VeMc+2M181OQ7ZbLc/xHNGcc7RjpkCgD1vVfHfhtGY2WmXF3LnJa4lYgnHXsOa5TxD46vNV0i50yOztbSyl27lhQKThlYfqBXIg8nglR70OQVYjnjkn60Af//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Magnetic resonance imaging of a cavernous hemangioma in an asymptomatic 52-year-old man. Panel A: Heavily T2-weighted MR image shows the masses (arrows) as very high signal intensity. Panels B-D: Dynamic T1-weighted gradient-echo MR images before (B), during the arterial-phase of gadolinium chelate-enhancement (C) and during the portal phase of enhancement (D) shows initial nodular peripheral enhancement (arrowheads), which starts to fill in the hemangiomas (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Eric Outwater, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_42_16035=[""].join("\n");
var outline_f15_42_16035=null;
var title_f15_42_16036="TEE descending thoracic aorta";
var content_f15_42_16036=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79300&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 566px\">",
"   <div class=\"ttl\">",
"    Descending thoracic aorta on transesophageal echocardiogram",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 546px; height: 424px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Panel A: Horizontal (0&ordm;) imaging plane shows the descending thoracic aorta which is circular in appearance. Panel B: Vertical (90&ordm;) imaging plane shows the superior regions on the right and inferior regions on the left. Panel C: Color flow Doppler obtained in the vertical (90&ordm;) imaging plane confirms the normal direction of blood flow in the descending thoracic aorta with flow towards the transducer (yellow-red) followed by flow of blood away from the transducer (blue).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Warren Manning, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_42_16036=[""].join("\n");
var outline_f15_42_16036=null;
var title_f15_42_16037="12-lead ECG right posteroseptal WPW II";
var content_f15_42_16037=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F57211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F57211&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 534px\">",
"   <div class=\"ttl\">",
"    12-lead electrocardiogram (ECG) of a right posteroseptal accessory AV pathway",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 514px; height: 311px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electrocardiogram during rapid atrial pacing from a patient with Wolff-Parkinson-White syndrome. The QRS complex is maximally excited; the PR interval is short, and there is a left bundle branch morphology, left axis deviation, and early transition across the anterior precordial leads. The delta waves are positive in the lateral leads I, aVL, and V6 and negative in the inferior leads, localizing the pathway to the posteroseptal region. The negative delta wave in lead II places the pathway on the right, in the area between the coronary sinus os and middle cardiac vein.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_42_16037=[""].join("\n");
var outline_f15_42_16037=null;
var title_f15_42_16038="PBC after treatment - low power";
var content_f15_42_16038=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57230&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    PBC after treatment (low power, Masson trichrome)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 258px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Patient had been treated with methotrexate for three years, then methotrexate plus ursodiol for two additional years.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Marshall M. Kaplan, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_42_16038=[""].join("\n");
var outline_f15_42_16038=null;
var title_f15_42_16039="Plasma cell leukemia";
var content_f15_42_16039=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Plasma cell leukemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/42/16039/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16039/contributors\">",
"     S Vincent Rajkumar, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/42/16039/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16039/contributors\">",
"     Robert A Kyle, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/42/16039/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16039/contributors\">",
"     Rebecca F Connor, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/42/16039/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 15, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma cell leukemia (PCL) is a rare, yet aggressive form of multiple myeloma characterized by high levels of plasma cells circulating in the peripheral blood. PCL can either originate de novo (primary PCL) or as a secondary leukemic transformation of multiple myeloma (secondary PCL).",
"   </p>",
"   <p>",
"    The epidemiology, clinical presentation, diagnosis, prognosis, and treatment of plasma cell leukemia are discussed here. The related disorders of multiple myeloma and plasmacytoma are presented separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16662?source=see_link\">",
"     \"Diagnosis and management of solitary extramedullary plasmacytoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44535?source=see_link\">",
"     \"Diagnosis and management of solitary plasmacytoma of bone\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;PCL is a rare variant of multiple myeloma that presents either as a progression of previously diagnosed multiple myeloma (ie, secondary PCL) or as the initial manifestation of disease (ie, primary PCL).",
"   </p>",
"   <p>",
"    The most extensive data on the epidemiology of PCL come from a report of series of 291 patients identified in the Surveillance, Epidemiology and End Results (SEER) database between 1973 and 2004 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/1\">",
"     1",
"    </a>",
"    ]. During this period, approximately 49,000 patients with multiple myeloma were identified, for a relative incidence of 0.6 percent. In this series there were no significant differences based upon gender, age, or race compared with patients with multiple myeloma. This SEER study did not distinguish between primary and secondary PCL. The incidence of PCL in Europe is approximately 4 cases per 10,000,000 persons per year [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Secondary PCL occurs as a progression of disease in 1 to 4 percent of all cases of multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. Primary PCL presents at a slightly younger age with median ages at diagnosis of 55 and 66 for patients with primary and secondary PCL, respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL PRESENTATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Presenting signs and symptoms can include those seen in multiple myeloma (eg, renal dysfunction, hypercalcemia, lytic bone lesions, bone pain, anemia) and in other leukemias (eg, anemia, thrombocytopenia, infections, hepatomegaly, splenomegaly). Approximately 40 percent of patients will have already been diagnosed with multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an example, a retrospective analysis reported the following clinical features in patients presenting with PCL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Median white blood cell count: 18.6 x 10",
"      <sup>",
"       9",
"      </sup>",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"     </li>",
"     <li>",
"      Median hemoglobin: 9.2",
"      <span class=\"nowrap\">",
"       g/dL",
"      </span>",
"     </li>",
"     <li>",
"      Median platelet count: 75 x 10",
"      <sup>",
"       9",
"      </sup>",
"      <span class=\"nowrap\">",
"       platelets/microL",
"      </span>",
"     </li>",
"     <li>",
"      Osteolytic lesions: 44 percent",
"     </li>",
"     <li>",
"      Extramedullary plasmacytoma: 14 percent",
"     </li>",
"     <li>",
"      Hepatomegaly: 21 percent",
"     </li>",
"     <li>",
"      Splenomegaly: 13 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, laboratory evaluation frequently demonstrates elevated levels of lactate dehydrogenase (LDH) and beta-2-microglobulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGIC FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of a patient with suspected plasma cell leukemia is identical to multiple myeloma, and should include a review of the peripheral blood smear, bone marrow aspiration and biopsy, serum protein electrophoresis (SPEP) with immunofixation, and protein electrophoresis of an aliquot from a 24-hour urine collection (UPEP).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Peripheral blood",
"    </span>",
"    &nbsp;&mdash;&nbsp;The peripheral blood smear of patients with PCL demonstrates a leukocytosis with circulating plasma cells. The absolute plasma cell count typically exceeds",
"    <span class=\"nowrap\">",
"     2000/microL",
"    </span>",
"    or 20 percent of the peripheral white blood cell count. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The morphological features of plasma cells can differ depending upon their maturity and, at times, may be indistinguishable from myeloblasts. Mature plasma cells are oval with abundant basophilic cytoplasm (",
"    <a class=\"graphic graphic_picture graphicRef63684 \" href=\"UTD.htm?19/27/19888\">",
"     picture 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76557 \" href=\"UTD.htm?28/45/29393\">",
"     picture 2",
"    </a>",
"    ). The nucleus is round and eccentrically located with a marked perinuclear hof, or cytoplasmic clearing. The nucleus contains \"clock-face\" or \"spoke wheel\" chromatin without nucleoli. Immature plasma cells have dispersed nuclear chromatin, prominent nucleoli and a high nuclear to cytoplasmic ratio.",
"   </p>",
"   <p>",
"    Immunohistochemistry or flow cytometry can be used to determine the immunophenotype of the neoplastic plasma cells revealing a malignant clone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. The cytoplasm of the neoplastic plasma cells contains either kappa or lambda light chains, but not both, indicating that the cells are clonal. Increased levels of CD138 and CD38 are frequently found. If present, CD45 is of low intensity. CD19 or CD20 are usually absent. In contrast to most patients with multiple myeloma, the malignant cells in PCL frequently lack CD56 expression.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Bone marrow aspiration and biopsy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The findings on bone marrow aspiration and biopsy are similar to those seen in multiple myeloma without plasma cell leukemia and demonstrate an increased number of monoclonal plasma cells (",
"    <a class=\"graphic graphic_picture graphicRef61145 \" href=\"UTD.htm?33/12/33990\">",
"     picture 3",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical features, laboratory manifestations, and diagnosis of multiple myeloma\", section on 'Bone marrow examination'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Protein electrophoresis and immunofixation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protein electrophoresis of the serum and an aliquot from a 24-hour urine collection usually demonstrates monoclonal immunoglobulin production (",
"    <a class=\"graphic graphic_figure graphicRef67685 \" href=\"UTD.htm?21/3/21566\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H8#H8\">",
"     \"Recognition of monoclonal proteins\", section on 'Serum protein electrophoresis (SPEP)'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum immunofixation will reveal production of one of the following immunoglobulins: IgG, IgA, IgD, or IgE in 33, 20, 3, and 1 percent of cases, respectively (",
"    <a class=\"graphic graphic_figure graphicRef55916 \" href=\"UTD.htm?4/39/4735\">",
"     figure 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/5\">",
"     5",
"    </a>",
"    ]. Approximately 35 percent of patients will have light chain only disease and less than 10 percent will be non-secretors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=see_link&amp;anchor=H16#H16\">",
"     \"Recognition of monoclonal proteins\", section on 'Serum immunofixation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of PCL is made based upon an evaluation of the peripheral blood smear, bone marrow aspiration and biopsy, and protein electrophoresis. The diagnosis is made when a monoclonal population of plasma cells is present in the peripheral blood with an absolute plasma cell count exceeding",
"    <span class=\"nowrap\">",
"     2000/microL",
"    </span>",
"    or 20 percent of the peripheral blood white cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. These cut-offs are arbitrary, and PCL should be considered whenever circulating plasma cells are readily detected on conventional complete blood count evaluation. Repeat testing will usually clarify the diagnosis. Significant involvement of the liver or pleural effusions with positive cytology for malignant plasma cells usually suggests plasma cell leukemia.",
"   </p>",
"   <p>",
"    The cytoplasm of the neoplastic plasma cells must contain either kappa or lambda light chains, but not both, indicating that the cells are clonal.",
"   </p>",
"   <p>",
"    Bone marrow aspiration and biopsy will demonstrate a monoclonal population of plasma cells. Monoclonal protein on SPEP or UPEP supports, but is not necessary for making the diagnosis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     DIFFERENTIAL DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of PCL includes other leukemias and lymphomas with abnormal cells circulating in the peripheral blood. It also includes reactive polyclonal plasmacytosis that can be related to infectious or autoimmune disorders.",
"   </p>",
"   <p>",
"    The majority of cases will be easily distinguished from other forms of leukemia and lymphoma by morphology with confirmation by flow cytometry or immunohistochemistry. Patients with multiple myeloma or other plasma cell dyscrasias are arbitrarily distinguished from plasma cell leukemia by lower numbers of circulating plasma cells, if present. A diagnosis of reactive polyclonal plasmacytosis can be excluded based upon absence of kappa or lambda light chain restriction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis of PCL is poor; in multiple studies, median survival was only 6 to 11 months, with up to 28 percent dying within the first month after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/1,5,9,11\">",
"     1,5,9,11",
"    </a>",
"    ]. Survival is even shorter (two to seven months) when PCL (secondary) occurs in the context of refractory or relapsing multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/5\">",
"     5",
"    </a>",
"    ]. The impact of new agents on the overall survival of PCL has not been assessed well, but it is likely that these agents have contributed to improved survival as they have in multiple myeloma.",
"   </p>",
"   <p>",
"    It is likely that the reasons for poor outcome in PCL is related to a high proliferative rate and the fact that the malignant cells often harbor multiple cytogenetic abnormalities that are known to be associated with rapidly progressive, or high risk, multiple myeloma. In one retrospective study, patients with PCL were noted to have the following high risk abnormalities [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Deletion of chromosome 13 by FISH in 67 to 85 percent",
"     </li>",
"     <li>",
"      t(4;14) in 16 percent",
"     </li>",
"     <li>",
"      t(14;16) in 16 percent",
"     </li>",
"     <li>",
"      del 17q13 in 50 to 75 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Genetic markers of high risk myeloma are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=see_link&amp;anchor=H6#H6\">",
"     \"Pathobiology of multiple myeloma\", section on 'Cytogenetic abnormalities'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H5#H5\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Risk stratification'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There have been no prospective randomized trials investigating the treatment of PCL. Recommendations are primarily based upon data from small retrospective series, case reports, and extrapolation of data from patients with multiple myeloma. In general, patients younger than 65 in good performance status are treated with aggressive induction therapy, such as VDT-PACE (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ) followed by hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/12\">",
"     12",
"    </a>",
"    ]. Eligibility for HCT is discussed separately. Chemotherapy alone is the principal option for those ineligible for HCT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=see_link&amp;anchor=H7#H7\">",
"     \"Determination of initial therapy in patients with multiple myeloma\", section on 'Determining transplant eligibility'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Induction therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The best induction regimen for plasma cell leukemia is not known and there is great variability in clinical practice. Historically, patients with PCL have had poor overall survival with conventional therapy for multiple myeloma such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"     vincristine",
"    </a>",
"    , adriamycin, plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    (VAD) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/5,13,14\">",
"     5,13,14",
"    </a>",
"    ]. Newer agents that are being incorporated into frontline therapy for multiple myeloma have also demonstrated activity in PCL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In particular, combinations that incorporate the proteasome inhibitor",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    may be very active.",
"   </p>",
"   <p>",
"    Retrospective analyses and early reports from prospective trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    suggest that this agent may be one of our most active therapies in patients with high risk multiple myeloma as defined by genetic abnormalities. Since patients with PCL often demonstrate these same genetic abnormalities, bortezomib has been tested in PCL. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=see_link&amp;anchor=H4#H4\">",
"     \"Initial chemotherapy for patients with high risk multiple myeloma\", section on 'Bortezomib-based initial therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The following is a survey of retrospective analyses and case series that have investigated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    in the treatment of PCL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      There are a number of single case reports and case series of patients with PCL responding to chemotherapy combinations which have included",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/17-26\">",
"       17-26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A multicenter retrospective study of 73 patients with PCL included 14 patients initially treated with a regimen that contained",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/6\">",
"       6",
"      </a>",
"      ]. Of these, 10 (71 percent) demonstrated an at least partial response (four complete responses). Among patients initially treated with bortezomib,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      , or a combination of the two drugs, the median survival was 12.6 months, but among patients responding to bortezomib, approximately half were alive without relapse at 26 months from diagnosis. In this study, the choice of initial therapy did not affect survival, but the sample size does not permit adequate comparisons and no conclusions can be made.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The above reports show the safety and feasibility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    -based initial therapy. In our practice, for patients with PCL, we suggest induction therapy with a bortezomib-based regimen, such as VDT-PACE (bortezomib,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"     thalidomide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"     cisplatin",
"    </a>",
"    , adriamycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"     etoposide",
"    </a>",
"    ), VDT (bortezomib, thalidomide, dexamethasone), VRD (bortezomib,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/25/16793?source=see_link\">",
"     lenalidomide",
"    </a>",
"    , dexamethasone), or VMP (bortezomib,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"     melphalan",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    ) (",
"    <a class=\"graphic graphic_table graphicRef55107 \" href=\"UTD.htm?27/39/28286\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=see_link&amp;anchor=H9#H9\">",
"     \"Initial chemotherapy for patients with high risk multiple myeloma\", section on 'Patients who are not candidates for HCT'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This suggestion is based upon a desire to maximize the potential yet largely unknown beneficial effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    given the known poor outcome with other therapies. For patients who are candidates for transplantation, we suggest proceeding after induction therapy to high dose therapy plus HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;High dose chemotherapy followed by autologous hematopoietic cell transplantation (HCT) results in superior overall survival in patients with multiple myeloma and has become part of the standard of care for eligible patients. The role of HCT in PCL is less clear. Prospective randomized trials of HCT have not included patients with PCL. Case reports and case series have recorded some long term responses to autologous or allogeneic HCT in PCL [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/6,29-31\">",
"     6,29-31",
"    </a>",
"    ]. However, most of these data are based upon patients who were treated with non-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    -based induction regimens.",
"   </p>",
"   <p>",
"    Due to the poor prognosis with chemotherapy alone in these patients, we offer high dose chemotherapy followed by autologous stem cell rescue to eligible patients with PCL. This approach follows",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"     bortezomib",
"    </a>",
"    -based induction therapy (as discussed in the previous section). Following HCT, consideration should be given to some form of maintenance therapy to prevent relapse.",
"   </p>",
"   <p>",
"    The following is a compilation of reports on the use of HCT in PCL:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A retrospective study from the Center for International Blood and Marrow Transplant Research analyzed the outcomes of patients with PCL who underwent autologous (97 patients, median age 56 years) or allogeneic (50 patients, median age 48 years) HCT within 18 months of diagnosis between 1995 and 2006 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/31\">",
"       31",
"      </a>",
"      ]. Following autologous HCT, estimated rates of progression-free survival, relapse, non-relapse mortality, and overall survival at three years were 34, 61, 5, and 64 percent, respectively. Corresponding rates following allogeneic HCT were 20, 38, 41, and 39 percent, respectively, indicating inferior outcome with allogeneic compared with autologous transplantation in this patient population.",
"     </li>",
"     <li>",
"      A multicenter retrospective analysis of 73 patients with primary PCL included 23 patients who had undergone a single autologous HCT (nine patients), a double autologous HCT (eight patients), an allogeneic HCT (two patients) or a tandem",
"      <span class=\"nowrap\">",
"       autologous/allogeneic",
"      </span>",
"      HCT (four patients) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/6\">",
"       6",
"      </a>",
"      ]. Among patients who underwent HCT, the median overall survival and duration of response were 38 and 27 months, respectively. In this highly selected group, patients who survived initial therapy and received HCT had superior survival and response durations when compared with those who did not receive HCT.",
"     </li>",
"     <li>",
"      An observational series that included 41 patients with primary PCL reported a longer median overall survival in patients treated with multiagent intravenous chemotherapy, such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?1/29/1498?source=see_link\">",
"       vincristine",
"      </a>",
"      , adriamycin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      (VAD) when compared with patients who received",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/54/22376?source=see_link\">",
"       melphalan",
"      </a>",
"      plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"       prednisone",
"      </a>",
"      (15 versus 4 months, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/5\">",
"       5",
"      </a>",
"      ]. In this same series, 30 percent of patients treated with multiagent intravenous chemotherapy proceeded to HCT. In this setting, patients who received HCT had a longer median overall survival when compared with those who received multiagent intravenous chemotherapy alone (34 versus 11 months). Part of this survival benefit may reflect selection bias with younger patients who survived initial therapy proceeding to HCT.",
"     </li>",
"     <li>",
"      A case series of 17 patients with primary PCL treated with either autologous or allogeneic HCT reported that 4 patients (24 percent) were alive with a mean follow-up of 45 months [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/29\">",
"       29",
"      </a>",
"      ]. Of those who died, 50 percent of deaths were due to progressive disease while others died due to infectious complications or graft-versus-host disease.",
"     </li>",
"     <li>",
"      Other case reports have shown long term survival in some patients treated with autologous or allogeneic HCT [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16039/abstract/13,30,32,33\">",
"       13,30,32,33",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At present, the data above suggest that HCT may be of value in PCL, although no definite conclusions can be made due to lack of randomized data. Further, there are no data on whether allogeneic approaches offer any additional benefit compared with autologous HCT.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma cell leukemia (PCL) is a rare, yet aggressive variant of multiple myeloma characterized by high levels of plasma cells circulating in the peripheral blood. PCL can either originate de novo (primary PCL) or as a secondary leukemic transformation of multiple myeloma (secondary PCL). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Presenting signs and symptoms can include those seen in multiple myeloma (eg, renal dysfunction, hypercalcemia, lytic bone lesions, anemia) and in other leukemias (eg, anemia, thrombocytopenia, infections, hepatomegaly, splenomegaly). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical presentation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnostic evaluation of a patient with suspected plasma cell leukemia is identical to multiple myeloma and should include a review of the peripheral blood smear, bone marrow aspiration and biopsy, serum protein electrophoresis (SPEP) with immunofixation, and protein electrophoresis of an aliquot from a 24-hour urine collection (UPEP). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Pathologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The diagnosis is made when a monoclonal population of plasma cells is present in the peripheral blood typically with an absolute plasma cell count exceeding",
"      <span class=\"nowrap\">",
"       2000/microL",
"      </span>",
"      or 20 percent of the peripheral blood white cells. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H9\">",
"       'Differential diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prognosis of PCL is poor with a median survival of 7 to 11 months. Survival is even shorter (two to seven months) when PCL occurs in the context of refractory or relapsing multiple myeloma. Survival may have improved with incorporation of new agents into the treatment strategy. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There have been no prospective randomized trials investigating the treatment of PCL. Recommendations are primarily based upon data from small retrospective series, case reports, and extrapolation of data from patients with multiple myeloma. In general, patients are treated with induction therapy followed by hematopoietic cell transplantation (HCT) in those who are appropriate candidates for this approach. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The best induction regimen for plasma cell leukemia is not known and there is great variability in clinical practice. For patients with PCL we suggest induction therapy with a",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/63/11257?source=see_link\">",
"       bortezomib",
"      </a>",
"      -based regimen, such as VDT-PACE (bortezomib,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      ) (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Induction therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are candidates for transplantation, we suggest proceeding after induction therapy to high dose therapy plus autologous HCT (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Transplantation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/1\">",
"      Ramsingh G, Mehan P, Luo J, et al. Primary plasma cell leukemia: a Surveillance, Epidemiology, and End Results database analysis between 1973 and 2004. Cancer 2009; 115:5734.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/2\">",
"      Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood 2010; 116:3724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/3\">",
"      Blad&eacute; J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am 1999; 13:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/4\">",
"      Gertz MA. Managing plasma cell leukemia. Leuk Lymphoma 2007; 48:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/5\">",
"      Tiedemann RE, Gonzalez-Paz N, Kyle RA, et al. Genetic aberrations and survival in plasma cell leukemia. Leukemia 2008; 22:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/6\">",
"      Pagano L, Valentini CG, De Stefano V, et al. Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. Ann Oncol 2011; 22:1628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/7\">",
"      Craig FE, Foon KA. Flow cytometric immunophenotyping for hematologic neoplasms. Blood 2008; 111:3941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/8\">",
"      Ioannou MG, Stathakis E, Lazaris AC, et al. Immunohistochemical evaluation of 95 bone marrow reactive plasmacytoses. Pathol Oncol Res 2009; 15:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/9\">",
"      Noel P, Kyle RA. Plasma cell leukemia: an evaluation of response to therapy. Am J Med 1987; 83:1062.",
"     </a>",
"    </li>",
"    <li>",
"     Grogan TM, Van Camp B, Kyle RA. Plasma cell neoplasms. In: World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues, Jaffe ES, Harris NL, Stein H, Vardiman JW (Eds), IARC Press, Lyon 2001. p.142.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/11\">",
"      Avet-Loiseau H, Daviet A, Brigaudeau C, et al. Cytogenetic, interphase, and multicolor fluorescence in situ hybridization analyses in primary plasma cell leukemia: a study of 40 patients at diagnosis, on behalf of the Intergroupe Francophone du My&eacute;lome and the Groupe Fran&ccedil;ais de Cytog&eacute;n&eacute;tique H&eacute;matologique. Blood 2001; 97:822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/12\">",
"      Rajkumar SV. Multiple myeloma: 2012 update on diagnosis, risk-stratification, and management. Am J Hematol 2012; 87:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/13\">",
"      Garc&iacute;a-Sanz R, Orf&atilde;o A, Gonz&aacute;lez M, et al. Primary plasma cell leukemia: clinical, immunophenotypic, DNA ploidy, and cytogenetic characteristics. Blood 1999; 93:1032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/14\">",
"      Dimopoulos MA, Palumbo A, Delasalle KB, Alexanian R. Primary plasma cell leukaemia. Br J Haematol 1994; 88:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/15\">",
"      Musto P, Pietrantuono G, Guariglia R, et al. Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. Leuk Res 2008; 32:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/16\">",
"      Benson DM Jr, Smith MK. Effectiveness of lenalidomide (Revlimid) for the treatment of plasma cell leukemia. Leuk Lymphoma 2007; 48:1423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/17\">",
"      Espar&iacute;s-Ogando A, Alegre A, Aguado B, et al. Bortezomib is an efficient agent in plasma cell leukemias. Int J Cancer 2005; 114:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/18\">",
"      Jaskiewicz AD, Herrington JD, Wong L. Tumor lysis syndrome after bortezomib therapy for plasma cell leukemia. Pharmacotherapy 2005; 25:1820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/19\">",
"      Grassinger J, S&uuml;dhoff T, Andreesen R, Hennemann B. Complete remission and successful stem cell mobilization after treatment of refractory plasma cell leukemia with bortezomib. Ann Hematol 2006; 85:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/20\">",
"      Ataergin S, Arpaci F, Kaya A, et al. VAD combination chemotherapy followed by bortezomib may be an effective treatment in secondary plasma cell leukemia. Am J Hematol 2006; 81:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/21\">",
"      Finnegan DP, Kettle P, Drake M, et al. Bortezomib is effective in primary plasma cell leukemia. Leuk Lymphoma 2006; 47:1670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/22\">",
"      Ali R, Beksac M, Ozkalemkas F, et al. Efficacy of bortezomib in combination chemotherapy on secondary plasma cell leukemia. Leuk Lymphoma 2007; 48:1426.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/23\">",
"      Katodritou E, Verrou E, Gastari V, et al. Response of primary plasma cell leukemia to the combination of bortezomib and dexamethasone: do specific cytogenetic and immunophenotypic characteristics influence treatment outcome? Leuk Res 2008; 32:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/24\">",
"      Musto P, Rossini F, Gay F, et al. Efficacy and safety of bortezomib in patients with plasma cell leukemia. Cancer 2007; 109:2285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/25\">",
"      Gozzetti A, Musto P, Defina M, et al. Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia. Br J Haematol 2012; 157:497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/26\">",
"      D'Arena G, Valentini CG, Pietrantuono G, et al. Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. Ann Oncol 2012; 23:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/27\">",
"      Pineda-Roman M, Zangari M, Haessler J, et al. Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2. Br J Haematol 2008; 140:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/28\">",
"      Santamar&iacute;a CM, Chill&oacute;n MC, Garc&iacute;a-Sanz R, et al. Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia. Blood 2009; 114:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/29\">",
"      Saccaro S, Fonseca R, Veillon DM, et al. Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature. Am J Hematol 2005; 78:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/30\">",
"      Hovenga S, de Wolf JT, Klip H, Vellenga E. Consolidation therapy with autologous stem cell transplantation in plasma cell leukemia after VAD, high-dose cyclophosphamide and EDAP courses: a report of three cases and a review of the literature. Bone Marrow Transplant 1997; 20:901.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/31\">",
"      Mahindra A, Kalaycio ME, Vela-Ojeda J, et al. Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research. Leukemia 2012; 26:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/32\">",
"      Panizo C, Rif&oacute;n J, Rodr&iacute;guez-Wilhelmi P, et al. Long-term survival in primary plasma cell leukemia after therapy with VAD, autologous blood stem cell transplantation and interferon-alpha. Acta Haematol 1999; 101:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16039/abstract/33\">",
"      Nonami A, Miyamoto T, Kuroiwa M, et al. Successful treatment of primary plasma cell leukaemia by allogeneic stem cell transplantation from haploidentical sibling. Jpn J Clin Oncol 2007; 37:969.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6646 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-109.224.62.197-08224556E3-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_42_16039=[""].join("\n");
var outline_f15_42_16039=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL PRESENTATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGIC FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Peripheral blood",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Bone marrow aspiration and biopsy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Protein electrophoresis and immunofixation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      DIFFERENTIAL DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Induction therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/6646\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6646|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/3/21566\" title=\"figure 1\">",
"      Monoclonal pattern on SPEP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?4/39/4735\" title=\"figure 2\">",
"      Monoclonal pattern immunofixation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6646|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/27/19888\" title=\"picture 1\">",
"      Plasma cell",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?28/45/29393\" title=\"picture 2\">",
"      Plasma cell leukemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?33/12/33990\" title=\"picture 3\">",
"      Multiple myeloma marrow",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/6646|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/39/28286\" title=\"table 1\">",
"      VMP for multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/13/35034?source=related_link\">",
"      Clinical features, laboratory manifestations, and diagnosis of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/29/8666?source=related_link\">",
"      Determination of initial therapy in patients with multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/17/16662?source=related_link\">",
"      Diagnosis and management of solitary extramedullary plasmacytoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/31/44535?source=related_link\">",
"      Diagnosis and management of solitary plasmacytoma of bone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/52/32584?source=related_link\">",
"      Initial chemotherapy for patients with high risk multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/20/27977?source=related_link\">",
"      Pathobiology of multiple myeloma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/58/10154?source=related_link\">",
"      Recognition of monoclonal proteins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_42_16040="Pathology of breast cancer";
var content_f15_42_16040=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"14\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathology of breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/42/16040/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16040/contributors\">",
"     Ira J Bleiweiss, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/42/16040/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16040/contributors\">",
"     Anees B Chagpar, MD, MSc, MA, MPH, FACS, FRCS(C)",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/42/16040/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16040/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/42/16040/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Nov 26, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most breast malignancies arise from epithelial elements and are categorized as carcinomas. Breast carcinomas are a diverse group of lesions that differ in microscopic appearance and biologic behavior, although these disorders are often discussed as a single disease.",
"   </p>",
"   <p>",
"    The in situ carcinomas of the breast are either ductal (also known as intraductal carcinoma) or lobular. This distinction is primarily based upon the growth pattern and cytologic features of the lesions, rather than their anatomic location within the mammary ductal-lobular system.",
"   </p>",
"   <p>",
"    The invasive breast carcinomas consist of several histologic subtypes; the estimated percentages are from a contemporary population-based series of 135,157 women with breast cancer reported to the Surveillance Epidemiology and End Results (SEER) database of the National Cancer Institute between 1992 and 2001 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Infiltrating ductal - 76 percent",
"     </li>",
"     <li>",
"      Invasive lobular - 8 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Ductal/lobular",
"      </span>",
"      - 7 percent",
"     </li>",
"     <li>",
"      Mucinous (colloid) - 2.4 percent",
"     </li>",
"     <li>",
"      Tubular - 1.5 percent",
"     </li>",
"     <li>",
"      Medullary - 1.2 percent",
"     </li>",
"     <li>",
"      Papillary - 1 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other subtypes, including metaplastic breast cancer and invasive micropapillary breast cancer, all account for fewer than 5 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic will review the histology of ductal carcinoma in situ and invasive breast carcinoma. The pathologies of atypical hyperplasia, lobular carcinoma in situ, and other subtypes of breast cancer are discussed separately.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=see_link\">",
"       \"Atypia and lobular carcinoma in situ: High risk lesions of the breast\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=see_link\">",
"       \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=see_link\">",
"       \"Paget disease of the breast\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36150?source=see_link\">",
"       \"Breast lymphoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=see_link\">",
"       \"Measurement of prognostic factors in breast cancer\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1220079795\">",
"    <span class=\"h1\">",
"     DUCTAL CARCINOMA IN SITU",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term ductal carcinoma in situ (DCIS) encompasses a heterogeneous group of lesions that differ in their clinical presentation, histologic appearance, and biological potential. DCIS is characterized by proliferation of presumably malignant epithelial cells within the mammary ductal system, with no evidence of invasion into the surrounding stroma on routine light microscopic examination [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/3\">",
"     3",
"    </a>",
"    ]. Ductal carcinoma in situ differs from lobular carcinoma in situ with regard to radiologic features, morphology, biologic behavior, and anatomic distribution in the breast (",
"    <a class=\"graphic graphic_table graphicRef72750 \" href=\"UTD.htm?26/22/26987\">",
"     table 1",
"    </a>",
"    ). Lobular carcinoma in situ is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=see_link\">",
"     \"Atypia and lobular carcinoma in situ: High risk lesions of the breast\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Classification schemes that divide DCIS histologically into a variety of subtypes emphasize architectural features or growth pattern of the neoplastic cells, cytologic features, and cell necrosis, both singly and in combination. The traditional method for classifying DCIS lesions is primarily based upon the growth pattern (architectural features) of the tumor and recognizes five major types [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The comedo type is characterized by prominent necrosis in the center of the involved spaces. The necrotic material frequently becomes calcified; the calcifications may be detected mammographically, characteristically as linear, branching (\"casting\") calcifications. The tumor cells are large and show nuclear pleomorphism; mitotic activity may be prominent (",
"      <a class=\"graphic graphic_picture graphicRef77048 \" href=\"UTD.htm?12/0/12292\">",
"       picture 1",
"      </a>",
"      ). The comedo type is more often associated with invasion [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/8,9\">",
"       8,9",
"      </a>",
"      ], and the degree of comedo necrosis in patients with DCIS appears to be a strong predictor for the risk of ipsilateral breast recurrence after treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The cribriform type is characterized by the formation of back to back glands without intervening stroma. The cells comprising this subtype are typically small to medium sized and have relatively uniform hyperchromatic nuclei. Mitoses are infrequent and necrosis is limited to single cells or small cell clusters (",
"      <a class=\"graphic graphic_picture graphicRef71553 \" href=\"UTD.htm?16/15/16629\">",
"       picture 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The micropapillary type features small tufts of cells that are oriented perpendicular to the basement membrane of the involved spaces and project into the lumina. The apical region of these small papillations is frequently broader than the base, imparting a club-shaped appearance. The micropapillae lack fibrovascular cores. The cells comprising this type of DCIS are usually small to medium in size, and the nuclei show diffuse hyperchromasia; mitoses are infrequent (",
"      <a class=\"graphic graphic_picture graphicRef58302 \" href=\"UTD.htm?25/18/25893\">",
"       picture 3",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The papillary type shows intraluminal projections of tumor cells that, in contrast to the micropapillary variant, demonstrate fibrovascular cores and thereby constitute true papillations. A variant of papillary DCIS, intracystic papillary carcinoma, is characterized by tumor cells that are primarily or exclusively present in a single cystically dilated space [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/11,12\">",
"       11,12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The solid type is not as well defined as the other subtypes. It features tumor cells that fill and distend the involved spaces and lack significant necrosis, fenestrations, or papillations. The tumor cells may be large, medium, or small.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Less common variants of DCIS include the \"clinging\" carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/4,13\">",
"     4,13",
"    </a>",
"    ], intraductal signet ring cell carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/14\">",
"     14",
"    </a>",
"    ], and cystic hypersecretory duct carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Similar to the comedo type, these variants may show calcifications that can be detected mammographically. However, the mammographic appearance of these microcalcifications is less distinctive than the pattern seen in comedo lesions and can resemble a number of benign processes.",
"   </p>",
"   <p>",
"    A number of authors have proposed alternative classification systems for DCIS (",
"    <a class=\"graphic graphic_table graphicRef67963 \" href=\"UTD.htm?10/53/11099\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. Although they use different terminology, all are primarily based upon nuclear grade",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence or absence of necrosis, and have in common the recognition of three main categories of DCIS (eg, high, intermediate, and low grade).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      High-grade lesions typically exhibit aneuploidy, lack estrogen and progesterone receptors, and have a high proliferative rate, overexpression of the HER2 oncogene, mutations of the p53 tumor suppressor gene with accumulation of its protein product, and angiogenesis in the surrounding stroma.",
"     </li>",
"     <li>",
"      Low-grade lesions are typically diploid, estrogen- and progesterone receptor-positive, have a low proliferative rate, and rarely (if ever) show abnormalities of the",
"      <span class=\"nowrap\">",
"       HER2/neu",
"      </span>",
"      or p53 oncogenes.",
"     </li>",
"     <li>",
"      Lesions categorized histologically as intermediate grade are also intermediate between the high-grade and low-grade lesions with regard to the frequency of alterations in these biological markers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These classification systems appear to correlate with biological prognostic markers and predict groups of patients who are likely to have a recurrence of cancer following breast conservation therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/17,20-32\">",
"     17,20-32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=see_link\">",
"     \"Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In 1997, a consensus conference was convened in an attempt to reach agreement on the classification of DCIS [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/33\">",
"     33",
"    </a>",
"    ]. Although the panel did not endorse any single classification system, they recommended that certain features be routinely documented in the pathology report for DCIS lesions, including nuclear grade, the presence of necrosis, cell polarization, and architectural pattern(s).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INFILTRATING DUCTAL CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infiltrating ductal carcinoma is the most common type of invasive breast cancer, accounting for 70 to 80 percent of invasive lesions. It is also termed infiltrating carcinoma of no special type or infiltrating carcinoma not otherwise specified (NOS).",
"   </p>",
"   <p>",
"    On gross pathologic evaluation, these lesions are typically hard, gray-white, gritty masses which invade the surrounding tissue in a haphazard fashion to create the characteristic irregular, stellate shape. They are characterized microscopically by cords and nests of tumor cells with varying amounts of gland formation, and cytologic features that range from bland to highly malignant. The malignant cells induce a fibrous response as they infiltrate the breast parenchyma, and this reaction is, in large part, responsible for the clinically and grossly palpable mass, the radiologic density, and solid sonographic characteristics of typical invasive carcinomas.",
"   </p>",
"   <p>",
"    Infiltrating ductal carcinomas are divided into three grades based upon a combination of architectural and cytologic features, usually assessed utilizing a scoring system based on three parameters [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/34\">",
"     34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Well-differentiated (grade 1) - Well-differentiated tumors have cells that infiltrate the stroma as solid nests of glands. The nuclei are relatively uniform with little or no evidence of mitotic activity (",
"      <a class=\"graphic graphic_picture graphicRef76328 \" href=\"UTD.htm?35/9/35991\">",
"       picture 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Moderately differentiated (grade 2) - Moderately differentiated tumors have cells that infiltrate as solid nests with some glandular differentiation. There is some nuclear pleomorphism and a moderate mitotic rate (",
"      <a class=\"graphic graphic_picture graphicRef55284 \" href=\"UTD.htm?14/18/14632\">",
"       picture 5",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Poorly differentiated (grade 3) - Poorly differentiated tumors are composed of solid nests of neoplastic cells without evidence of gland formation. There is marked nuclear atypia and considerable mitotic activity (",
"      <a class=\"graphic graphic_picture graphicRef67082 \" href=\"UTD.htm?18/49/19224\">",
"       picture 6",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A variable amount of associated ductal carcinoma in situ (DCIS) is present in most cases; the extent of DCIS but not lobular carcinoma in situ (LCIS) is an important prognostic factor in patients treated with breast conserving therapy in whom the surgical goal is complete excision of both intraductal and invasive carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INFILTRATING LOBULAR CARCINOMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infiltrating lobular carcinomas are the second most common type of invasive breast cancer, accounting for about 5 to 10 percent of invasive lesions.",
"   </p>",
"   <p>",
"    Incidence rates of lobular cancer are rising faster than the rates of ductal carcinoma in the United States, and postmenopausal hormone therapy may be more strongly related to lobular cancer risk than to ductal cancer risk. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=see_link&amp;anchor=H150020086#H150020086\">",
"     \"Postmenopausal hormone therapy and the risk of breast cancer\", section on 'Prognosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=see_link\">",
"     \"Factors that modify breast cancer risk in women\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Some infiltrating lobular carcinomas have a macroscopic appearance identical to that of infiltrating ductal cancers. However, in many cases no mass lesion is grossly evident, and the excised breast tissue may have a normal or only slightly firm consistency. Thus, the microscopic size of invasive lobular carcinoma may be significantly greater than that measured grossly. Some pathologists have used lack of immunohistochemical staining for E-cadherin to distinguish invasive lobular carcinoma from invasive duct carcinoma. While it appears to be a reasonably accurate test, it is for the most part unnecessary in practice.",
"   </p>",
"   <p>",
"    These tumors are characterized microscopically by small cells that insidiously infiltrate the mammary stroma and adipose tissue individually and in a single file pattern, often growing in a target-like configuration around normal breast ducts, frequently inducing only minimal fibrous reaction (",
"    <a class=\"graphic graphic_picture graphicRef54150 \" href=\"UTD.htm?39/54/40806\">",
"     picture 7",
"    </a>",
"    ). Associated lobular carcinoma in situ (LCIS) is present in approximately two-thirds of cases; however, DCIS may also accompany invasive lobular carcinoma.",
"   </p>",
"   <p>",
"    In addition to their different histologic appearance and mammographic characteristics, there are distinct prognostic and biologic differences between infiltrating lobular and ductal cancers:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infiltrating lobular carcinomas have a higher frequency of bilaterality and multicentricity than infiltrating ductal carcinomas [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/36,37\">",
"       36,37",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Infiltrating lobular carcinomas arise in older women and are larger and better differentiated tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/36,38\">",
"       36,38",
"      </a>",
"      ]. As a rule, invasive lobular carcinomas are ER-positive, with variant lesions showing occasional variable expression.",
"     </li>",
"     <li>",
"      While older series report a similar prognosis for infiltrating lobular cancers and invasive ductal lesions, more recent reports suggest that outcomes (at least in the short-term) may be more favorable for lobular cancers and improving over time [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. However, variants of infiltrating lobular carcinoma exist, some of which have a poorer prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/36\">",
"       36",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As a group, invasive lobular carcinomas tend to metastasize later than invasive duct carcinomas and spread to unusual locations such as peritoneum, meninges, and the gastrointestinal tract [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There is an association between mutations in the cadherin (CDH1) gene and invasive lobular breast cancers. Lobular breast cancers have been observed to occur in 20 to 54 percent of women from families with hereditary diffuse gastric cancer who carry germline mutations in the CDH1 gene. However, germline CDH1 mutations can also be cosegregated with invasive lobular breast cancer in the absence of diffuse gastric cancer, suggesting that gastric cancer is not an obligatory hallmark of families with CDH1 mutations. Furthermore, approximately 50 percent of sporadic lobular breast cancers contain E-cadherin mutations [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/42,43\">",
"     42,43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2296?source=see_link&amp;anchor=H4#H4\">",
"     \"Hereditary diffuse gastric cancer\", section on 'Risk of other cancers'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=see_link&amp;anchor=H69480723#H69480723\">",
"     \"Characteristics of hereditary breast and ovarian cancer syndromes\", section on 'Inherited CDH1 mutations and hereditary diffuse gastric cancer syndrome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     OTHER HISTOLOGIC TYPES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of other histologic types account for the remaining invasive breast cancers. These include tubular carcinoma, mucinous carcinoma, medullary carcinoma, invasive micropapillary carcinoma, metaplastic carcinoma, adenoid cystic carcinoma, and others. Tumors of other histologies arising in the breast (lymphomas, sarcomas, phyllodes tumors) are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=see_link\">",
"     \"Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36150?source=see_link\">",
"     \"Breast lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Special clinical presentations of breast carcinomas, including Paget disease and inflammatory carcinoma, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=see_link\">",
"     \"Paget disease of the breast\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10103?source=see_link\">",
"     \"Inflammatory breast cancer: Pathology and molecular pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1642913985\">",
"    <span class=\"h2\">",
"     Tubular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubular carcinomas were relatively infrequent in the pre-mammography era, accounting for 2 percent or less of invasive breast cancers. However, in some series of mammographically screened populations the incidence is higher, accounting for 10 to 20 percent of invasive cancers.",
"   </p>",
"   <p>",
"    Tubular carcinoma is characterized by the presence of well-formed tubular or glandular structures infiltrating the stroma (",
"    <a class=\"graphic graphic_picture graphicRef50273 \" href=\"UTD.htm?8/44/8905\">",
"     picture 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The tubules tend to be elongated, and many have pointed ends",
"     </li>",
"     <li>",
"      The cells composing the tubules are cuboidal to columnar and often have apical cytoplasmic protrusions or \"snouts\"",
"     </li>",
"     <li>",
"      The tumor cells are cytologically low grade",
"     </li>",
"     <li>",
"      Associated DCIS, typically of the low-grade type, is present in about three-quarters of the cases",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These lesions have a relatively favorable prognosis compared with infiltrating ductal carcinomas; the natural history is favorable, and metastases are rare [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/1,39,44-46\">",
"     1,39,44-46",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1642913992\">",
"    <span class=\"h2\">",
"     Mucinous (colloid) carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mucinous carcinomas account for between 1 and 2 percent of invasive breast cancers and appear to be more common in older patients. These lesions usually have a soft gelatinous appearance on gross examination, and they tend to be well circumscribed. Mucinous carcinomas are characterized microscopically by nests of tumor cells dispersed in large pools of extracellular mucus; the cells tend to have uniform, low grade nuclei (",
"    <a class=\"graphic graphic_picture graphicRef79319 \" href=\"UTD.htm?7/51/7989\">",
"     picture 9",
"    </a>",
"    ). Similar to tubular carcinomas, these lesions also represent a prognostically favorable variant of invasive breast carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/1,39,45,47\">",
"     1,39,45,47",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1642913999\">",
"    <span class=\"h2\">",
"     Medullary carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Medullary carcinomas account for anywhere from 1 to 10 percent of invasive breast cancers. However, there is considerable interobserver variability in the diagnosis of this type of breast cancer which is, at least in part, dependent upon the classification system employed [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/48-50\">",
"     48-50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Medullary carcinomas are well circumscribed on macroscopic examination and are often soft and tan-brown with areas of hemorrhage or necrosis. Circumscription of the lesion is also evident microscopically. The tumor cells are poorly differentiated (high-grade), grow in a syncytial pattern, and have an intense associated lymphoplasmacytic infiltrate (",
"    <a class=\"graphic graphic_picture graphicRef59804 \" href=\"UTD.htm?19/23/19833\">",
"     picture 10",
"    </a>",
"    ), and this tumor is actually quite rare when strict diagnostic criteria are followed.",
"   </p>",
"   <p>",
"    Medullary and medullary-like carcinomas occur more frequently in younger patients than other types of breast cancer. They are also more frequent in women who inherit mutations of the BRCA-1 gene (10 percent of breast cancers are medullary in this population, as compared with &lt;1 percent of non-BRCA1-related breast cancers). However, the majority of breast cancers in patients with BRCA-1 gene mutations (90 percent) are not medullary [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/51\">",
"     51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis for pure medullary carcinomas appears to be somewhat more favorable than that of infiltrating ductal carcinomas, despite their aggressive histologic appearance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/1,39,45,52,53\">",
"     1,39,45,52,53",
"    </a>",
"    ]. For example, in a retrospective review of 12,409 patients with breast cancer, patients with medullary cancer (n = 127) had a significantly higher overall 14-year disease-free survival rate compared with patients with invasive ductal cancer (n = 8096) (76 versus 64 percent, hazard ratio [HR] 0.52, p = 0.0005) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/53\">",
"     53",
"    </a>",
"    ]. In addition, patients with medullary cancer also had a significantly higher overall survival rate (66 versus 57 percent, HR 0.75, p = 0.03).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16851103\">",
"    <span class=\"h2\">",
"     Tubulolobular carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tubulolobular carcinoma is an often unrecognized breast cancer variant that, as the name implies, has hybrid histologic characteristics of tubular and invasive lobular carcinoma with the same cells comprising well-formed glands contiguous with single file infiltration of stroma. While immunohistochemical studies imply a ductal phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/54\">",
"     54",
"    </a>",
"    ], from a radiologic and clinical point of view, the tumor is more akin to invasive lobular carcinoma in that its imaging characteristics are identical to lobular breast cancer, and there is the same tendency to multifocality and multicentricity. In terms of staging, however, the tumors behave more like invasive moderately differentiated ductal carcinoma in that they have the same likelihood of nodal metastases when matched by size. Often these tumors are misclassified as invasive carcinoma with mixed ductal and lobular features.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Micropapillary carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Invasive micropapillary carcinoma is a particularly aggressive form of cancer that has a proclivity for lymph node metastasis even when small in size [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Metaplastic carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metaplastic carcinoma is a well circumscribed tumor that consists of various combinations of poorly differentiated ductal adenocarcinoma, mesenchymal (sarcomatous), and other epithelial (eg, squamous cell) components [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Whether these tumors have a worse prognosis than ordinary invasive ductal cancers is unclear. Some studies suggest that tumors in which the squamous cell component predominates (more than 90 percent of the malignant cells are of squamous type) are more aggressive and frequently treatment-refractory when compared with other infiltrating ductal cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/58,59\">",
"     58,59",
"    </a>",
"    ]. However, because metaplastic breast cancer was not officially recognized as a distinct pathologic diagnosis until 2000, knowledge about treatment patterns and outcomes is limited.",
"   </p>",
"   <p>",
"    The characteristics of 892 metaplastic breast cancers reported to the National Cancer Database between 2001 and 2003 were compared with those of 255,164 typical infiltrating ductal carcinomas [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/57\">",
"     57",
"    </a>",
"    ]. In contrast to patients with infiltrating ductal cancers, the following significant differences were noted in the group with metaplastic tumors:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fewer T1 tumors (30 versus 65 percent)",
"     </li>",
"     <li>",
"      More node-negative tumors (78 versus 66 percent)",
"     </li>",
"     <li>",
"      More poorly-differentiated or undifferentiated tumor (68 versus 39 percent)",
"     </li>",
"     <li>",
"      Fewer estrogen receptor-positive tumors (11 versus 74 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Treatment outcomes were not reported. Despite the perception of a worse prognosis, all metaplastic breast cancers are treated similarly to other invasive breast cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/60-62\">",
"     60-62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Adenoid cystic carcinoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rare adenoid cystic carcinoma of the breast has a distinctive histologic pattern that is morphologically identical to adenoid cystic carcinoma found in the salivary glands (and other sites). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=see_link\">",
"     \"Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging\"",
"    </a>",
"    .) This tumor tends to be associated with a favorable prognosis, even when tumor size is large; the reported incidence of axillary metastases in most series is less than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/63,64\">",
"     63,64",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Histologic grading based upon the percentage of solid areas (as is used for salivary gland tumors) has been suggested as being prognostically useful [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/65\">",
"     65",
"    </a>",
"    ], although others disagree [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/64\">",
"     64",
"    </a>",
"    ]. At least two series in which outcomes were not as favorable as in most reports were predominated by patients with higher-grade tumors (ie, the solid variant) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16040/abstract/66,67\">",
"     66,67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      DCIS is characterized by a proliferation of abnormal cells confined within the mammary ductal system. (See",
"      <a class=\"local\" href=\"#H1220079795\">",
"       'Ductal carcinoma in situ'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      DCIS is commonly classified according to architectural and cytologic features and cell necrosis as low and intermediate grade (papillary, cribriform, and solid) and high grade (comedo).",
"     </li>",
"     <li>",
"      DCIS represents a precursor to invasive breast cancer.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The invasive breast carcinomas consist of several histologic subtypes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Infiltrating ductal carcinoma is the most common type of invasive breast cancer, accounting for 70 to 80 percent of invasive cancers. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Infiltrating ductal carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Infiltrating lobular carcinoma is the second most common invasive breast cancer, accounting for 5 to 10 percent of invasive cancers. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Infiltrating lobular carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      As compared with infiltrating ductal carcinomas, infiltrating lobular carcinomas tend to be multicentric",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      bilateral, more differentiated, hormone-receptor positive, arise in older women, metastasize later, and spread to unusual locations, such as meninges, peritoneum, or gastrointestinal tract. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Infiltrating lobular carcinoma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Other less common invasive breast carcinoma histologies include tubular, mucinous, and medullary carcinomas. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Other histologic types'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/1\">",
"      Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer 2005; 93:1046.",
"     </a>",
"    </li>",
"    <li>",
"     Schnitt SJ, Guidi AJ. Pathology of invasive breast cancer. In: Diseases of the Breast, 3rd, Harris JR, Lippman ME, Morrow M, Osborne CK (Eds), Lippincott, Williams and Wilkins, Philadelphia 2004. p.393.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/3\">",
"      Allred DC. Ductal carcinoma in situ: terminology, classification, and natural history. J Natl Cancer Inst Monogr 2010; 2010:134.",
"     </a>",
"    </li>",
"    <li>",
"     Azzopardi JG. Problems in Breast Pathology, WB Saunders, Philadelphia 1963. p.244.",
"    </li>",
"    <li>",
"     Page DL, Anderson TJ. Diagnostic Histopathology of the Breast, Churchill Livingstone, Edinburgh 1987. p.157.",
"    </li>",
"    <li>",
"     Rosen PP, Oberman H. Tumors of the Mammary Gland, Armed Forces Institute of Pathology, Washington, DC 1993. p.143.",
"    </li>",
"    <li>",
"     Morrow M, Schnitt SJ, Harris JR. Ductal carcinoma in situ. In: Diseases of the Breast, Harris JR, Lippman ME, Morrow M, Hellman S (Eds), Lippincott-Raven, Philadelphia 1995. p.355.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/8\">",
"      Schwartz GF, Patchefsky AS, Finklestein SD, et al. Nonpalpable in situ ductal carcinoma of the breast. Predictors of multicentricity and microinvasion and implications for treatment. Arch Surg 1989; 124:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/9\">",
"      Silverstein MJ, Waisman JR, Gamagami P, et al. Intraductal carcinoma of the breast (208 cases). Clinical factors influencing treatment choice. Cancer 1990; 66:102.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/10\">",
"      Fisher ER, Dignam J, Tan-Chiu E, et al. Pathologic findings from the National Surgical Adjuvant Breast Project (NSABP) eight-year update of Protocol B-17: intraductal carcinoma. Cancer 1999; 86:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/11\">",
"      Grabowski J, Salzstein SL, Sadler GR, Blair S. Intracystic papillary carcinoma: a review of 917 cases. Cancer 2008; 113:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/12\">",
"      Lefkowitz M, Lefkowitz W, Wargotz ES. Intraductal (intracystic) papillary carcinoma of the breast and its variants: a clinicopathological study of 77 cases. Hum Pathol 1994; 25:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/13\">",
"      Eusebi V, Foschini MP, Cook MG, et al. Long-term follow-up of in situ carcinoma of the breast with special emphasis on clinging carcinoma. Semin Diagn Pathol 1989; 6:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/14\">",
"      Fisher ER, Brown R. Intraductal signet ring carcinoma. A hitherto undescribed form of intraductal carcinoma of the breast. Cancer 1985; 55:2533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/15\">",
"      Rosen PP, Scott M. Cystic hypersecretory duct carcinoma of the breast. Am J Surg Pathol 1984; 8:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/16\">",
"      Guerry P, Erlandson RA, Rosen PP. Cystic hypersecretory hyperplasia and cystic hypersecretory duct carcinoma of the breast. Pathology, therapy, and follow-up of 39 patients. Cancer 1988; 61:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/17\">",
"      Lagios MD, Margolin FR, Westdahl PR, Rose MR. Mammographically detected duct carcinoma in situ. Frequency of local recurrence following tylectomy and prognostic effect of nuclear grade on local recurrence. Cancer 1989; 63:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/18\">",
"      Poller DN, Silverstein MJ, Galea M, et al. Ideas in pathology. Ductal carcinoma in situ of the breast: a proposal for a new simplified histological classification association between cellular proliferation and c-erbB-2 protein expression. Mod Pathol 1994; 7:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/19\">",
"      Holland R, Peterse JL, Millis RR, et al. Ductal carcinoma in situ: a proposal for a new classification. Semin Diagn Pathol 1994; 11:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/20\">",
"      Silverstein MJ, Poller DN, Waisman JR, et al. Prognostic classification of breast ductal carcinoma-in-situ. Lancet 1995; 345:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/21\">",
"      Bur ME, Zimarowski MJ, Schnitt SJ, et al. Estrogen receptor immunohistochemistry in carcinoma in situ of the breast. Cancer 1992; 69:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/22\">",
"      Meyer JS. Cell kinetics of histologic variants of in situ breast carcinoma. Breast Cancer Res Treat 1986; 7:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/23\">",
"      Killeen JL, Namiki H. DNA analysis of ductal carcinoma in situ of the breast. A comparison with histologic features. Cancer 1991; 68:2602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/24\">",
"      van de Vijver MJ, Peterse JL, Mooi WJ, et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988; 319:1239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/25\">",
"      Bartkova J, Barnes DM, Millis RR, Gullick WJ. Immunohistochemical demonstration of c-erbB-2 protein in mammary ductal carcinoma in situ. Hum Pathol 1990; 21:1164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/26\">",
"      Lodato RF, Maguire HC Jr, Greene MI, et al. Immunohistochemical evaluation of c-erbB-2 oncogene expression in ductal carcinoma in situ and atypical ductal hyperplasia of the breast. Mod Pathol 1990; 3:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/27\">",
"      Poller DN, Roberts EC, Bell JA, et al. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Hum Pathol 1993; 24:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/28\">",
"      O'Malley FP, Vnencak-Jones CL, Dupont WD, et al. p53 mutations are confined to the comedo type ductal carcinoma in situ of the breast. Immunohistochemical and sequencing data. Lab Invest 1994; 71:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/29\">",
"      Guidi AJ, Fischer L, Harris JR, Schnitt SJ. Microvessel density and distribution in ductal carcinoma in situ of the breast. J Natl Cancer Inst 1994; 86:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/30\">",
"      Bobrow LG, Happerfield LC, Gregory WM, et al. The classification of ductal carcinoma in situ and its association with biological markers. Semin Diagn Pathol 1994; 11:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/31\">",
"      Zafrani B, Leroyer A, Fourquet A, et al. Mammographically-detected ductal in situ carcinoma of the breast analyzed with a new classification. A study of 127 cases: correlation with estrogen and progesterone receptors, p53 and c-erbB-2 proteins, and proliferative activity. Semin Diagn Pathol 1994; 11:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/32\">",
"      W&auml;rnberg F, Nordgren H, Bergh J, Holmberg L. Ductal carcinoma in situ of the breast from a population-defined cohort: an evaluation of new histopathological classification systems. Eur J Cancer 1999; 35:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/33\">",
"      Consensus Conference on the classification of ductal carcinoma in situ. The Consensus Conference Committee. Cancer 1997; 80:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/34\">",
"      Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19:403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/35\">",
"      Abner AL, Connolly JL, Recht A, et al. The relation between the presence and extent of lobular carcinoma in situ and the risk of local recurrence for patients with infiltrating carcinoma of the breast treated with conservative surgery and radiation therapy. Cancer 2000; 88:1072.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/36\">",
"      Orvieto E, Maiorano E, Bottiglieri L, et al. Clinicopathologic characteristics of invasive lobular carcinoma of the breast: results of an analysis of 530 cases from a single institution. Cancer 2008; 113:1511.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/37\">",
"      Winchester DJ, Chang HR, Graves TA, et al. A comparative analysis of lobular and ductal carcinoma of the breast: presentation, treatment, and outcomes. J Am Coll Surg 1998; 186:416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/38\">",
"      Pestalozzi BC, Zahrieh D, Mallon E, et al. Distinct clinical and prognostic features of infiltrating lobular carcinoma of the breast: combined results of 15 International Breast Cancer Study Group clinical trials. J Clin Oncol 2008; 26:3006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/39\">",
"      Li CI, Moe RE, Daling JR. Risk of mortality by histologic type of breast cancer among women aged 50 to 79 years. Arch Intern Med 2003; 163:2149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/40\">",
"      Cristofanilli M, Gonzalez-Angulo A, Sneige N, et al. Invasive lobular carcinoma classic type: response to primary chemotherapy and survival outcomes. J Clin Oncol 2005; 23:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/41\">",
"      Ferlicot S, Vincent-Salomon A, M&eacute;dioni J, et al. Wide metastatic spreading in infiltrating lobular carcinoma of the breast. Eur J Cancer 2004; 40:336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/42\">",
"      Berx G, Cleton-Jansen AM, Strumane K, et al. E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. Oncogene 1996; 13:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/43\">",
"      De Leeuw WJ, Berx G, Vos CB, et al. Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. J Pathol 1997; 183:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/44\">",
"      Liu GF, Yang Q, Haffty BG, Moran MS. Clinical-pathologic features and long-term outcomes of tubular carcinoma of the breast compared with invasive ductal carcinoma treated with breast conservation therapy. Int J Radiat Oncol Biol Phys 2009; 75:1304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/45\">",
"      Thurman SA, Schnitt SJ, Connolly JL, et al. Outcome after breast-conserving therapy for patients with stage I or II mucinous, medullary, or tubular breast carcinoma. Int J Radiat Oncol Biol Phys 2004; 59:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/46\">",
"      Sullivan T, Raad RA, Goldberg S, et al. Tubular carcinoma of the breast: a retrospective analysis and review of the literature. Breast Cancer Res Treat 2005; 93:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/47\">",
"      Di Saverio S, Gutierrez J, Avisar E. A retrospective review with long term follow up of 11,400 cases of pure mucinous breast carcinoma. Breast Cancer Res Treat 2008; 111:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/48\">",
"      Gaffey MJ, Mills SE, Frierson HF Jr, et al. Medullary carcinoma of the breast: interobserver variability in histopathologic diagnosis. Mod Pathol 1995; 8:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/49\">",
"      Ridolfi RL, Rosen PP, Port A, et al. Medullary carcinoma of the breast: a clinicopathologic study with 10 year follow-up. Cancer 1977; 40:1365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/50\">",
"      Wargotz ES, Silverberg SG. Medullary carcinoma of the breast: a clinicopathologic study with appraisal of current diagnostic criteria. Hum Pathol 1988; 19:1340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/51\">",
"      Armes JE, Venter DJ. The pathology of inherited breast cancer. Pathology 2002; 34:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/52\">",
"      Vu-Nishino H, Tavassoli FA, Ahrens WA, Haffty BG. Clinicopathologic features and long-term outcome of patients with medullary breast carcinoma managed with breast-conserving therapy (BCT). Int J Radiat Oncol Biol Phys 2005; 62:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/53\">",
"      Huober J, Gelber S, Goldhirsch A, et al. Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials. Ann Oncol 2012; 23:2843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/54\">",
"      Esposito NN, Chivukula M, Dabbs DJ. The ductal phenotypic expression of the E-cadherin/catenin complex in tubulolobular carcinoma of the breast: an immunohistochemical and clinicopathologic study. Mod Pathol 2007; 20:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/55\">",
"      Walsh MM, Bleiweiss IJ. Invasive micropapillary carcinoma of the breast: eighty cases of an underrecognized entity. Hum Pathol 2001; 32:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/56\">",
"      Tavassoli FA. Classification of metaplastic carcinomas of the breast. Pathol Annu 1992; 27 Pt 2:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/57\">",
"      Pezzi CM, Patel-Parekh L, Cole K, et al. Characteristics and treatment of metaplastic breast cancer: analysis of 892 cases from the National Cancer Data Base. Ann Surg Oncol 2007; 14:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/58\">",
"      Hennessy BT, Krishnamurthy S, Giordano S, et al. Squamous cell carcinoma of the breast. J Clin Oncol 2005; 23:7827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/59\">",
"      Behranwala KA, Nasiri N, Abdullah N, et al. Squamous cell carcinoma of the breast: clinico-pathologic implications and outcome. Eur J Surg Oncol 2003; 29:386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/60\">",
"      Dave G, Cosmatos H, Do T, et al. Metaplastic carcinoma of the breast: a retrospective review. Int J Radiat Oncol Biol Phys 2006; 64:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/61\">",
"      Rayson D, Adjei AA, Suman VJ, et al. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann Oncol 1999; 10:413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/62\">",
"      Chao TC, Wang CS, Chen SC, Chen MF. Metaplastic carcinomas of the breast. J Surg Oncol 1999; 71:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/63\">",
"      Arpino G, Clark GM, Mohsin S, et al. Adenoid cystic carcinoma of the breast: molecular markers, treatment, and clinical outcome. Cancer 2002; 94:2119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/64\">",
"      Kleer CG, Oberman HA. Adenoid cystic carcinoma of the breast: value of histologic grading and proliferative activity. Am J Surg Pathol 1998; 22:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/65\">",
"      Ro JY, Silva EG, Gallager HS. Adenoid cystic carcinoma of the breast. Hum Pathol 1987; 18:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/66\">",
"      Millar BA, Kerba M, Youngson B, et al. The potential role of breast conservation surgery and adjuvant breast radiation for adenoid cystic carcinoma of the breast. Breast Cancer Res Treat 2004; 87:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16040/abstract/67\">",
"      Shin SJ, Rosen PP. Solid variant of mammary adenoid cystic carcinoma with basaloid features: a study of nine cases. Am J Surg Pathol 2002; 26:413.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 783 Version 8.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_42_16040=[""].join("\n");
var outline_f15_42_16040=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1220079795\">",
"      DUCTAL CARCINOMA IN SITU",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INFILTRATING DUCTAL CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INFILTRATING LOBULAR CARCINOMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      OTHER HISTOLOGIC TYPES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1642913985\">",
"      Tubular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1642913992\">",
"      Mucinous (colloid) carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1642913999\">",
"      Medullary carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16851103\">",
"      Tubulolobular carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Micropapillary carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Metaplastic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Adenoid cystic carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/783\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/783|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?12/0/12292\" title=\"picture 1\">",
"      Comedo ductal carcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?16/15/16629\" title=\"picture 2\">",
"      Cribriform ductal carcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?25/18/25893\" title=\"picture 3\">",
"      Micropapillary ductal carcinoma in situ",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?35/9/35991\" title=\"picture 4\">",
"      Grade I infiltrating ductal carcinoma of the breast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/18/14632\" title=\"picture 5\">",
"      Grade II infiltrating carcinoma of the breast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?18/49/19224\" title=\"picture 6\">",
"      Grade III infiltrating ductal carcinoma of the breast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?39/54/40806\" title=\"picture 7\">",
"      Infiltrating lobular carcinoma of the breast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/44/8905\" title=\"picture 8\">",
"      Tubular carcinoma of the breast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/51/7989\" title=\"picture 9\">",
"      Mucinous carcinoma of the breast",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/23/19833\" title=\"picture 10\">",
"      Medullary carcinoma of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/783|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/22/26987\" title=\"table 1\">",
"      DCIS versus LCIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/53/11099\" title=\"table 2\">",
"      Classification of DCIS",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/14/44265?source=related_link\">",
"      Atypia and lobular carcinoma in situ: High risk lesions of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/33/6680?source=related_link\">",
"      Breast ductal carcinoma in situ: Epidemiology, clinical manifestations, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/19/36150?source=related_link\">",
"      Breast lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/3/28729?source=related_link\">",
"      Breast sarcoma: Epidemiology, risk factors, clinical presentation, diagnosis, and staging",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44025?source=related_link\">",
"      Characteristics of hereditary breast and ovarian cancer syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/17/28954?source=related_link\">",
"      Factors that modify breast cancer risk in women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/15/2296?source=related_link\">",
"      Hereditary diffuse gastric cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/55/10103?source=related_link\">",
"      Inflammatory breast cancer: Pathology and molecular pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/28/43465?source=related_link\">",
"      Measurement of prognostic factors in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/0/14?source=related_link\">",
"      Paget disease of the breast",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/11/11449?source=related_link\">",
"      Postmenopausal hormone therapy and the risk of breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9927?source=related_link\">",
"      Salivary gland tumors: Epidemiology, diagnosis, evaluation, and staging",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_42_16041="Treatment of hypercalcemia";
var content_f15_42_16041=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment of hypercalcemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/42/16041/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16041/contributors\">",
"     Elizabeth Shane, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16041/contributors\">",
"     James R Berenson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/42/16041/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16041/contributors\">",
"     Clifford J Rosen, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/42/16041/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16041/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/42/16041/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment for hypercalcemia should be aimed both at lowering the serum calcium concentration and, if possible, treating the underlying disease. Effective treatments reduce serum calcium by inhibiting bone resorption, increasing urinary calcium excretion, or decreasing intestinal calcium absorption (",
"    <a class=\"graphic graphic_table graphicRef73030 \" href=\"UTD.htm?30/29/31196\">",
"     table 1",
"    </a>",
"    ). The optimal choice varies with the cause and severity of hypercalcemia.",
"   </p>",
"   <p>",
"    The treatment of hypercalcemia will be reviewed here, with emphasis on the management of hypercalcemia in patients with malignant disease. The modalities described below apply in varying degrees to patients with other causes of hypercalcemia. The clinical manifestations, etiology, and diagnostic approach to hypercalcemia are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=see_link\">",
"     \"Etiology of hypercalcemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=see_link\">",
"     \"Diagnostic approach to hypercalcemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INTERPRETATION OF SERUM CALCIUM",
"    </span>",
"    &nbsp;&mdash;&nbsp;Calcium in serum is bound to proteins, principally albumin. As a result, total serum calcium concentrations in patients with low or high serum albumin levels may not accurately reflect the physiologically important ionized (or free) calcium concentration. As an example, in patients with hypoalbuminemia, total serum calcium concentration may be normal when serum ionized calcium is elevated.",
"   </p>",
"   <p>",
"    Alternatively, patients with hyperalbuminemia due to severe volume depletion and rare patients with multiple myeloma, who have a calcium-binding paraprotein, have increased protein binding of calcium. This can cause an elevation in the serum total calcium concentration without any rise in the serum ionized calcium concentration. This phenomenon is called pseudohypercalcemia (or factitious hypercalcemia), since the patient has a normal ionized serum calcium concentration.",
"   </p>",
"   <p>",
"    In patients with hypoalbuminemia or hyperalbuminemia, the measured serum calcium concentration should be corrected for the abnormality in albumin (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?17/35/17969?source=see_link\">",
"     calculator 1",
"    </a>",
"    ) or for standard units (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?14/51/15153?source=see_link\">",
"     calculator 2",
"    </a>",
"    ). If a laboratory known to measure ionized calcium reliably is available, some authorities prefer to measure the serum ionized calcium in this situation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23685?source=see_link\">",
"     \"Relation between total and ionized serum calcium concentration\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     INDICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypercalcemia may be associated with a spectrum of clinical manifestations, ranging from few or no symptoms in patients with mild chronic hypercalcemia to severe obtundation and coma. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=see_link\">",
"     \"Clinical manifestations of hypercalcemia\"",
"    </a>",
"    .) The degree of hypercalcemia, along with the rate of rise of serum calcium concentration, often determines symptoms and the urgency of therapy. The therapeutic approach should reflect these differences [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with asymptomatic or mildly symptomatic (eg, constipation) hypercalcemia (calcium &lt;12",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    do not require immediate treatment. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Preferred approach'",
"    </a>",
"    below.) Similarly, a serum calcium of 12 to 14",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3 to 3.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    may be well-tolerated chronically, and may not require immediate treatment. However, an acute rise to these concentrations may cause marked changes in sensorium, which requires more aggressive measures. In addition, patients with a serum calcium concentration &gt;14",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    require treatment, regardless of symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     SALINE HYDRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial therapy of severe hypercalcemia includes the simultaneous administration of saline,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    , and a bisphosphonate. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Severe hypercalcemia'",
"    </a>",
"    below.) Isotonic saline corrects possible volume depletion due to hypercalcemia-induced urinary salt wasting and, in some cases, vomiting. Hypovolemia exacerbates hypercalcemia by impairing the renal clearance of calcium (",
"    <a class=\"graphic graphic_table graphicRef73030 \" href=\"UTD.htm?30/29/31196\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The rate of saline infusion depends upon several factors, including the severity of hypercalcemia, the age of the patient, and presence of comorbid conditions, particularly underlying cardiac or renal disease. A reasonable regimen, in the absence of edema, is the administration of isotonic saline at an initial rate of 200 to 300",
"    <span class=\"nowrap\">",
"     mL/hour",
"    </span>",
"    that is then adjusted to maintain the urine output at 100 to 150",
"    <span class=\"nowrap\">",
"     mL/hour.",
"    </span>",
"   </p>",
"   <p>",
"    Saline therapy requires careful monitoring, since it can lead to fluid overload in patients who cannot excrete the administered salt because of impaired renal function, which can be induced by hypercalcemia or heart failure. The saline infusion should be stopped in patients who develop edema and a loop diuretic may be used as necessary.",
"   </p>",
"   <p>",
"    Saline therapy rarely normalizes the serum calcium concentration in patients with more than mild hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/3\">",
"     3",
"    </a>",
"    ]. In the past, administration of a loop diuretic was initiated routinely once fluid repletion had been achieved to further increase urinary calcium excretion. However, this practice was based upon an approach that involved intensive administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"     furosemide",
"    </a>",
"    (80 to 100 mg every one to two hours) with aggressive fluid hydration (10 liters daily) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Saline therapy beyond that necessary to restore euvolemia has fallen out of favor for two reasons [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The availability of drugs such as the bisphosphonates and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"       calcitonin",
"      </a>",
"      that inhibit bone resorption, which is primarily responsible for the hypercalcemia.",
"     </li>",
"     <li>",
"      The requirement for careful monitoring because of the potential fluid and electrolyte complications resulting from a massive saline infusion and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/52/28488?source=see_link\">",
"       furosemide",
"      </a>",
"      -induced diuresis such as hypokalemia, hypomagnesemia, and volume depletion if the diuretic-induced losses are not replaced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Concurrent treatment with bisphosphonates with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    is typically required to treat moderate to severe hypercalcemia. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Preferred approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CALCITONIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pharmacologic doses of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    reduce the serum calcium concentration by increasing renal calcium excretion and, more importantly, by decreasing bone resorption via interference with osteoclast function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Salmon calcitonin (4 international",
"    <span class=\"nowrap\">",
"     units/kg)",
"    </span>",
"    is usually administered intramuscularly or subcutaneously every 12 hours; doses can be increased up to 6 to 8 international",
"    <span class=\"nowrap\">",
"     units/kg",
"    </span>",
"    every six hours. Nasal application of calcitonin is not efficacious for treatment of hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"     Calcitonin",
"    </a>",
"    is safe and relatively nontoxic (other than mild nausea and the rare hypersensitivity reaction). Although a relatively weak agent, it works rapidly, lowering the serum calcium concentration by a maximum of 1 to 2",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (0.3 to 0.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    beginning within four to six hours (",
"    <a class=\"graphic graphic_table graphicRef73030 \" href=\"UTD.htm?30/29/31196\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/1,10-12\">",
"     1,10-12",
"    </a>",
"    ]. Thus, it is useful in combination with hydration for the initial management of severe hypercalcemia.",
"   </p>",
"   <p>",
"    The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    is limited to the first 48 hours, even with repeated doses, indicating the development of tachyphylaxis, perhaps due to receptor downregulation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/1,8,13,14\">",
"     1,8,13,14",
"    </a>",
"    ]. Because of its limited duration of effect, calcitonin is most beneficial in symptomatic patients with calcium &gt;14",
"    <span class=\"nowrap\">",
"     mg/L",
"    </span>",
"    (3.5",
"    <span class=\"nowrap\">",
"     mmol/L),",
"    </span>",
"    when combined with hydration and bisphosphonates. Calcitonin and hydration provide a rapid reduction in serum calcium concentration, while a bisphosphonate provides a more sustained effect.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BISPHOSPHONATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The bisphosphonates are nonhydrolyzable analogs of inorganic pyrophosphate that adsorb to the surface of bone hydroxyapatite and inhibit calcium release by interfering with osteoclast-mediated bone resorption [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/15\">",
"     15",
"    </a>",
"    ]. They are effective in treating hypercalcemia resulting from excessive bone resorption of any cause (",
"    <a class=\"graphic graphic_table graphicRef73030 \" href=\"UTD.htm?30/29/31196\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11333?source=see_link\">",
"     \"Pharmacology of bisphosphonates\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All of the bisphosphonates are relatively nontoxic compounds and they are more potent than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    and saline for patients with moderate or severe hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/1,16-22\">",
"     1,16-22",
"    </a>",
"    ]. As a result, they have become the preferred agents for management of hypercalcemia due to excessive bone resorption from a variety of causes, including malignancy-related hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/22-24\">",
"     22-24",
"    </a>",
"    ]. Their maximum effect occurs in two to four days, so that they are usually given in conjunction with saline",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    calcitonin, which reduce calcium concentration more rapidly. (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Preferred approach'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Although bisphosphonates are most commonly used to treat established hypercalcemia, they have also been given to prevent hypercalcemia and adverse skeletal events, particularly in patients with metastatic cancer to bone. The use of bisphosphonates to improve outcomes for patients with cancer is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=see_link\">",
"     \"Bisphosphonates and denosumab in patients with metastatic cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Among the currently available agents for the treatment of malignancy-associated hypercalcemia (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    ), intravenous zoledronic acid (ZA) or pamidronate are our bisphosphonates of choice. ZA is favored by some because it is more potent than pamidronate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/21\">",
"     21",
"    </a>",
"    ] and can be administered over a shorter time period (15 minutes compared to two hours).",
"   </p>",
"   <p>",
"    Repetitive IV use of bisphosphonates has been associated with risk of developing osteonecrosis of the jaw in patients with multiple myeloma or metastatic bone disease. Some data suggest a higher risk of osteonecrosis of the jaw following the repeated use of ZA. As a result, some groups favor use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    over ZA in particular cancer patients, such as those with multiple myeloma. However, osteonecrosis of the jaw is a complication of long-term, high dose IV bisphosphonate therapy. Therefore, concerns about the risk of osteonecrosis of the jaw are of limited relevance in the management of acute hypercalcemia. (See",
"    <a class=\"local\" href=\"#H11\">",
"     'Side effects and precautions'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=see_link&amp;anchor=H488895#H488895\">",
"     \"The use of bisphosphonates in patients with multiple myeloma\", section on 'Choice of agent'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/10/24743?source=see_link\">",
"     Alendronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?16/41/17047?source=see_link\">",
"     risedronate",
"    </a>",
"    are potent-third generation bisphosphonates that can be given orally. However, neither is used for the treatment of severe or acute hypercalcemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Pamidronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of observational studies and some randomized trials have demonstrated the efficacy of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    for the treatment of hypercalcemia due to excessive bone resorption from a variety of causes, including malignancy, acute primary hyperparathyroidism, immobilization, hypervitaminosis D, and sarcoidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/1,18,25-34\">",
"     1,18,25-34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Early trials showed",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    (60 mg over 24 hours) was more effective in ameliorating hypercalcemia of malignancy than intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    (70 percent versus 41 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/18\">",
"     18",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/31\">",
"     31",
"    </a>",
"    ]. Subsequent trials showed that shorter infusion times (two to four hours) were safe and effective, maintaining normocalcemia for two or more weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/19,32\">",
"     19,32",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The maximal calcium response occurs at 90 mg IV [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/33\">",
"     33",
"    </a>",
"    ]. However, many clinicians vary the usual initial dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    according to the degree of hypercalcemia: 60 mg if the serum calcium concentration is up to 13.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3 to 3.4",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and 90 mg for higher levels. Serum calcium concentrations begin to decrease in one or two days. Doses should not be repeated sooner than a minimum of seven days.",
"   </p>",
"   <p>",
"    Intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    is well tolerated, with a low incidence of fever being the main side effect. A less favorable response may be seen in patients with humoral hypercalcemia of malignancy, a paraneoplastic syndrome typically resulting from autonomous production of parathyroid hormone-related protein (PTHrP) by the tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/35-37\">",
"     35-37",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=see_link&amp;anchor=H5#H5\">",
"     \"Hypercalcemia of malignancy\", section on 'PTH-related protein'",
"    </a>",
"    .) Such patients may have a better response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     zoledronic acid",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Zoledronic acid",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"     Zoledronic acid",
"    </a>",
"    (ZA) is considered by many the agent of choice for malignancy-associated hypercalcemia because it is more potent and effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    . Although it can be administered over a shorter time period (15 minutes as compared with two hours), which may be more convenient, this may not be as important in the setting of hypercalcemia since many of these patients require hospitalization. ZA is currently approved by the United States Food and Drug Administration for treatment of hypercalcemia of malignancy at a dose of 4 mg IV over at least 15 minutes.",
"   </p>",
"   <p>",
"    In a pooled analysis of two separate phase III trials involving a total of 275 patients with tumor-induced hypercalcemia, a single dose of ZA (either 4 mg or 8 mg) normalized the corrected serum calcium concentration in 87 to 88 percent of patients, compared with only 70 percent of those receiving",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    (90 mg) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, the median duration of serum calcium control was longer for those receiving ZA (32 to 43 versus 18 days).",
"   </p>",
"   <p>",
"    Although renal events were reported more frequently with ZA than with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    in trials evaluating chronic use of these drugs to treat patients with metastatic bone disease, there was no difference in the frequency of grade 3 or 4 renal toxicity with either drug. The efficacy of the 4 and 8 mg ZA doses were similar, but the 4 mg dose was recommended because there was greater renal toxicity with the 8 mg dose (5.2 versus 2.3 percent with 4 mg) and higher all-cause mortality (33 versus 19 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Dosing in renal impairment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Ibandronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     Ibandronate",
"    </a>",
"    effectively treats hypercalcemia of malignancy. In combined trials with over 320 patients, ibandronate doses of 2 mg IV administered over two hours normalized serum calcium in up to 67 percent of patients, and doses up to 6 mg were safe and well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. The frequency of response was significantly higher with 4 or 6 mg than with 2 mg (76 to 77 versus 50 percent), but the duration of response was not dose-dependent [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     Ibandronate",
"    </a>",
"    appears to be as effective as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    . Ibandronate (2 or 4 mg IV) was directly compared with pamidronate (15 to 90 mg IV) in a randomized trial involving 72 patients with hypercalcemia of malignancy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/41\">",
"     41",
"    </a>",
"    ]. The number of patients responding to both agents was similar (77 and 76 percent for ibandronate and pamidronate, respectively) but the median time until the serum calcium began to rise again was significantly longer with ibandronate (14 versus 4 days). However, four days is an unusually short duration of effect for pamidronate and may reflect inadequate dosing or the small size of the clinical trial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Clodronate and etidronate",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     Clodronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    are first generation bisphosphonates that were introduced over 20 years ago. They are relatively weak inhibitors of bone resorption compared with the newer agents. Clodronate is widely available outside the United States.",
"   </p>",
"   <p>",
"    In randomized trials of patients with multiple myeloma or metastatic breast cancer, the administration of oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    to decrease skeletal complications was associated with fewer episodes of severe hypercalcemia. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8042?source=see_link\">",
"     \"Osteoclast inhibition in the management of bone metastases from breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=see_link&amp;anchor=H487409#H487409\">",
"     \"The use of bisphosphonates in patients with multiple myeloma\", section on 'Oral bisphosphonates'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, the poor oral bioavailability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/3/9270?source=see_link\">",
"     clodronate",
"    </a>",
"    , the size of the tablets, and the need to take them on an empty stomach with nothing to eat for one hour afterward increases the risk of noncompliance [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/22\">",
"     22",
"    </a>",
"    ]. As a result, IV clodronate is often preferred at the onset of therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/42\">",
"     42",
"    </a>",
"    ], with oral clodronate being used for maintenance therapy.",
"   </p>",
"   <p>",
"    When used for treatment of malignancy-associated hypercalcemia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    must be given intravenously (7.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    in 250 mL of saline over four hours) for at least three consecutive days [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. Prolonging treatment to five days increases responsiveness from 60 percent to almost 100 percent of patients. Other effective treatment schedules include a single 24-hour infusion (30",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    or 4.3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV daily for seven consecutive days [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. Serum calcium levels may not decrease until approximately four days after treatment is started.",
"   </p>",
"   <p>",
"    Prolonged administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    has been associated with hyperphosphatemia due to increased tubular reabsorption of phosphate. The dose of etidronate should be reduced by 50 percent in patients with impaired renal function because it is excreted in the urine.",
"   </p>",
"   <p>",
"    The inconvenience of prolonged intravenous treatment and the relatively weak potency has diminished the utility of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    , and it is not generally recommended unless other bisphosphonates are not available [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Side effects and precautions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although intravenous bisphosphonates are generally well tolerated, side effects may include flu-like symptoms (fever, arthralgias, myalgia, fatigue, bone pain), ocular inflammation (uveitis), hypocalcemia, hypophosphatemia, impaired renal function, nephrotic syndrome, and osteonecrosis of the jaw [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. These side effects are discussed in detail elsewhere; the incidence varies somewhat with the indication for use due in part to the higher doses used in cancer patients compared to those with osteoporosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=see_link\">",
"     \"Risks of therapy with bone modifying agents in patients with advanced malignancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=see_link&amp;anchor=H37#H37\">",
"     \"Bisphosphonates in the management of osteoporosis in postmenopausal women\", section on 'Adverse effects'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Dosing in renal impairment",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned in the preceding section, bisphosphonates have potential nephrotoxicity. A separate issue is dosing of bisphosphonates in patients with underlying renal disease.",
"   </p>",
"   <p>",
"    In clinical trials of ZA for the treatment of hypercalcemia of malignancy, patients with serum creatinine concentrations as high as 4.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (400",
"    <span class=\"nowrap\">",
"     micromol/L)",
"    </span>",
"    were eligible for participation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/21\">",
"     21",
"    </a>",
"    ]. In addition, there are case reports of successful use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/8/12423?source=see_link\">",
"     ibandronate",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    for patients with renal failure and multiple myeloma [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/47\">",
"     47",
"    </a>",
"    ], renal insufficiency (creatinine &ge;1.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [133",
"    <span class=\"nowrap\">",
"     micromol/L])",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/48\">",
"     48",
"    </a>",
"    ], and in hemodialysis patients with severe hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. However, we suggest caution when using intravenous bisphosphonates to treat hypercalcemia in patients with impaired renal function (creatinine &gt;4.5",
"    <span class=\"nowrap\">",
"     mg/dL).",
"    </span>",
"    Adequate hydration with saline and treatment with a reduced dose",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    slower infusion rate (4 mg ZA over 30 to 60 minutes, 30 to 45 mg pamidronate over four hours, 2 mg ibandronate over one hour) may minimize risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     GLUCOCORTICOIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Increased absorption of dietary calcium is primarily, but not completely, responsible for the hypercalcemia associated with the excess administration or ingestion of vitamin D, or with the endogenous overproduction of calcitriol (1,25-dihydroxyvitamin D, the most active metabolite of vitamin D). Increased calcitriol production can occur in patients with chronic granulomatous diseases (eg, sarcoidosis) and in occasional patients with lymphoma. In such patients, glucocorticoids (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    in a dose of 20 to 40",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    will usually reduce serum calcium concentrations within two to five days by decreasing calcitriol production by the activated mononuclear cells in the lung and lymph nodes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=see_link\">",
"     \"Hypercalcemia in granulomatous diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     GALLIUM NITRATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The calcium-lowering effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/60/22467?source=see_link\">",
"     gallium nitrate",
"    </a>",
"    were initially discovered when hypocalcemia developed in patients undergoing gallium imaging who previously had normal serum calcium levels [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/51\">",
"     51",
"    </a>",
"    ]. Gallium inhibits osteoclastic bone resorption, in part via inhibition of an ATPase dependent proton pump on the osteoclast ruffled membrane, without being directly cytotoxic or acting as a metabolic toxin to bone cells [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/52\">",
"     52",
"    </a>",
"    ]. Gallium also inhibits PTH secretion from parathyroid cells in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike bisphosphonates, gallium appears to be effective in both PTHrP-mediated, and non-PTHrP-mediated hypercalcemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/51,54-56\">",
"     51,54-56",
"    </a>",
"    ]. Preliminary data from clinical trials indicated that it is more potent than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/23/22902?source=see_link\">",
"     etidronate",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/54-56\">",
"     54-56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of gallium was more rigorously examined in a trial of 64 patients with malignancy-associated hypercalcemia (serum calcium &ge;12",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3",
"    <span class=\"nowrap\">",
"     mmol/L]",
"    </span>",
"    after intravenous hydration) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/56\">",
"     56",
"    </a>",
"    ]. Patients were randomly assigned to daily intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/60/22467?source=see_link\">",
"     gallium nitrate",
"    </a>",
"    (200",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    daily for five days or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    (60 mg, or 90 mg if initial calcium &ge;13.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3.8",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    for one day followed by four days of placebo infusions.",
"   </p>",
"   <p>",
"    Normocalcemia (serum calcium &le;10.5",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [2.7",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    was achieved within 10 days in 69 and 56 percent of the gallium and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    treated patients, respectively, and the estimated duration of normocalcemia in responders was 14 and 10 days, respectively. The disadvantages of gallium include its potential for nephrotoxicity, and the need for continuous infusion over five days [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/57\">",
"     57",
"    </a>",
"    ]. Therefore, for the treatment of hypercalcemia due to excessive bone resorption, we prefer to use bisphosphonates rather than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/60/22467?source=see_link\">",
"     gallium nitrate",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     OTHER THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Calcimimetics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Primary hyperparathyroidism is the most common outpatient cause of hypercalcemia. The elevation in serum calcium is usually mild and treatment is typically directed at correcting the hyperparathyroidism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link\">",
"     \"Management of primary hyperparathyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, a calcimimetic agent (only",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/23/26998?source=see_link\">",
"     cinacalcet",
"    </a>",
"    is currently available) reduces the serum calcium concentration in patients with severe hypercalcemia due to parathyroid carcinoma and in hemodialysis patients with an elevated calcium-phosphorous product and secondary hyperparathyroidism. Calcimimetics have also been evaluated in patients with primary hyperparathyroidism, but are not standard therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=see_link&amp;anchor=H12#H12\">",
"     \"Parathyroid carcinoma\", section on 'Calcimimetics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=see_link&amp;anchor=H25#H25\">",
"     \"Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients\", section on 'Calcimimetics'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link&amp;anchor=H20#H20\">",
"     \"Management of primary hyperparathyroidism\", section on 'Calcimimetics'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hemodialysis with little or no calcium in the dialysis fluid and peritoneal dialysis (though it is slower) are both effective therapies for hypercalcemia, and are considered treatments of last resort. Dialysis may be indicated in patients with severe malignancy-associated hypercalcemia and renal insufficiency or heart failure, in whom hydration cannot be safely administered [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of hemodialysis for patients with hypercalcemia but without renal failure may require alterations in the composition of conventional dialysis solutions in order to avoid an exacerbation or induction of other metabolic abnormalities, particularly hypophosphatemia. As an example, hemodialysis with a dialysis solution enriched with phosphorus (final phosphorous concentration of 4",
"    <span class=\"nowrap\">",
"     mg/dL)",
"    </span>",
"    resulted in rapid correction of all abnormalities in one patient in whom medical therapy had failed to reverse hypercalcemia, mental status changes, and hypophosphatemia due to primary hyperparathyroidism [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     PREFERRED APPROACH",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Mild hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with asymptomatic or mildly symptomatic hypercalcemia (calcium &lt;12",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    do not require immediate treatment. However, they should be advised to avoid factors that can aggravate hypercalcemia, including thiazide diuretics and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    carbonate therapy, volume depletion, prolonged bed rest or inactivity, and a high calcium diet (&gt;1000",
"    <span class=\"nowrap\">",
"     mg/day).",
"    </span>",
"    Adequate hydration (at least six to eight glasses of water per day) is recommended to minimize the risk of nephrolithiasis. Additional therapy depends mostly upon the cause of the hypercalcemia. (See",
"    <a class=\"local\" href=\"#H22\">",
"     'Other'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Moderate hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Asymptomatic or mildly symptomatic individuals with chronic moderate hypercalcemia (calcium between 12 and 14",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [3 to 3.5",
"    <span class=\"nowrap\">",
"     mmol/L])",
"    </span>",
"    may not require immediate therapy. However, they should follow the same precautions described above for mild hypercalcemia.",
"   </p>",
"   <p>",
"    It is important to note that an acute rise to these concentrations may cause marked changes in sensorium, which requires more aggressive therapy. In these patients, we typically treat with saline hydration and bisphosphonates, as described for severe hypercalcemia (below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Severe hypercalcemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with calcium &gt;14",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (3.5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    require more aggressive therapy. The acute therapy of such patients consists of a three-pronged approach [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/1,2,11\">",
"     1,2,11",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Volume expansion with isotonic saline at an initial rate of 200 to 300",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      that is then adjusted to maintain the urine output at 100 to 150",
"      <span class=\"nowrap\">",
"       mL/hour.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Saline hydration'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      In the absence of renal failure or heart failure, loop diuretic therapy to directly increase calcium excretion is not recommended because of potential complications and the availability of drugs that inhibit bone resorption, which is primarily responsible for the hypercalcemia.",
"     </li>",
"     <li>",
"      Administration of salmon",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"       calcitonin",
"      </a>",
"      (4 international",
"      <span class=\"nowrap\">",
"       units/kg)",
"      </span>",
"      and repeat measurement of serum calcium in several hours. If a hypocalcemic response is noted, then the patient is calcitonin-sensitive and the calcitonin can be repeated every 6 to 12 hours (4 to 8 international",
"      <span class=\"nowrap\">",
"       units/kg).",
"      </span>",
"      We typically administer calcitonin (along with a bisphosphonate) in patients with calcium &gt;14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      who are also symptomatic.",
"     </li>",
"     <li>",
"      The concurrent administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      (4 mg IV over 15 minutes) or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      (60 to 90 mg over two hours), preferably zoledronic acid, because it is superior to pamidronate in reversing hypercalcemia related to malignancy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"     calcitonin",
"    </a>",
"    plus saline should result in substantial reduction in serum calcium concentrations within 12 to 48 hours. The bisphosphonate will be effective by the second to fourth day, thereby maintaining control of the hypercalcemia.",
"   </p>",
"   <p>",
"    Follow-up therapy is aimed at preventing recurrence of hypercalcemia. In patients with hypercalcemia of malignancy, progressive hypercalcemia will inevitably accompany tumor progression, and therefore the underlying disease causing the hypercalcemia should be treated, if at all possible. Many patients with malignancy may also have metastatic bone disease and will receive intravenous ZA or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"     pamidronate",
"    </a>",
"    every three to four weeks as part of their treatment to prevent skeletal complications. As a result, recurrent hypercalcemia will be prevented.",
"   </p>",
"   <p>",
"    Additional, more aggressive measures are necessary in the rare patient with very severe, symptomatic hypercalcemia. Hemodialysis should be considered, in addition to the above treatments, in patients who have serum calcium concentrations in the range of 18 to 20",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    (4.5 to 5",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    and neurologic symptoms but a stable circulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;The modalities described above apply in varying degrees to patients with all causes of hypercalcemia. The treatment of some disorders is discussed in detail in other topic reviews. Summarized briefly:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hyperparathyroidism is the most common outpatient cause of mild hypercalcemia. The treatment is typically directed at correcting the hyperparathyroidism or monitoring for complications of primary hyperparathyroidism. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=see_link\">",
"       \"Management of primary hyperparathyroidism\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with lymphoma, sarcoidosis or other granulomatous causes of hypercalcemia have enhanced intestinal calcium absorption due to increased endogenous calcitriol production. The major modalities of therapy are a low calcium diet, corticosteroids, and treatment of the underlying disease. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=see_link\">",
"       \"Hypercalcemia in granulomatous diseases\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hypercalcemia due to ingestion of calcitriol as treatment for hypoparathyroidism or for the hypocalcemia and hyperparathyroidism of renal failure usually lasts only one to two days because of the relatively short biologic half-life of calcitriol. Thus, stopping the calcitriol, increasing salt and fluid intake, or perhaps hydration with intravenous saline may be the only therapy that is needed.",
"      <br/>",
"      <br/>",
"      Hypercalcemia caused by vitamin D or calcidiol lasts longer, so that more aggressive therapy such as glucocorticoids and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       pamidronate",
"      </a>",
"      may be necessary [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16041/abstract/29\">",
"       29",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hypercalcemia is typically not treated in patients with familial hypocalciuric hypercalcemia because the elevation in serum calcium is typically mild and produces few if any symptoms. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=see_link\">",
"       \"Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with asymptomatic or mildly symptomatic hypercalcemia (calcium &lt;12",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      do not require immediate treatment. However, they should be advised to avoid factors that can aggravate hypercalcemia, including thiazide diuretic and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"       lithium",
"      </a>",
"      carbonate therapy, volume depletion, prolonged bed rest or inactivity, and a high calcium diet (&gt;1000",
"      <span class=\"nowrap\">",
"       mg/day).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Preferred approach'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic or mildly symptomatic individuals with chronic moderate hypercalcemia (calcium between 12 and 14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3 to 3.5",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      may not require immediate therapy. However, an acute rise to these levels may cause gastrointestinal side effects and changes in sensorium, which requires treatment as described for severe hypercalcemia. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Moderate hypercalcemia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with more severe (calcium &gt;14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      [3.5",
"      <span class=\"nowrap\">",
"       mmol/L])",
"      </span>",
"      or symptomatic hypercalcemia are usually dehydrated and require saline hydration as initial therapy. A reasonable regimen is the administration of isotonic saline at an initial rate of 200 to 300",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"      that is then adjusted to maintain the urine output at 100 to 150",
"      <span class=\"nowrap\">",
"       mL/hour.",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Saline hydration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with hypercalcemia receiving saline hydration, we suggest not routinely using a loop diuretic (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). However, in individuals with renal insufficiency or heart failure, careful monitoring and judicious use of loop diuretics may be required to prevent fluid overload. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Saline hydration'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For immediate short-term management of hypercalcemia, we suggest administration of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/9/28821?source=see_link\">",
"       calcitonin",
"      </a>",
"      (in addition to saline hydration) only in patients with calcium &gt;14",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      (3.5",
"      <span class=\"nowrap\">",
"       mmol/L)",
"      </span>",
"      who are also symptomatic (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Calcitonin'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For longer-term control of hypercalcemia in patients with more severe (calcium &gt;14",
"      <span class=\"nowrap\">",
"       mg/dL)",
"      </span>",
"      or symptomatic hypercalcemia due to excessive bone resorption, we suggest the addition of a bisphosphonate rather than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/60/22467?source=see_link\">",
"       gallium nitrate",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Bisphosphonates'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Gallium nitrate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among intravenous bisphosphonates, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/1/9241?source=see_link\">",
"       zoledronic acid",
"      </a>",
"      (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/62/3048?source=see_link\">",
"       Pamidronate",
"      </a>",
"      is an alternative option when zoledronic acid is not available. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Bisphosphonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Glucocorticoids are effective in treating hypercalcemia due to some lymphomas, sarcoid, or other granulomatous diseases. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Glucocorticoids'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Dialysis is generally reserved for those with severe hypercalcemia. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Severe hypercalcemia'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/1\">",
"      Bilezikian JP. Clinical review 51: Management of hypercalcemia. J Clin Endocrinol Metab 1993; 77:1445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/2\">",
"      Bilezikian JP. Management of acute hypercalcemia. N Engl J Med 1992; 326:1196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/3\">",
"      Hosking DJ, Cowley A, Bucknall CA. Rehydration in the treatment of severe hypercalcaemia. Q J Med 1981; 50:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/4\">",
"      Suki WN, Yium JJ, Von Minden M, et al. Acute treatment of hypercalcemia with furosemide. N Engl J Med 1970; 283:836.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/5\">",
"      Body JJ. Hypercalcemia of malignancy. Semin Nephrol 2004; 24:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/6\">",
"      LeGrand SB, Leskuski D, Zama I. Narrative review: furosemide for hypercalcemia: an unproven yet common practice. Ann Intern Med 2008; 149:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/7\">",
"      Austin LA, Heath H 3rd. Calcitonin: physiology and pathophysiology. N Engl J Med 1981; 304:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/8\">",
"      Deftos LJ, First BP. Calcitonin as a drug. Ann Intern Med 1981; 95:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/9\">",
"      Dumon JC, Magritte A, Body JJ. Nasal human calcitonin for tumor-induced hypercalcemia. Calcif Tissue Int 1992; 51:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/10\">",
"      Wisneski LA. Salmon calcitonin in the acute management of hypercalcemia. Calcif Tissue Int 1990; 46 Suppl:S26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/11\">",
"      Fatemi S, Singer FR, Rude RK. Effect of salmon calcitonin and etidronate on hypercalcemia of malignancy. Calcif Tissue Int 1992; 50:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/12\">",
"      Vaughn CB, Vaitkevicius VK. The effects of calcitonin in hypercalcemia in patients with malignancy. Cancer 1974; 34:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/13\">",
"      Ljunghall S. Use of clodronate and calcitonin in hypercalcemia due to malignancy. Recent Results Cancer Res 1989; 116:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/14\">",
"      Chevallier B, Peyron R, Basuyau JP, et al. [Human calcitonin in neoplastic hypercalcemia. Results of a prospective randomized trial]. Presse Med 1988; 17:2375.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/15\">",
"      Carano A, Teitelbaum SL, Konsek JD, et al. Bisphosphonates directly inhibit the bone resorption activity of isolated avian osteoclasts in vitro. J Clin Invest 1990; 85:456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/16\">",
"      Ryzen E, Martodam RR, Troxell M, et al. Intravenous etidronate in the management of malignant hypercalcemia. Arch Intern Med 1985; 145:449.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/17\">",
"      Singer FR, Ritch PS, Lad TE, et al. Treatment of hypercalcemia of malignancy with intravenous etidronate. A controlled, multicenter study. The Hypercalcemia Study Group. Arch Intern Med 1991; 151:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/18\">",
"      Gucalp R, Ritch P, Wiernik PH, et al. Comparative study of pamidronate disodium and etidronate disodium in the treatment of cancer-related hypercalcemia. J Clin Oncol 1992; 10:134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/19\">",
"      Gucalp R, Theriault R, Gill I, et al. Treatment of cancer-associated hypercalcemia. Double-blind comparison of rapid and slow intravenous infusion regimens of pamidronate disodium and saline alone. Arch Intern Med 1994; 154:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/20\">",
"      Rizzoli R, Thi&eacute;baud D, Bundred N, et al. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. J Clin Endocrinol Metab 1999; 84:3545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/21\">",
"      Major P, Lortholary A, Hon J, et al. Zoledronic acid is superior to pamidronate in the treatment of hypercalcemia of malignancy: a pooled analysis of two randomized, controlled clinical trials. J Clin Oncol 2001; 19:558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/22\">",
"      Berenson JR. Treatment of hypercalcemia of malignancy with bisphosphonates. Semin Oncol 2002; 29:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/23\">",
"      Body JJ, Bartl R, Burckhardt P, et al. Current use of bisphosphonates in oncology. International Bone and Cancer Study Group. J Clin Oncol 1998; 16:3890.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/24\">",
"      Stewart AF. Clinical practice. Hypercalcemia associated with cancer. N Engl J Med 2005; 352:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/25\">",
"      Massagli TL, Cardenas DD. Immobilization hypercalcemia treatment with pamidronate disodium after spinal cord injury. Arch Phys Med Rehabil 1999; 80:998.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/26\">",
"      Jansson S, Tisell LE, Lindstedt G, Lundberg PA. Disodium pamidronate in the preoperative treatment of hypercalcemia in patients with primary hyperparathyroidism. Surgery 1991; 110:480.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/27\">",
"      Mark S. Hypercalcaemia in an immobilised patient with pneumonia. Br J Clin Pract 1995; 49:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/28\">",
"      McIntyre HD, Cameron DP, Urquhart SM, Davies WE. Immobilization hypercalcaemia responding to intravenous pamidronate sodium therapy. Postgrad Med J 1989; 65:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/29\">",
"      Selby PL, Davies M, Marks JS, Mawer EB. Vitamin D intoxication causes hypercalcaemia by increased bone resorption which responds to pamidronate. Clin Endocrinol (Oxf) 1995; 43:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/30\">",
"      Gibbs CJ, Peacock M. Hypercalcaemia due to sarcoidosis corrects with bisphosphonate treatment. Postgrad Med J 1986; 62:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/31\">",
"      Ralston SH, Gallacher SJ, Patel U, et al. Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia. Lancet 1989; 2:1180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/32\">",
"      Sawyer N, Newstead C, Drummond A, Cunningham J. Fast (4-h) or slow (24-h) infusions of pamidronate disodium (aminohydroxypropylidene diphosphonate (APD)) as single shot treatment of hypercalcaemia. Bone Miner 1990; 9:121.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/33\">",
"      Nussbaum SR, Younger J, Vandepol CJ, et al. Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages. Am J Med 1993; 95:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/34\">",
"      Wimalawansa SJ. Optimal frequency of administration of pamidronate in patients with hypercalcaemia of malignancy. Clin Endocrinol (Oxf) 1994; 41:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/35\">",
"      Gurney H, Grill V, Martin TJ. Parathyroid hormone-related protein and response to pamidronate in tumour-induced hypercalcaemia. Lancet 1993; 341:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/36\">",
"      Walls J, Ratcliffe WA, Howell A, Bundred NJ. Response to intravenous bisphosphonate therapy in hypercalcaemic patients with and without bone metastases: the role of parathyroid hormone-related protein. Br J Cancer 1994; 70:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/37\">",
"      Wimalawansa SJ. Significance of plasma PTH-rp in patients with hypercalcemia of malignancy treated with bisphosphonate. Cancer 1994; 73:2223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/38\">",
"      Schwartz LM, Woloshin S. Lost in transmission--FDA drug information that never reaches clinicians. N Engl J Med 2009; 361:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/39\">",
"      Ralston SH, Thi&eacute;baud D, Herrmann Z, et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br J Cancer 1997; 75:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/40\">",
"      Pecherstorfer M, Herrmann Z, Body JJ, et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996; 14:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/41\">",
"      Pecherstorfer M, Steinhauer EU, Rizzoli R, et al. Efficacy and safety of ibandronate in the treatment of hypercalcemia of malignancy: a randomized multicentric comparison to pamidronate. Support Care Cancer 2003; 11:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/42\">",
"      O'Rourke NP, McCloskey EV, Vasikaran S, et al. Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate. Br J Cancer 1993; 67:560.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/43\">",
"      Flores JF, Rude RK, Chapman RA, et al. Evaluation of a 24-hour infusion of etidronate disodium for the treatment of hypercalcemia of malignancy. Cancer 1994; 73:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/44\">",
"      Meunier PJ, Chapuy MC, Delmas P, et al. Intravenous disodium etidronate therapy in Paget's disease of bone and hypercalcemia of malignancy. Effects on biochemical parameters and bone histomorphometry. Am J Med 1987; 82:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/45\">",
"      Tanvetyanon T, Stiff PJ. Management of the adverse effects associated with intravenous bisphosphonates. Ann Oncol 2006; 17:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/46\">",
"      Zojer N, Keck AV, Pecherstorfer M. Comparative tolerability of drug therapies for hypercalcaemia of malignancy. Drug Saf 1999; 21:389.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/47\">",
"      Henrich D, Hoffmann M, Uppenkamp M, Bergner R. Ibandronate for the treatment of hypercalcemia or nephrocalcinosis in patients with multiple myeloma and acute renal failure: Case reports. Acta Haematol 2006; 116:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/48\">",
"      Machado CE, Flombaum CD. Safety of pamidronate in patients with renal failure and hypercalcemia. Clin Nephrol 1996; 45:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/49\">",
"      Trimarchi H, Lombi F, Forrester M, et al. Disodium pamidronate for treating severe hypercalcemia in a hemodialysis patient. Nat Clin Pract Nephrol 2006; 2:459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/50\">",
"      Davenport A, Goel S, Mackenzie JC. Treatment of hypercalcaemia with pamidronate in patients with end stage renal failure. Scand J Urol Nephrol 1993; 27:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/51\">",
"      Warrell RP Jr, Bockman RS, Coonley CJ, et al. Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia. J Clin Invest 1984; 73:1487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/52\">",
"      Bockman R. The effects of gallium nitrate on bone resorption. Semin Oncol 2003; 30:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/53\">",
"      Ridefelt P, Gylfe E, Akerstr&ouml;m G, Rastad J. Effects of the antihypercalcemic drugs gallium nitrate and pamidronate on hormone release of pathologic human parathyroid cells. Surgery 1995; 117:56.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/54\">",
"      Warrell RP Jr, Israel R, Frisone M, et al. Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin. Ann Intern Med 1988; 108:669.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/55\">",
"      Warrell RP Jr, Murphy WK, Schulman P, et al. A randomized double-blind study of gallium nitrate compared with etidronate for acute control of cancer-related hypercalcemia. J Clin Oncol 1991; 9:1467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/56\">",
"      Cvitkovic F, Armand JP, Tubiana-Hulin M, et al. Randomized, double-blind, phase II trial of gallium nitrate compared with pamidronate for acute control of cancer-related hypercalcemia. Cancer J 2006; 12:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/57\">",
"      Chitambar CR. Gallium nitrate revisited. Semin Oncol 2003; 30:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/58\">",
"      Koo WS, Jeon DS, Ahn SJ, et al. Calcium-free hemodialysis for the management of hypercalcemia. Nephron 1996; 72:424.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16041/abstract/59\">",
"      Leehey DJ, Ing TS. Correction of hypercalcemia and hypophosphatemia by hemodialysis using a conventional, calcium-containing dialysis solution enriched with phosphorus. Am J Kidney Dis 1997; 29:288.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 850 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-115.25.216.6-8C22B84DCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_42_16041=[""].join("\n");
var outline_f15_42_16041=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H23\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INTERPRETATION OF SERUM CALCIUM",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      INDICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      SALINE HYDRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CALCITONIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BISPHOSPHONATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Pamidronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Zoledronic acid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Ibandronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Clodronate and etidronate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Side effects and precautions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Dosing in renal impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      GLUCOCORTICOIDS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      GALLIUM NITRATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      OTHER THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Calcimimetics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      PREFERRED APPROACH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Mild hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Moderate hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Severe hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/850\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/850|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/29/31196\" title=\"table 1\">",
"      Treatment of hypercalcemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?17/35/17969?source=related_link\" title=\"calculator 1\">",
"      Calculator: Calcium correction in hypoalbuminemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?14/51/15153?source=related_link\" title=\"calculator 2\">",
"      Calculator: Calcium correction in hypoalbuminemia (SI units)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/18/13608?source=related_link\">",
"      Bisphosphonates and denosumab in patients with metastatic cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40842?source=related_link\">",
"      Bisphosphonates in the management of osteoporosis in postmenopausal women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/56/33669?source=related_link\">",
"      Clinical manifestations of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/28/20934?source=related_link\">",
"      Diagnostic approach to hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/51/19258?source=related_link\">",
"      Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/22/28007?source=related_link\">",
"      Etiology of hypercalcemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/16/2310?source=related_link\">",
"      Hypercalcemia in granulomatous diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/48/41734?source=related_link\">",
"      Hypercalcemia of malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/47/8954?source=related_link\">",
"      Management of primary hyperparathyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/36/38474?source=related_link\">",
"      Management of secondary hyperparathyroidism and mineral metabolism abnormalities in dialysis patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/54/8042?source=related_link\">",
"      Osteoclast inhibition in the management of bone metastases from breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/23/13688?source=related_link\">",
"      Parathyroid carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/4/11333?source=related_link\">",
"      Pharmacology of bisphosphonates",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/8/23685?source=related_link\">",
"      Relation between total and ionized serum calcium concentration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/43/39610?source=related_link\">",
"      Risks of therapy with bone modifying agents in patients with advanced malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/27/30137?source=related_link\">",
"      The use of bisphosphonates in patients with multiple myeloma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_42_16042="High altitude, air travel, and heart disease";
var content_f15_42_16042=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   High altitude, air travel, and heart disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/42/16042/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16042/contributors\">",
"     Troy Tuttle, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16042/contributors\">",
"     Asif Ali, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16042/contributors\">",
"     David Filsoof, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16042/contributors\">",
"     John Higgins, MD, MBA, MPHIL, FACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/42/16042/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16042/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16042/contributors\">",
"     David R Fulton, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16042/contributors\">",
"     Bernard J Gersh, MB, ChB, DPhil, FRCP, MACC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?15/42/16042/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?15/42/16042/contributors\">",
"     Gordon M Saperia, MD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?15/42/16042/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 30, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The number of individuals exposed to high altitude through air travel and recreational activities has increased greatly in recent decades. High altitude is well tolerated in most individuals. However, patients with cardiovascular disease, as well as some healthy individuals, are at risk of complications from tissue hypoxia, sympathetic stimulation, increased myocardial demand, and alterations in hemodynamics that may occur with exposure to high altitude [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These complications are caused by the acute effects of hypobaric hypoxia where the high altitude provides a unique physiologic challenge to the cardiovascular system. The cardiovascular response to high altitude exposure in healthy individuals and in patients with heart disease will be reviewed here. A general discussion of high altitude disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic will discuss the impact of high altitude on the heart. Altitude exposure can also lead to a variety of well-described clinical syndromes including some not directly involving the cardiovascular system: acute mountain sickness, high altitude pulmonary edema, high altitude cerebral edema, and high altitude retinal hemorrhage. These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link\">",
"     \"High altitude pulmonary edema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=see_link\">",
"     \"Acute mountain sickness and high altitude cerebral edema\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link&amp;anchor=H14#H14\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\", section on 'Other altitude-related illnesses'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     BAROMETRIC PRESSURE AND PIO2",
"    </span>",
"    &nbsp;&mdash;&nbsp;An understanding of barometric pressure, the primary determinant of the partial pressure of oxygen in inspired air (PiO2), is important to understanding the cardiovascular stress of high altitude. When moving from sea level to high altitude, there are reductions in atmospheric pressure, oxygen pressure, humidity, and temperature [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/2\">",
"     2",
"    </a>",
"    ]. Significant changes occur above 2500 m above sea level [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/3\">",
"     3",
"    </a>",
"    ]. Factors such as degree of change in elevation, degree of hypoxia, rate of ascent, level of acclimatization, exercise intensity, previous history of severe high-altitude illness, history of migraine, genetics, and age also affect the degree of changes experienced by the human body [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although altitude is the most obvious determinant of barometric pressure and its resulting physiologic stress, other factors can contribute to a reduction in barometric pressure and can increase the physiologic consequences of altitude:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A decrease in temperature",
"     </li>",
"     <li>",
"      Deteriorating weather, such as blizzards, hail, or extreme winds",
"     </li>",
"     <li>",
"      Latitude (distance from equator). Due to a large mass of cold air in the stratosphere above the equator, the pressure at a given altitude at the equator tends to be higher than at distances from the equator.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relationship between the PiO2 (in mmHg), the fraction of oxygen in inspired air (FiO2), and barometric pressure (in mmHg) is described by the following equation:",
"   </p>",
"   <p>",
"    &nbsp;PiO2 &nbsp;= &nbsp;FiO2 &nbsp;x &nbsp;barometric pressure",
"   </p>",
"   <p>",
"    The FiO2 is about 21 percent at sea level and decreases at higher altitudes. In addition, oxygen within inspired air is reduced by the presence of water vapor obtained during transport into the lungs (typically 47 mmHg). As a result, the above equation can be written as:",
"   </p>",
"   <p>",
"    &nbsp;PiO2 &nbsp;= &nbsp;0.21 &nbsp;x &nbsp;(barometric pressure &nbsp;- &nbsp;47)",
"   </p>",
"   <p>",
"    The approximate pressures of oxygen in the atmosphere, inspired air, alveoli, and arterial blood at a variety of altitudes are shown in the following table (",
"    <a class=\"graphic graphic_table graphicRef63773 \" href=\"UTD.htm?9/36/9804\">",
"     table 1",
"    </a>",
"    ). At 2439 meters (8000 feet), which is the maximal allowable cabin pressure (altitude equivalent) in commercial airliners, the barometric pressure is decreased to 564 mmHg (compared to 760 mmHg at sea level). The net effect is a PiO2 of 108 mmHg, with associated partial pressures of oxygen in the alveoli and arterial blood of normal individuals of 69 mmHg and 60 mmHg, respectively. At sea level the oxygen saturation is 99 to 100 percent. At",
"    <span class=\"nowrap\">",
"     2439m/8000",
"    </span>",
"    feet it is 60 percent. The PiO2 is greater than the alveolar and arterial pO2 at any altitude. This is caused by anatomical dead space in the respiratory system in which all inspired oxygen (air in mouth and trachea) does not take part in gas exchange. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"     \"Traveling with oxygen aboard commercial air carriers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NORMAL CARDIOVASCULAR RESPONSE TO HIGH ALTITUDE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Information on the physiologic cardiovascular consequences of altitude exposure comes from both \"at altitude\" studies and those in which altitude is simulated in a hypobaric chamber.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Short-term altitude exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several circulatory changes occur within minutes of exposure to high altitude. Maximal aerobic exercise capacity is decreased at high altitudes in both normal individuals and patients with cardiovascular disease due to a decreased arterial oxygen content from decreased inspired partial pressure of oxygen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/5\">",
"     5",
"    </a>",
"    ]. This causes tissue hypoxia (hypobaric hypoxia) from inspiring oxygen-poor air, which results in the compensatory physiological changes at rest and exercise at higher altitudes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The initial response to hypoxia is an attempt to inhale more oxygen. The minute ventilate rate and tidal volume are increased to allow for optimal systemic arterial tension [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/7\">",
"     7",
"    </a>",
"    ]. Furthermore, the pulmonary arteries constrict in response to tissue hypoxia, a condition known as hypoxic pulmonary vasoconstriction. This physiologic phenomenon is present to redirect blow flow to alveoli located within areas containing the highest oxygen content. The hypoxic vasoconstriction ultimately leads to pulmonary hypertension and furthermore an increase in the alveolar-arterial oxygen (A-a) gradient (the difference between the alveolar and arterial concentration of oxygen that is used in diagnosing the source of hypoxemia) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/8\">",
"     8",
"    </a>",
"    ]. The increased A-a gradient is caused by an unequal perfusion to the lungs from hypoxic vasoconstriction and is important in the development of high altitude pulmonary edema [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/9\">",
"     9",
"    </a>",
"    ]. For instance, after 24 hours, 15 percent of subjects develop pulmonary edema without symptoms, while 75 percent have an increase in pulmonary extravascular fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/10\">",
"     10",
"    </a>",
"    ]. Sustained exposure to high altitude for 24 hours or greater is needed for pulmonary edema to develop. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=see_link\">",
"     \"High altitude pulmonary edema\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hyperventilation leads to a decrease in carbon dioxide and causes respiratory alkalosis. This leads to a shift of the oxygen-hemoglobin dissociation curve to the left leading to increased oxygen binding to hemoglobin and less delivery to tissues. However, after a few hours, there is an increase in 2,3-diphosphoglycerate that shifts the curve back to the right, facilitating unloading of oxygen to tissues. However, consequently, this makes it more difficult for oxygen to bind to hemoglobin in the lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Oxygen delivery is the product of cardiac output and oxygen content. Given the reduction in oxygen content with increased altitude, cardiac output must increase to maintain the same oxygen delivery to the tissues. At high altitudes, the cardiac output is generally higher due to an increased heart rate [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/6\">",
"     6",
"    </a>",
"    ]. The heart rate is elevated at rest, but there is a reduced maximum heart rate and ultimately lower peak cardiac output at high altitudes than at sea level. Such limitations are autonomic responses to limit myocardial oxygen consumption during times of reduced oxygen availability. Over one to two weeks, the stroke volume is decreased from a lowered plasma volume from respiratory (hyperventilation), urinary (hypoxic diuresis), and cutaneous losses. Increased urine output is a response to high altitude hypoxia. The diuresis serves to increase bicarbonate losses in the urine to stimulate increased breathing. These losses do yield an increase in hematocrit by 1 to 2",
"    <span class=\"nowrap\">",
"     g/dl",
"    </span>",
"    that serves to increase the oxygen carrying capacity of the blood per unit volume [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/12\">",
"     12",
"    </a>",
"    ]. Within hours of exposure to altitude, red blood cell count begins to increase in response to an increase in erythropoietin. However, the overall count buildup process is slow, taking months to reach equilibrium. The degree of polycythemia is related to the altitude.",
"   </p>",
"   <p>",
"    The increase in rate-pressure product (heart rate times systolic blood pressure), reduction in arterial oxygen saturation, and elevation in lactate concentration illustrate the potential oxygen",
"    <span class=\"nowrap\">",
"     supply/demand",
"    </span>",
"    mismatch with exercise at altitude [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/2\">",
"     2",
"    </a>",
"    ]. Even though the cardiac output and rate-pressure product at a given activity level tend to be higher as altitude increases, paradoxically, the maximum attainable cardiac output, heart rate, and maximum attainable workload fall with altitude as discussed above [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, after rapid ascent to high altitude, the sympathetic nervous system is activated, which stimulates release of epinephrine [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/14\">",
"     14",
"    </a>",
"    ]. This shift towards sympathetic predominance during acute exposure to hypoxia has also been manifested by reduced heart rate variability [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/15\">",
"     15",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=see_link\">",
"     \"Heart rate variability: Technical aspects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35449?source=see_link\">",
"     \"Heart rate variability: Uses other than after myocardial infarction\"",
"    </a>",
"    .) The higher the altitude, the higher the arterial epinephrine concentration rises to enhance cardiac output, foster bronchodilation in the lungs, and further vasodilation in skeletal muscles [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/16\">",
"     16",
"    </a>",
"    ]. Vasodilation counterbalances the increase in cardiac output such that blood pressure does not change [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Several changes are observed in the resting electrocardiogram (ECG) and Doppler imaging for normal individuals exposed to high altitude.",
"   </p>",
"   <p>",
"    During ECG recordings taken from members of an expedition who climbed Mount Everest and achieved altitudes of 5335, 6250, and 7988 meters (17,500, 20,500 and 26,200 feet) ECG changes included [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increase in resting HR",
"     </li>",
"     <li>",
"      Prolongation of the QT interval",
"     </li>",
"     <li>",
"      ST-T wave flattening",
"     </li>",
"     <li>",
"      A rightward shift in the frontal QRS axis",
"     </li>",
"     <li>",
"      An increase in P wave amplitude in lead II",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The last two changes are thought to reflect evidence of right ventricular and right atrial \"strain\" arising from hypoxia-induced pulmonary hypertension. At the most extreme altitude, 3 of 12 patients developed a new right bundle branch block and three others showed changes consistent with right ventricular hypertrophy. Some of the ECG changes, primarily the increased heart rate, QT lengthening, and ST-T wave abnormalities, can be blunted with beta blocker administration [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/20\">",
"     20",
"    </a>",
"    ], suggesting a role for catecholamines in their development. Since virtually all ECG abnormalities abate upon descent, they are not thought to be clinically significant.",
"   </p>",
"   <p>",
"    Doppler imaging studies of healthy men and women at rest after rapid ascent to high altitudes have noted [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A threefold increase in mean pulmonary artery pressure",
"     </li>",
"     <li>",
"      Altered right and left ventricular diastolic function",
"     </li>",
"     <li>",
"      Prolonged isovolumic relaxation time",
"     </li>",
"     <li>",
"      Maintained right ventricular systolic function",
"     </li>",
"     <li>",
"      Improved left ventricular systolic function",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Long-term altitude exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;After three to four days, the initial sympathetic nervous system manifestations of altitude exposure resolve as early acclimatization begins. Longer-term exposure to altitude is associated with a number of other adaptive physiologic responses. These include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Resetting of the \"hypoxic ventilatory response\" to allow increased ventilation at a given hypoxic stimulus",
"     </li>",
"     <li>",
"      Increase in red blood cell mass mediated by erythropoietin",
"     </li>",
"     <li>",
"      Leftward shift of the oxygen-hemoglobin dissociation curve",
"     </li>",
"     <li>",
"      Increased tissue capillary density",
"     </li>",
"     <li>",
"      Reduction in the alveolar-arterial oxygen gradient",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     ALTITUDE STRESS IN HEART DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effects of high altitude exposure may have important implications for patients with various types of heart disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to the stress on the cardiovascular system, the possible development of high altitude diseases (mountain sickness or pulmonary or cerebral edema) can add further stress to the cardiovascular system. As a result, cardiac patients engaged in recreational activities at altitude should be warned about the signs of altitude illness, and in certain circumstances carry appropriate prophylactic medicines such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5752?source=see_link\">",
"     acetazolamide",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , and follow usual advice about altitude illness prevention, most notably gradual ascent and avoidance of dehydration. They should be advised that the quickest and most effective treatment of altitude-related illness is descent. Supplementary oxygen may also be beneficial in some individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Coronary heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Exercise at real or simulated altitude in patients with stable coronary heart disease (CHD) appears to be relatively safe, provided patients take the same precautions as they would at sea level [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/22-25\">",
"     22-25",
"    </a>",
"    ]. However, the acute hemodynamic changes associated with",
"    <span class=\"nowrap\">",
"     altitude/hypoxemia",
"    </span>",
"    result in an earlier onset of angina symptoms or ischemic ECG changes (shorter time to symptoms) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/24,26\">",
"     24,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study that compared 23 patients (mean age 51 years) with stable coronary heart disease and a mean left ventricular ejection fraction (LVEF) of 39 percent to controls during maximal bicycle ergometer stress testing at both sea level and 1000m (3280 feet), the following findings were noted [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/22\">",
"     22",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with CHD, who were more often receiving therapy with a beta blocker and angiotensin converting enzyme inhibitor, had lower peak rate-pressure product (beta blocker effect) than controls at both altitudes.",
"     </li>",
"     <li>",
"      In both patients and controls, exercise capacity was lower at altitude compared to baseline, while the maximal heart rate was the same at baseline and 8200 feet.",
"     </li>",
"     <li>",
"      Both groups maintained percent oxygen saturations in the low to mid 90s at rest and with exercise at baseline and altitude. There were no complications, such as high-grade arrhythmias or provocation of significant ischemia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In another report that demonstrates both the effect and safety of exercise at altitude, nine patients with stable CHD were evaluated during maximal treadmill stress testing both at baseline (1750m) and at altitude (3390m) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/23\">",
"     23",
"    </a>",
"    ]. Exercise at altitude was associated with the expected increase in minute ventilation and reductions in both maximal exercise duration and maximal oxygen uptake. Although the rate-pressure product at which angina or significant ST-segment depression occurred was similar at both altitudes, this occurred at a lower level of exercise when at altitude. Exercise was not associated with an increase in the extent or complexity of ventricular arrhythmias.",
"   </p>",
"   <p>",
"    A third study of the response to and safety of exercise at altitude evaluated 22 patients with prior myocardial infarction following revascularization with stress tests both at rest and within one to three hours following rapid ascent to 3454 m [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients were required to have a left ventricular ejection fraction above 45 percent, no evidence of ischemia on a baseline stress test, and controlled blood pressure. Beta blockers were withheld from patients for five days prior to the study protocol. All patients tolerated the rapid ascent, none of the cardiopulmonary stress tests were needed to be stopped prematurely, and neither evidence of ischemia nor significant arrhythmias were seen in any patients during stress testing at high altitude.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Patients without diagnosed CHD",
"    </span>",
"    &nbsp;&mdash;&nbsp;A separate issue is the frequency with which ischemia is provoked with exercise at altitude in subjects with no history of CHD. This was addressed in a study in which Holter monitor evaluation was performed in 149 selected skiers beginning at an altitude of 3430 meters [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/27\">",
"     27",
"    </a>",
"    ]. Only 5.6 percent of the skiers over age 40 showed ECG evidence of ischemia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/27\">",
"     27",
"    </a>",
"    ]. This is similar to the 5 percent incidence of ischemia noted in screening stress tests in asymptomatic individuals at sea level [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The studies above suggest that both ascending to altitude and exercising at altitude can be safe in patients with stable coronary artery disease or a remote acute coronary event. We suggest that when advising a patient with coronary heart disease (CHD) who is planning a trip to altitude, the health care provider needs to consider the patient's functional level, clinical status, and anticipated stress. In addition, our specific recommendations are as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with recent acute coronary syndromes who have not had revascularization, their ascent to altitude should be curtailed until maximal stress testing has been performed and shows an absence of overt ischemia. Patients with myocardial infarction within two weeks should only undergo air travel, a potential stress in itself, if there is no angina, dyspnea, or hypoxemia at rest and no fear of flying. In addition, they should fly with a companion, carry",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      , and be able to cope with the emotional and physical demands of travel [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/29,30\">",
"       29,30",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients should be warned that anginal symptoms will probably occur more easily at lower workloads, and so strenuous activities should be approached with more caution, particularly during the first three or four days at altitude [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/22,25\">",
"       22,25",
"      </a>",
"      ]. Access to appropriate medicines and medical care should be confirmed before arrival at altitude.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Heart failure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with heart failure are especially susceptible to the physiologic changes from high altitude exposure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/31\">",
"     31",
"    </a>",
"    ]. The increased sympathetic activity elevates the systemic vascular resistance, blood pressure, and heart rate, which results in a reduced exercise capacity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link&amp;anchor=H2#H2\">",
"     \"High altitude illness: Physiology, risk factors, and general prevention\", section on 'High altitude physiology'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The pulmonary vasoconstriction and hypertension that results from high altitude (hypoxemia) impairs right ventricle filling and output [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/33\">",
"     33",
"    </a>",
"    ]. This appears to be the most significant factor in reducing cardiovascular performance in patients with heart failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/34-36\">",
"     34-36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other factors in patients with chronic heart failure (HF) that may predispose them to exacerbations at high altitude include: [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/36\">",
"     36",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Chronically elevated catecholamine levels (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=see_link\">",
"       \"Pathophysiology of heart failure: Neurohumoral adaptations\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Increased transcapillary permeability in the lung",
"     </li>",
"     <li>",
"      Poor skeletal muscle metabolism (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17847?source=see_link\">",
"       \"Skeletal muscle dysfunction and exercise intolerance in heart failure\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      High oxygen extraction in the periphery (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7241?source=see_link\">",
"       \"Exercise capacity and VO2 in heart failure\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Poor pulmonary function",
"     </li>",
"     <li>",
"      Concurrent CHD",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In one study the response to various simulated altitudes (from 92 to 3000 meters [302 to 9840 feet]) during bicycle ergometry was studied in 14 control patients and 38 patients with stable HF who were categorized on the basis of mild, moderate, or severe impairment in baseline functional capacity (peak VO2) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/37\">",
"     37",
"    </a>",
"    ]. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All patients and controls showed the expected decreases in maximum workload attained and peak oxygen consumption with increasing altitude, but the percentage decrease was greater in the patients with HF, particularly those with the worst baseline functional capacity (peak VO2 &lt;15",
"      <span class=\"nowrap\">",
"       mL/min",
"      </span>",
"      per kg) (",
"      <a class=\"graphic graphic_figure graphicRef78575 \" href=\"UTD.htm?22/25/22942\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      None of the patients, including 12 with the worst functional capacity, were limited at altitude by arrhythmia, angina, or electrocardiographic evidence of ischemia.",
"     </li>",
"     <li>",
"      In patients with heart failure, maximum work rate decreased in parallel with increased simulated altitude, with a greater reduction in maximum physical activity in proportion to their exercise capacity at sea level.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Similar considerations apply to patients with left ventricular dysfunction. As described above, patients with stable CHD and a mean ejection fraction of at least 39 percent showed no complications with exercise during brief exposure to 8200 feet [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H7\">",
"     'Coronary heart disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    We agree with the 2010 report of a working group of the British Cardiovascular Society &ldquo;Fitness to fly for passenger with cardiovascular disease,&rdquo; which recommended that patients should wait approximately six weeks before flying or altitude exposure following an episode of acute left ventricular failure [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    An observational study on heart transplant patients found that those living at 2000 to 4000 feet had improved survival compared with those living at lower levels, suggesting that chronic exposure to higher altitude may benefit this group [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study of 23 healthy subjects reported that those with a significantly elevated brain natriuretic peptide (BNP) levels while exercising at 5150 m elevation (compared with at sea level) were more likely to suffer acute mountain sickness [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Only limited information and guidance from clinical studies are available concerning altitude exposure in patients with chronic heart failure (HF). Prior to approving exposure to altitude, the following should be assessed in individuals with a history of HF:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Baseline functional capacity",
"     </li>",
"     <li>",
"      Expected altitude that will be encountered",
"     </li>",
"     <li>",
"      Anticipated activity level while at altitude",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For the patient who exhibits symptoms at rest or during minimal activity, or who requires oxygen therapy at rest (NYHA class IV), even the stress of air flight may be significant and should be approached with caution. In such patients, oxygen therapy should be considered and for patients already on oxygen, increased flow rates can be used to alleviate symptoms.",
"   </p>",
"   <p>",
"    In comparison, patients with only mild functional compromise at sea level will probably tolerate moderate altitudes, but should be warned that they will become symptomatic at lesser degrees of exercise.",
"   </p>",
"   <p>",
"    Patients with heart failure are likely to notice reduced functional capacity at moderate to high altitude when compared to function at sea level [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/2\">",
"     2",
"    </a>",
"    ]. It is essential that altitude be considered in the etiology of any symptoms and the patient advised to arrange immediate descent if decompensation occurs. Symptoms that would herald decompensation include: chest pain, palpitations, shortness of breath, dyspnea, and fatigue.",
"   </p>",
"   <p>",
"    We agree with the 2010 report of a working group of the British Cardiovascular Society &ldquo;Fitness to fly for passenger with cardiovascular disease,&rdquo; which suggested no flying or exposure to altitude for six weeks after an acute left ventricular failure episode [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Arrhythmias",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of arrhythmias at altitude is variable and depends upon the patient group under study. Heightened sympathetic activity associated with high altitude may increase the frequency and duration of supraventricular and ventricular arrhythmias in patients with underlying heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative freedom from arrhythmias among young healthy individuals was documented in a hypobaric chamber study of eight healthy men aged 21 to 31, who were observed during exercise at simulated altitudes up to the equivalent of the summit of Mount Everest [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/43\">",
"     43",
"    </a>",
"    ]. No arrhythmias or conduction defects were seen [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In comparison, older patients may experience altitude-induced arrhythmias. In a Holter monitor study of healthy middle-aged men, the incidence of both supraventricular and ventricular premature beats (VPBs) was nearly doubled at an altitude of 1350 meters (4428 feet) as compared to 200 meters (656 feet) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/44\">",
"     44",
"    </a>",
"    ]. At still higher altitude (2632 meters [8633 feet]), the frequency of ectopy was increased six- to sevenfold [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/45\">",
"     45",
"    </a>",
"    ]. It was felt that the increase in premature beats was due to beta adrenergic stimulation at the higher altitude brought on by the early release of catecholamines.",
"   </p>",
"   <p>",
"    Patients with stable CHD have also been evaluated. In a previously described study, 10 elderly patients with exercise-induced ischemic changes at sea level were studied at 2500 meters (8200 feet), both acutely and after five days of acclimatization [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/24\">",
"     24",
"    </a>",
"    ]. VPBs were significantly increased with acute exposure, but returned to sea level values after acclimatization. This suggests an early sympathetic stimulation on acute exposure to altitude is driving these changes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;It appears that altitude can aggravate arrhythmias, particularly during acute exposure and with exercise, in patients with the appropriate underlying substrate (especially older adults and those with known arrhythmias or CHD). Air travel alone is probably of low risk, except in those with baseline (resting) ventricular and supraventricular arrhythmias in whom the added stress of mild hypoxemia might lead to decompensation. Such patients should be cautioned about air travel,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    be considered for supplemental oxygen.",
"   </p>",
"   <p>",
"    Similar recommendations apply to those contemplating vacationing at high altitude. The patient should be warned to keep activities less than their sea level baseline, particularly during the first five days at altitude, and should be aware of and treat immediately both cardiac and noncardiac manifestations of altitude exposure.",
"   </p>",
"   <p>",
"    Caution is clearly needed in patients with poorly controlled rhythm disorders. Deaths at high altitude are often sudden and, while ascertainment of the cause of death is often difficult, the possibility that rhythm-related causes are being underestimated needs to be kept in mind.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Pacemaker function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The issue of pacemaker safety at altitude and the possibility of alterations in stimulation thresholds are uncertain since data are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an early study simulating altitude with inhalation of 10 percent oxygen, a significant but reversible increase in stimulation thresholds was noted [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/46\">",
"       46",
"      </a>",
"      ]. In another phase of threshold testing, hypocapnia, induced by mechanic hyperventilation, led to a reduction in pacing stimulation thresholds.",
"     </li>",
"     <li>",
"      In a more contemporary report, stepwise simulated hypobaric chamber ascent from 450 meters to 4000 meters (1476 to 13,120 feet) produced no change in stimulation threshold in spite of significant fall in PaO2 [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/47\">",
"       47",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It seems likely that the competing effects of hypoxia and hypocapnia, each pushing the pacing stimulation threshold in a different direction, may balance each other and prevent any net change during the physiologic stress of true altitude exposure.",
"   </p>",
"   <p>",
"    Based on the limited data, it appears that pacing thresholds can be expected to remain unchanged at the moderate altitudes seen with air travel and recreational skiing. The safety of pacemakers at the extreme altitudes, as with trekking and mountaineering, is not known.",
"   </p>",
"   <p>",
"    Airport security gates may detect pacemakers and defibrillators, but do not appear to interfere with device function [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/25\">",
"     25",
"    </a>",
"    ]. In contrast, there is a theoretical risk that handheld metal detectors may interfere with personal electronic devices [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Congenital heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital heart disease associated with intracardiac or extracardiac shunts may be associated with a net shunting of blood from the left, high pressure side of the heart to the right, low pressure side. However, with exposure to high altitude and hypobaric hypoxia, pulmonary vascular resistance and right-sided pressures are increased [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/9\">",
"     9",
"    </a>",
"    ]. This results in an increase in right to left shunting leading to arterial oxygen desaturation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/48-50\">",
"     48-50",
"    </a>",
"    ]. The extent to which arterial oxygen desaturation occurs will depend upon many factors, including the size of the communication, baseline right-sided pressures, and the extent of altitude-induced pulmonary hypertension.",
"   </p>",
"   <p>",
"    It is important to appreciate whether there is an increased prevalence of congenital heart disease (ie, patent foramen ovale or patent ductus arteriosus [PDA]) at high altitudes. This might be due to a persistence of the fetal pattern of the pulmonary vasculature (thick, smooth muscle cells, narrow lumens, small pulmonary vessels, increased pulmonary, and right ventricular pressures) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/51-53\">",
"     51-53",
"    </a>",
"    ]. In a prospective study of 1116 school children, there was a high prevalence of PDA and atrial septal defect at three high altitude sites, as well as a graded effect as altitude increased [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/54\">",
"     54",
"    </a>",
"    ]. One explanation is that this results from a failure of the lower oxygen tension to constrict the ductus and thus foramen ovale closure is inhibited.",
"   </p>",
"   <p>",
"    A large cross-sectional study examined children aged 4 to 18 years in the Qinghai province of China where 1633 cases of congenital heart disease were discovered. Of those, the prevalence of congenital heart disease was found to increase in a gradient-like fashion as the altitude increased by 4.9 per thousand at 2535m, 5.7 per thousand at 3600m, and 8.7 per thousand at 4200m [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study demonstrated higher pulmonary artery pressures in children with atrial septal defects born at altitude compared with both those without such defects at altitude and those with similar defects not at altitude [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/56\">",
"     56",
"    </a>",
"    ]. Similar findings were noted in another report in which children with ventricular septal defects born in Denver (elevation 1609 m or 5280 feet above sea level) had twice the pulmonary vascular resistance of children born with such defects at sea level [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/57\">",
"     57",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For those individuals with congenital defects who then progress into adulthood, it was found that exposure to moderate altitude (1,500 to 2,500m) has been reported to be safe in a small study of adults with cyanotic congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/58\">",
"     58",
"    </a>",
"    ]. The altitude of 2500m in this study is relevant in that airplanes are pressurized at this altitude when flying.",
"   </p>",
"   <p>",
"    Moreover, data from a limited study suggest that it is safe for Eisenmenger patients to travel in commercial airlines as long as the airplanes are adequately pressurized. Supplemental oxygen should be available, although its efficacy is unproven. The approach to patients with Eisenmenger syndrome who wish to either travel in commercial airlines or visit geographies at altitude is discussed in detail elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/59\">",
"     59",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=see_link&amp;anchor=H14#H14\">",
"     \"Medical management of Eisenmenger syndrome\", section on 'High altitude'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"     \"Traveling with oxygen aboard commercial air carriers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Advice to the child or adult with congenital heart disease contemplating altitude exposure must be individualized and based upon the nature of the congenital defect and expected stresses. Patients most at risk are those with intracardiac communication defects and the propensity to worsen right-to-left shunting in the presence of elevated right-sided pressure. Consultation with a pediatric or adult cardiologist specializing in congenital defects should precede altitude exposure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     AIR TRAVEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with well-compensated heart disease can travel without difficulty. The safety of air travel has been increased by a Federal Aviation Administration requirement, implemented in April 2004, that all aircraft carrying at least 30 passengers and having at least one flight attendant should carry an emergency medical kit and an automated external defibrillator (AED) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/60,61\">",
"     60,61",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=see_link\">",
"     \"Automated external defibrillators\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A variety of practical tips for the cardiopulmonary patient traveling by air are found in the following table (",
"    <a class=\"graphic graphic_table graphicRef52930 \" href=\"UTD.htm?22/6/22636\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Potential risk",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although commercial airplanes typically cruise between 6700 and 13,400 meters (22,000 and 44,000 feet) to improve efficiency, the pressurization process maintains cabin pressure at an altitude equivalent to 2439 meters (8000 feet) or less, with typical cabin pressures ranging from 1524 to 2439 meters (5000 to 8000 feet) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/62,63\">",
"     62,63",
"    </a>",
"    ]. At that altitude, the barometric pressure is decreased to 564 mmHg (compared to 760 mmHg at sea level). The net effect is a PiO2 of 108 mmHg, with associated partial pressures of oxygen in the alveoli and arterial blood of normal individuals of 69 mmHg and 60 mmHg, respectively. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Barometric pressure and PiO2'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    While the person with a normal cardiopulmonary reserve can easily compensate for the reduced arterial PO2 at these altitudes and maintain adequate tissue oxygen delivery, those with little or no reserve are at risk of profound arterial desaturation and cardiopulmonary decompensation. Persons with limited cardiopulmonary reserve exposed to high altitude may experience light headedness, chest pain, tingling in the extremities, palpitations, dyspnea, and hyperventilation. Further stress from air travel may result from associated immobility, jet lag, vibration, noise, and low humidity [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Incidence of problems",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have reported on the incidence of serious health problems occurring during flight and, in the absence of any central registries or reporting requirements by airlines, it is likely that incidences are underestimated. In a recent United States study, the most common reasons for a flight to be diverted were cardiac incidents (28 percent), neurological problems (20 percent), and food poisoning (20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/65-68\">",
"     65-68",
"    </a>",
"    ]. It is likely that the majority of cardiac incidents are vasovagal syncope related to dehydration, alcohol, recumbency, and emotional stress. Various figures are also reported for in-flight deaths, in the range of one death per 1.5 to 4.7 billion passenger miles flown.",
"   </p>",
"   <p>",
"    The incidence of in-flight problems in patients with known coronary artery disease has not been well studied in patients receiving contemporary medical and revascularization therapies. One study reported experience in transporting patients with recent myocardial infarction using a medical repatriation (returning a person back to one's place of origin or citizenship) company. During the period from April of 2004 through November of 2005, a total of 213 patients were transported 6 to 38 days (mean 12.9 days) following presentation with ST elevation MI (STEMI) or non-ST elevation MI (NSTEMI) [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/69\">",
"     69",
"    </a>",
"    ]. No serious complications occurred in any of these patients. Despite relatively frequent asymptomatic hypoxemia (defined as pulse oximetry &lt;92 percent), none of 56 patients with prior NSTEMI experienced in-flight angina, and only 3 of 157 patients with prior STEMI had angina. Among those experiencing angina, all were within 14 days of their MI; no patients experienced angina when flying after 14 days from their myocardial infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Recommendations",
"    </span>",
"    &nbsp;&mdash;&nbsp;A 2010 report of a working group of the British Cardiovascular Society &ldquo;Fitness to fly for passenger with cardiovascular disease&rdquo; made the following general recommendations, with which we agree [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Arrive at the airport in sufficient time to avoid rushing",
"     </li>",
"     <li>",
"      Warn the carrier",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      airport authority of any requirements for assistance, including the requirement for in-flight oxygen, well in advance or the date of departure",
"     </li>",
"     <li>",
"      Carry and appropriate supply of medication, as well as a clear list of all medications and doses",
"     </li>",
"     <li>",
"      Carry a letter from their caregiver(s) explaining their condition, drugs, allergies and devices (such as pacemaker or implantable cardioverter defibrillator).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with poorly-controlled heart disease should be advised against air travel. The key cardiac contraindications to air travel include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/60\">",
"     60",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Unstable angina",
"     </li>",
"     <li>",
"      High-grade ventricular premature beats or uncontrolled ventricular or supraventricular arrhythmias",
"     </li>",
"     <li>",
"      Severe decompensated heart failure (HF) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/60,70\">",
"       60,70",
"      </a>",
"      ]. Patients with class III or IV New York Heart Association HF should be carefully assessed to determine whether they will need in-flight oxygen. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=see_link\">",
"       \"Evaluation of the patient with suspected heart failure\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"       \"Traveling with oxygen aboard commercial air carriers\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Symptomatic valvular heart disease is a relative contraindication to airline travel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Supplemental oxygen",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who require supplemental oxygen at sea level will require supplemental oxygen during air travel [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/60\">",
"     60",
"    </a>",
"    ]. In addition, supplemental oxygen is widely recommended empirically for individuals whose in&ndash;flight resting PaO2 is predicted to be less than 50 mmHg. Standard techniques for determining the predicted PaO2 at altitude are available [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/62\">",
"     62",
"    </a>",
"    ]. As a practical matter, a PaO2 less than 72 mmHg at sea level predicts the need for supplemental in&ndash;flight oxygen in most subjects. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=see_link\">",
"     \"Traveling with oxygen aboard commercial air carriers\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Stable coronary artery disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evaluation of the patient with known coronary disease before flying should include a careful history and physical examination to identify symptoms or signs of recent angina, volume overload or dysrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/60\">",
"     60",
"    </a>",
"    ]. A resting electrocardiogram should be obtained, and, if it is abnormal, a copy should be given to the patient to carry during travel. Among patients with chronic stable angina, routine stress testing prior to air travel is not necessary unless there has been a recent significant change in clinical status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Myocardial infarction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The 2004 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart Association",
"    <span class=\"nowrap\">",
"     (ACC/AHA)",
"    </span>",
"    guidelines on ST elevation myocardial infarction (MI), which were not changed in the 2007 or 2009 focused updates, recommend that air travel within the first two weeks after an MI should be undertaken only if the patient has no angina, no dyspnea at rest and no fear of flying [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/71-73\">",
"     71-73",
"    </a>",
"    ]. The patient should have a companion, carry",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"     nitroglycerin",
"    </a>",
"    , and request airport transportation to avoid rushing. Patients with an MI complicated by severely depressed cardiac function or an untoward event (ie, heart failure, sudden cardiac arrest, or cardiogenic shock) should not fly until two weeks after they are deemed medically stable.",
"   </p>",
"   <p>",
"    In contrast, the Aerospace Medical Association recommends that no air travel be undertaken within two to three weeks of an uncomplicated MI and within six weeks of a complicated MI [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The 2010 report of a working group of the British Cardiovascular Society &ldquo;Fitness to fly for passenger with cardiovascular disease&rdquo; performed a comprehensive review of the evidence (mostly observational) upon which recommendations for air flight after an acute coronary syndrome can be made [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/38\">",
"     38",
"    </a>",
"    ]. They concluded that such passengers should be risk stratified into very low, medium, and high, and that air travel is reasonable after 3 and 10 days for the low and medium risk groups. Those at high risk or awaiting further",
"    <span class=\"nowrap\">",
"     investigation/treatment",
"    </span>",
"    should defer air travel until a more stable situation is achieved, deferring altitude exposure for a minimum of six weeks. These three groups were defined as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Very low risk: ages &lt;65 years, first event, successful reperfusion, left ventricular ejection fraction (LVEF) &gt;45 percent, no complications and no planned investigations or interventions.",
"     </li>",
"     <li>",
"      Low (or medium) risk: LVEF &gt;40 percent, no symptoms of heart failure (HF), no evidence of inducible ischemia or arrhythmia and no further investigations or interventions planned.",
"     </li>",
"     <li>",
"      High risk: LVEF &lt;40 percent with signs and symptoms of heart failure, those pending further investigations with a view to revascularization or device therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Our experts believe that the approach proposed by the British Cardiovascular Society is reasonable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h3\">",
"     Percutaneous coronary intervention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediately after coronary stent placement, airline travel should be avoided, due to the increased risk of acute stent thrombosis during this time [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/60\">",
"     60",
"    </a>",
"    ]. We suggest postponing travel arrangements for two days in uncomplicated cases, or two weeks in complicated cases following such a procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Coronary artery bypass graft surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Those who have undergone coronary artery bypass grafting should wait at least 10 days, as there is a potential risk of barotrauma caused by expanding gases artificially introduced to the chest during coronary bypass surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Implanted devices",
"    </span>",
"    &nbsp;&mdash;&nbsp;Air travel has not been shown to interfere with the function of implantable cardioverter defibrillators (ICDs) or pacemakers [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/74-76\">",
"     74-76",
"    </a>",
"    ]. Such patients are advised to request a hand search, if possible [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/60\">",
"     60",
"    </a>",
"    ]. If a handheld detector must be used, the patient should request that it not be held over the implanted device for more than a few seconds, and that at least 30 seconds should elapse between passes. In addition such patients should carry a card identifying the type of device [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/60\">",
"     60",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H14\">",
"     'Pacemaker function'",
"    </a>",
"    above.) We agree the 2010 report of a working group of the British Cardiovascular Society &ldquo;Fitness to fly for passenger with cardiovascular disease&rdquo; which suggested that following placement of ICD or pacemaker, in the absence of pneumothorax or other complication (bleeding, electrode problem) patients can travel to altitude within two days of implantation [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/38\">",
"     38",
"    </a>",
"    ]. They should be advised to restrict arm movements",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    carrying heavy loads on the ipsilateral side to minimize mechanical complications such as lead displacement.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Deep vein thrombosis and pulmonary embolism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients at risk of pulmonary embolism (PE) should be advised to exercise their limbs at regular intervals, and with especially long flights, take walks within the aisle every hour. The use of below the knee compression stockings should also be considered. For the patient at high risk of PE contemplating a prolonged flight, anticoagulation therapy may be appropriate. A more detailed discussion of these issues is found elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13737?source=see_link&amp;anchor=H8#H8\">",
"     \"Patient assessment for air travel\", section on 'Deep vein thrombosis'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=see_link\">",
"     \"Prevention of venous thromboembolic disease in surgical patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h1\">",
"     TREKKING AND MOUNTAINEERING",
"    </span>",
"    &nbsp;&mdash;&nbsp;The allure of the high altitude environment is attracting increasing numbers to high mountains around the world. Although the most extreme ascents are still performed by young and middle-aged adults who appear to be at risk only from altitude related illness and trauma (as opposed to exacerbation of cardiopulmonary disease), an increasing number of older individuals are venturing into the mountains as well.",
"   </p>",
"   <p>",
"    Based upon an analysis of information provided by tourists seeking visas in Nepal (where about one-third come for trekking), 20 percent were 50 years or older [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/77\">",
"     77",
"    </a>",
"    ]. This analysis also found that cardiac illness contributed to only about 5 percent of helicopter evacuations and none of the reported deaths.",
"   </p>",
"   <p>",
"    Another review evaluated sudden deaths among participants engaging in high mountain hiking, skiing, or both in Austria between 1985 and 1991 [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/78\">",
"     78",
"    </a>",
"    ]. Four-hundred-sixteen deaths were deemed sudden, representing about 30 percent of all mountain sport related deaths [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/78\">",
"     78",
"    </a>",
"    ]. Most of the deaths occurred at altitudes between 1100 to 2100 meters (3600 to 6900 feet). Hikers were more than two times as likely as skiers to die. Among the hikers, the risk of death was highly influenced by age and lack of prior physical activity.",
"   </p>",
"   <p>",
"    The relatively low incidence of cardiac complications among trekkers and mountaineers likely results from the low incidence of cardiovascular disease in this population. In a survey of ski mountaineers in the Austrian Alps, for instance, only 5.7 percent of women and 12.0 percent of men over the age of 40 reported any type of cardiovascular disease [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Prior myocardial infarction appears to be the greatest predictor of risk regarding sudden cardiac death (SCD) among those who downhill ski. In a case control study of 68 skiers with sudden death compared with 204 controls, those with a previous MI had a 93 times higher adjusted SCD risk, those with hypertension a 9.0 higher risk, and those with known coronary heart disease without prior MI a 4.8 fold increased risk [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/79\">",
"     79",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Considering all of the above, exercising at high altitudes should be approached carefully, and an individual should consider his or her own fitness level as he or she plans such recreation. If someone regularly exercises at sea-level altitudes, he or she will be more likely to properly handle the added stressors experienced at higher altitudes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/59\">",
"     59",
"    </a>",
"    ]. In addition we suggest not exercising the first day at altitude and planning out gradual increases in intensity as a trip moves forward. Paying attention to adequate hydration and avoiding alcohol are both also important.",
"   </p>",
"   <p>",
"    From this limited information, potential trekkers should be evaluated on the basis of known cardiac disease as discussed above, and should be reminded of the importance of adequate training and conditioning before entering this extreme environment. Acute altitude-related illness remains a frequent cause of morbidity and mortality for trekkers either with or without cardiac disease. Among patients with heart disease who seek medical attention prior to such a trip, advice should include [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Adequate control of blood pressure, arrhythmias, and other cardiac issues prior to ascent.",
"     </li>",
"     <li>",
"      Strict attention to taking usual medications and dealing with cardiac symptoms should they arise.",
"     </li>",
"     <li>",
"      Slow ascent to allow time for acclimatization. A rule of thumb during mountaineering is to ascend no more than 305 meters (1000 feet) per day and to allow a day of rest (no ascent) after every third day [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Usual prophylactic measures to prevent altitude sickness. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=see_link\">",
"       \"High altitude illness: Physiology, risk factors, and general prevention\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Descent is the safest and quickest path to resolution of altitude-related symptoms.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ascent to high altitude without acclimatization can put patients with heart disease at risk for further cardiac events. Acute exposure to significant altitude leads to decreases in tissue oxygenation and forces compensatory adjustments of the cardiorespiratory system that may result in acute decompensation of underlying cardiac conditions. This is especially true in patients who have marginal cardiopulmonary function at sea level or those with active or recent unstable acute coronary syndromes [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Altitude stress in heart disease'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23\">",
"     'Myocardial infarction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There are few studies, and no randomized trials, upon which recommendations can be made for people with heart disease who want to travel (or exercise) at high altitude. Nevertheless, reasonable recommendations can be made using the following pieces of information:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Baseline functional capacity",
"     </li>",
"     <li>",
"      Expected altitude that will be encountered",
"     </li>",
"     <li>",
"      Anticipated activity level while at altitude.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With this information, we make the following suggestions for patients with heart disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Limit activity at moderate or high altitudes to a lower maximal level than typically performed at sea level (80 to 90 percent). This is especially true during the first few days.",
"     </li>",
"     <li>",
"      Raise sleeping altitude gradually (&lt;305 meters per night) if a prolonged trek is planned, with a &lsquo;no ascent day&rsquo; every third day.",
"     </li>",
"     <li>",
"      Achieve a moderate degree of physical conditioning at sea level before exercising at high altitude [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Consider performing an exercise stress test to evaluate heart disease before planning any activity at altitude if there are any concerns about cardiovascular status [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/80\">",
"       80",
"      </a>",
"      ]. However, we do not recommend routine exercise stress testing.",
"     </li>",
"     <li>",
"      For the patient within two weeks of acute myocardial infarction, consider air travel only if there is no angina, dyspnea or hypoxemia at rest, or fear of flying, and if the patient flies with a companion, carries",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/24/11656?source=see_link\">",
"       nitroglycerin",
"      </a>",
"      , and is able to avoid the emotional and physical demands of travel. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Coronary heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with unstable angina, uncontrolled ventricular or supraventricular arrhythmias, or decompensated heart failure should travel only for emergencies.",
"     </li>",
"     <li>",
"      Advise patients with CAD, arrhythmia, or CHF that they may become symptomatic at lower exercise workloads at high altitudes (&gt;2500 meters) [",
"      <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/22,25\">",
"       22,25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients who have undergone revascularization with either percutaneous coronary intervention or coronary artery bypass graft surgery within three weeks should not exercise above low altitude (&lt;1500 meters).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with recent, unstable cardiovascular conditions should be directed to refrain from altitude exposure. In contrast, stable patients who exercise at sea level without symptoms can generally exercise at altitude as long as they are vigilant regarding their heart rate and pressure, and plan to decrease the total intensity and duration of their exercise [",
"    <a class=\"abstract\" href=\"UTD.htm?15/42/16042/abstract/2\">",
"     2",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Heart failure'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H12\">",
"     'Arrhythmias'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H14\">",
"     'Pacemaker function'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H23\">",
"     'Myocardial infarction'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H24\">",
"     'Percutaneous coronary intervention'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H25\">",
"     'Coronary artery bypass graft surgery'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H26\">",
"     'Implanted devices'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/1\">",
"      Plant T, Aref-Adib G. Travelling to new heights: practical high altitude medicine. Br J Hosp Med (Lond) 2008; 69:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/2\">",
"      Higgins JP, Tuttle T, Higgins JA. Altitude and the heart: is going high safe for your cardiac patient? Am Heart J 2010; 159:25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/3\">",
"      Morgan, BJ, Alexander, JK, Nicoli, SA, et al. The patient with coronary heart disease at altitude: observations during acute exposure to 3100 meters. J Wilderness Med 1990; 1:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/4\">",
"      Richalet JP, Larmignat P, Poitrine E, et al. Physiological risk factors for severe high-altitude illness: a prospective cohort study. Am J Respir Crit Care Med 2012; 185:192.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/5\">",
"      Huez S, Faoro V, Gu&eacute;nard H, et al. Echocardiographic and tissue Doppler imaging of cardiac adaptation to high altitude in native highlanders versus acclimatized lowlanders. Am J Cardiol 2009; 103:1605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/6\">",
"      Nishihara F, Shimada H, Saito S. Rate pressure product and oxygen saturation in tourists at approximately 3000 m above sea level. Int Arch Occup Environ Health 1998; 71:520.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/7\">",
"      Jones JG, Bakewell SE, Heneghan CP, et al. Profound hypoxemia in pulmonary patients in airline-equivalent hypoxia: roles of VA/Q and shunt. Aviat Space Environ Med 2008; 79:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/8\">",
"      Wagner PD, Sutton JR, Reeves JT, et al. Operation Everest II: pulmonary gas exchange during a simulated ascent of Mt. Everest. J Appl Physiol 1987; 63:2348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/9\">",
"      Maggiorini M, M&eacute;lot C, Pierre S, et al. High-altitude pulmonary edema is initially caused by an increase in capillary pressure. Circulation 2001; 103:2078.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/10\">",
"      Cremona G, Asnaghi R, Baderna P, et al. Pulmonary extravascular fluid accumulation in recreational climbers: a prospective study. Lancet 2002; 359:303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/11\">",
"      Samaja M. Blood gas transport at high altitude. Respiration 1997; 64:422.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/12\">",
"      Sawka MN, Convertino VA, Eichner ER, et al. Blood volume: importance and adaptations to exercise training, environmental stresses, and trauma/sickness. Med Sci Sports Exerc 2000; 32:332.",
"     </a>",
"    </li>",
"    <li>",
"     Hultgren, HN. The systemic circulation. In: High Altitude Medicine, Hultgren Publications, Stanford 1997.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/14\">",
"      Mazzeo RS, Reeves JT. Adrenergic contribution during acclimatization to high altitude: perspectives from Pikes Peak. Exerc Sport Sci Rev 2003; 31:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/15\">",
"      Wille M, Mairer K, Gatterer H, et al. Changes in cardiac autonomic activity during a passive 8 hour acute exposure to 5&thinsp;500 m normobaric hypoxia are not related to the development of acute mountain sickness. Int J Sports Med 2012; 33:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/16\">",
"      Alexander JK. Coronary heart disease at altitude. Tex Heart Inst J 1994; 21:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/17\">",
"      Nault P, Halman S, Paradis J. Ankle-brachial index on Kilimanjaro: lessons from high altitude. Wilderness Environ Med 2009; 20:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/18\">",
"      Mytton OT, Simpson A, Thompson AA, et al. Manual assessment of the initial fall in blood pressure after orthostatic challenge at high altitude. Wilderness Environ Med 2008; 19:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/19\">",
"      Karliner JS, Sarnquist FF, Graber DJ, et al. The electrocardiogram at extreme altitude: experience on Mt. Everest. Am Heart J 1985; 109:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/20\">",
"      Saurenmann P, Koller EA. The ECG changes due to altitude and to catecholamines. Eur J Appl Physiol Occup Physiol 1984; 53:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/21\">",
"      Silva-Urra JA, Urizar C, Basualto-Alarc&oacute;n C, et al. Effects of oxygen supplementation on acute mountain sickness symptoms and functional capacity during a 2-kilometer walk test on Chajnantor plateau (5050 meters, Northern Chile). Wilderness Environ Med 2011; 22:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/22\">",
"      Erdmann J, Sun KT, Masar P, Niederhauser H. Effects of exposure to altitude on men with coronary artery disease and impaired left ventricular function. Am J Cardiol 1998; 81:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/23\">",
"      Morgan, BJ, Alexandere, JK, Nicoli, SA, et al. The patient with coronary heart disease at altitude: observations during acute exposure to 3100 meters. J Wilderness Med 1990; 1:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/24\">",
"      Levine BD, Zuckerman JH, deFilippi CR. Effect of high-altitude exposure in the elderly: the Tenth Mountain Division study. Circulation 1997; 96:1224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/25\">",
"      Schmid JP, Noveanu M, Gaillet R, et al. Safety and exercise tolerance of acute high altitude exposure (3454 m) among patients with coronary artery disease. Heart 2006; 92:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/26\">",
"      Wyss CA, Koepfli P, Fretz G, et al. Influence of altitude exposure on coronary flow reserve. Circulation 2003; 108:1202.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/27\">",
"      Grover RF, Tucker CE, McGroarty SR, Travis RR. The coronary stress of skiing at high altitude. Arch Intern Med 1990; 150:1205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/28\">",
"      Gordon DJ, Ekelund LG, Karon JM, et al. Predictive value of the exercise tolerance test for mortality in North American men: the Lipid Research Clinics Mortality Follow-up Study. Circulation 1986; 74:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/29\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction--executive summary. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol 2004; 44:671.",
"     </a>",
"    </li>",
"    <li>",
"     Anderson J, Adams C, Antman E, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, American College or Physicians, Society for Academic Emergency Medicine, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 2007; 50:e1 www.acc.org/qualityandscience/clinical/statements.htm (Accessed on September 18, 2007).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/31\">",
"      Negrao CE, Middlekauff HR. Adaptations in autonomic function during exercise training in heart failure. Heart Fail Rev 2008; 13:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/32\">",
"      Chen YC, Lin FC, Shiao GM, Chang SC. Effect of rapid ascent to high altitude on autonomic cardiovascular modulation. Am J Med Sci 2008; 336:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/33\">",
"      Pedrinelli R, Dell'Omo G, Talini E, et al. Systemic hypertension and the right-sided cardiovascular system: a review of the available evidence. J Cardiovasc Med (Hagerstown) 2009; 10:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/34\">",
"      Palatini P, Businaro R, Berton G, et al. Effects of low altitude exposure on 24-hour blood pressure and adrenergic activity. Am J Cardiol 1989; 64:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/35\">",
"      Wright A, Brearey S, Imray C. High hopes at high altitudes: pharmacotherapy for acute mountain sickness and high-altitude cerebral and pulmonary oedema. Expert Opin Pharmacother 2008; 9:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/36\">",
"      Kraus WE. Taking heart failure to new heights: its pathophysiology at simulated altitude. Am J Med 2000; 109:504.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/37\">",
"      Agostoni P, Cattadori G, Guazzi M, et al. Effects of simulated altitude-induced hypoxia on exercise capacity in patients with chronic heart failure. Am J Med 2000; 109:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/38\">",
"      Smith D, Toff W, Joy M, et al. Fitness to fly for passengers with cardiovascular disease. Heart 2010; 96 Suppl 2:ii1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/39\">",
"      Wozniak CJ, Baird BC, Stehlik J, et al. Improved survival in heart transplant patients living at high altitude. J Thorac Cardiovasc Surg 2012; 143:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/40\">",
"      Woods D, Hooper T, Hodkinson P, et al. Effects of altitude exposure on brain natriuretic peptide in humans. Eur J Appl Physiol 2011; 111:2687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/41\">",
"      Gibelli G, Fantoni C, Anz&agrave; C, et al. Arrhythmic risk evaluation during exercise at high altitude in healthy subjects: role of microvolt T-wave alternans. Pacing Clin Electrophysiol 2008; 31:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/42\">",
"      Faulhaber M, Flatz M, Burtscher M. Frequency of cardiovascular diseases among ski mountaineers in the Austrian Alps. Int J Sports Med 2007; 28:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/43\">",
"      Malconian M, Rock P, Hultgren H, et al. The electrocardiogram at rest and exercise during a simulated ascent of Mt. Everest (Operation Everest II). Am J Cardiol 1990; 65:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/44\">",
"      Kujan&iacute;k S, Sninc&aacute;k M, Vok&aacute;l' J, et al. Periodicity of arrhythmias in healthy elderly men at the moderate altitude. Physiol Res 2000; 49:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/45\">",
"      Kujan&iacute;k S, Sninc&aacute;k M, Galajdov&aacute; K, Rackov&aacute; K. Cardiovascular changes during sudden ascent in a cable cabin to the moderate altitude. Physiol Res 2000; 49:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/46\">",
"      Westerholm CJ. Threshold studies in transvenous cardiac pacemaker treatment. Direct measurement with special reference to short and long term stimulation and influence of certain metabolic, respiratory and pharmacological factors. Scand J Thorac Cardiovasc Surg Suppl 1971; 8:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/47\">",
"      Weilenmann D, Duru F, Sch&ouml;nbeck M, et al. Influence of acute exposure to high altitude and hypoxemia on ventricular stimulation thresholds in pacemaker patients. Pacing Clin Electrophysiol 2000; 23:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/48\">",
"      Sartori C, Allemann Y, Scherrer U. Pathogenesis of pulmonary edema: learning from high-altitude pulmonary edema. Respir Physiol Neurobiol 2007; 159:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/49\">",
"      Allemann Y, Hutter D, Lipp E, et al. Patent foramen ovale and high-altitude pulmonary edema. JAMA 2006; 296:2954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/50\">",
"      Das BB, Wolfe RR, Chan KC, et al. High-altitude pulmonary edema in children with underlying cardiopulmonary disorders and pulmonary hypertension living at altitude. Arch Pediatr Adolesc Med 2004; 158:1170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/51\">",
"      Szkutnik M, Menacho-Delgadillo R, Palmero-Zilveti E, Bialkowski J. Transcatheter closure of patent ductus arteriosus among native high-altitude habitants. Pediatr Cardiol 2008; 29:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/52\">",
"      Miao CY, Li WX, Geng D, et al. Effect of high altitude on prevalence of congenital heart disease. Chin Med J (Engl) 1988; 101:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/53\">",
"      Vargas E, Spielvogel H. Chronic mountain sickness, optimal hemoglobin, and heart disease. High Alt Med Biol 2006; 7:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/54\">",
"      Miao CY, Zuberbuhler JS, Zuberbuhler JR. Prevalence of congenital cardiac anomalies at high altitude. J Am Coll Cardiol 1988; 12:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/55\">",
"      Chen QH, Liu FY, Wang XQ, et al. [A cross-sectional study of congenital heart disease among children aged from 4 to 18 years at different altitudes in Qinghai province, China]. Zhonghua Liu Xing Bing Xue Za Zhi 2009; 30:1248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/56\">",
"      DALEN JE, BRUCE RA, COBB LA. Interaction of chronic hypoxia of moderate altitude on pulmonary hypertension complicating defect of the atrial septum. N Engl J Med 1962; 266:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/57\">",
"      Vogel JH, McNamara DG, Blount SG Jr. Role of hypoxia in determining pulmonary vascular resistance in infants with ventricular septal defects. Am J Cardiol 1967; 20:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/58\">",
"      Harinck E, Hutter PA, Hoorntje TM, et al. Air travel and adults with cyanotic congenital heart disease. Circulation 1996; 93:272.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/59\">",
"      Thompson, DL. Fitness Focus Copy-and-Share: Exercise at Altitude. ACSM's Health &amp; Fitness Journal 2009; 13:4.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/60\">",
"      Possick SE, Barry M. Evaluation and management of the cardiovascular patient embarking on air travel. Ann Intern Med 2004; 141:148.",
"     </a>",
"    </li>",
"    <li>",
"     Code of Federal Regulation 14 CFR 121. Appendix A:555-7. Office of the Federal Register; 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/62\">",
"      Gong H Jr. Air travel and oxygen therapy in cardiopulmonary patients. Chest 1992; 101:1104.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/63\">",
"      Cottrell JJ. Altitude exposures during aircraft flight. Flying higher. Chest 1988; 93:81.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/64\">",
"      Rayman RB. Passenger safety, health, and comfort: a review. Aviat Space Environ Med 1997; 68:432.",
"     </a>",
"    </li>",
"    <li>",
"     Garrett, JS. Experience with 1132 in-flight medical emergencies: what have we learned? Presented at South Californian Institute, 15 January 1999.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/66\">",
"      Goodwin T. In-flight medical emergencies: an overview. BMJ 2000; 321:1338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/67\">",
"      Gong H Jr. Exposure to moderate altitude and cardiorespiratory diseases. Cardiologia 1995; 40:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/68\">",
"      Beighton PH, Richards PR. Cardiovascular disease in air travellers. Br Heart J 1968; 30:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/69\">",
"      Thomas MD, Hinds R, Walker C, et al. Safety of aeromedical repatriation after myocardial infarction: a retrospective study. Heart 2006; 92:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/70\">",
"      Aerospace Medical Association Medical Guidelines Task Force. Medical Guidelines for Airline Travel, 2nd ed. Aviat Space Environ Med 2003; 74:A1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/71\">",
"      Antman EM, Anbe DT, Armstrong PW, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). Circulation 2004; 110:e82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/72\">",
"      Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008; 117:296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/73\">",
"      Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2009; 54:2205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/74\">",
"      Lampert R, Joska T, Burg MM, et al. Emotional and physical precipitants of ventricular arrhythmia. Circulation 2002; 106:1800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/75\">",
"      Fries R, K&ouml;nig J, Sch&auml;fers HJ, B&ouml;hm M. Triggering effect of physical and mental stress on spontaneous ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators. Clin Cardiol 2002; 25:474.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/76\">",
"      Kolb C, Schmieder S, Lehmann G, et al. Do airport metal detectors interfere with implantable pacemakers or cardioverter-defibrillators? J Am Coll Cardiol 2003; 41:2054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/77\">",
"      Shlim DR, Houston R. Helicopter rescues and deaths among trekkers in Nepal. JAMA 1989; 261:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/78\">",
"      Burtscher M, Philadelphy M, Likar R. Sudden cardiac death during mountain hiking and downhill skiing. N Engl J Med 1993; 329:1738.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/79\">",
"      Burtscher M, Pachinger O, Mittleman MA, Ulmer H. Prior myocardial infarction is the major risk factor associated with sudden cardiac death during downhill skiing. Int J Sports Med 2000; 21:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?15/42/16042/abstract/80\">",
"      Hultgren, HN. Coronary heart disease and trekking. J Wilderness Med 1990; 1:154.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1543 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-14.112.150.18-587BC34546-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_42_16042=[""].join("\n");
var outline_f15_42_16042=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H29\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      BAROMETRIC PRESSURE AND PIO2",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NORMAL CARDIOVASCULAR RESPONSE TO HIGH ALTITUDE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Short-term altitude exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Long-term altitude exposure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      ALTITUDE STRESS IN HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Coronary heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Patients without diagnosed CHD",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Heart failure",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Pacemaker function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      AIR TRAVEL",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Potential risk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Incidence of problems",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Recommendations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Supplemental oxygen",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Stable coronary artery disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      - Percutaneous coronary intervention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Coronary artery bypass graft surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Implanted devices",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Deep vein thrombosis and pulmonary embolism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      TREKKING AND MOUNTAINEERING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/1543\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1543|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/25/22942\" title=\"figure 1\">",
"      Altitude work load HF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/1543|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/36/9804\" title=\"table 1\">",
"      Physical effects of altitude",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?22/6/22636\" title=\"table 2\">",
"      Recommendations to cardiopulmonary patients who fly",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/6/1130?source=related_link\">",
"      Acute mountain sickness and high altitude cerebral edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/39/25208?source=related_link\">",
"      Automated external defibrillators",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/30/19945?source=related_link\">",
"      Evaluation of the patient with suspected heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7241?source=related_link\">",
"      Exercise capacity and VO2 in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/10/4264?source=related_link\">",
"      Heart rate variability: Technical aspects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/39/35449?source=related_link\">",
"      Heart rate variability: Uses other than after myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/18/297?source=related_link\">",
"      High altitude illness: Physiology, risk factors, and general prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/16/28936?source=related_link\">",
"      High altitude pulmonary edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/20/7496?source=related_link\">",
"      Medical management of Eisenmenger syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/44/32455?source=related_link\">",
"      Pathophysiology of heart failure: Neurohumoral adaptations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/26/13737?source=related_link\">",
"      Patient assessment for air travel",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/52/41802?source=related_link\">",
"      Prevention of venous thromboembolic disease in surgical patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/27/17847?source=related_link\">",
"      Skeletal muscle dysfunction and exercise intolerance in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/10/28840?source=related_link\">",
"      Traveling with oxygen aboard commercial air carriers",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f15_42_16043="Diagnosis delayed puberty";
var content_f15_42_16043=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F61490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F61490&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Delayed puberty versus secondary hypogonadism in males",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Favoring delayed puberty",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Consitutional short stature",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Delayed dental maturation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Family history of delayed puberty",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Favoring organic disease causing secondary hypogonadism",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Other pituitary hormonal deficiencies",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Chiasmal and other neurologic symptoms",
"           </td>",
"          </tr>",
"          <tr>",
"           <td>",
"            Nongonadal manifestations of Kallmann syndrome",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_42_16043=[""].join("\n");
var outline_f15_42_16043=null;
var title_f15_42_16044="Causes of anal pruritus";
var content_f15_42_16044=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F76063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F76063&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of anal pruritus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Fecal soilage due to:",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Diarrhea or poorly formed stools of any cause",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Transient internal relaxation of the internal anal sphincter",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Poor hygiene",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Anatomic abnormalities making cleansing difficult (eg, prolapsed internal hemorrhoids, large external hemorrhoids)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Dietary irritants",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Coffee",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Cola",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Beer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tomatoes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chocolate",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Tea",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Citrus fruits",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Anorectal diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Abscesses",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fissures",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fistulas",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Malignancies (eg, squamous cell cancer)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Dermatologic diseases",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Psoriasis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Contact dermatitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Atopic dermatitis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Hidradenitis suppurativa",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Paget's disease",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Infections",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Sexually transmitted diseases (condyloma, herpes, syphilis, gonorrhea)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bacterial infections (staphylococcus aureus)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Parasites (Pinworm, scabies)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Fungal infections (particularly candida)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Psychological causes",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Other",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Chemotherapy",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_42_16044=[""].join("\n");
var outline_f15_42_16044=null;
var title_f15_42_16045="Relationship between sodium intake and excretion in steady state";
var content_f15_42_16045=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F58458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F58458&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Relationship between sodium intake and excretion in the steady state",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 404px; height: 229px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Relation between sodium intake (solid line) and urinary sodium excretion (dashed line) as sodium intake is progressively increased from 10 to 350 meq/day in normal subjects. Although excretion rises in parallel to intake, there is a slight lag in equilibration, and the area under the curve represents the net amount of sodium retained. This volume expansion constitutes the signal to maintain sodium excretion at a high level.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Sagnella GA, Markandu ND, Buckley MG, et al. Am J Physiol 1989; 256:R1171.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_42_16045=[""].join("\n");
var outline_f15_42_16045=null;
var title_f15_42_16046="Neural crest and embryogenesis";
var content_f15_42_16046=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F53140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F53140&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 565px\">",
"   <div class=\"ttl\">",
"    The common embryogenesis of chromaffin cells and sympathetic ganglion cells from primitive cells of the neural crest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 545px; height: 296px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Although the adrenal medulla is well developed by 12 weeks of gestation, most of the chromaffin tissue in the fetus is present in scattered extramedullary paraaortic paraganglia, the largest of which are termed the organs of Zuckerkandl. After birth, these paraganglia gradually atrophy, disappearing by 2-3 years of age. The various tumors that can arise from any site along the migratory path of the cells of the autonomic nervous system are in boxes. The chromaffin cells located in the paraganglia predominantly produce norepinephrine while those in the adrenal medulla typically secrete a greater quantity of epinephrine than norepinephrine.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_42_16046=[""].join("\n");
var outline_f15_42_16046=null;
var title_f15_42_16047="AED for primary generalized tonic-clonic seizures";
var content_f15_42_16047=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F61530%7ENEURO%2F79951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F61530%7ENEURO%2F79951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of primary generalized tonic-clonic seizures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drugs",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total daily adult dosage*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total daily pediatric dosage*",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Usual dosing interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maintenance",
"       </td>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maintenance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Primary generalized tonic-clonic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Drugs of choice:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Valproate",
"        <sup>",
"         &bull;,&Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3500 mg",
"       </td>",
"       <td>",
"        10-15 mg/kg",
"       </td>",
"       <td>",
"        15-60 mg/kg",
"       </td>",
"       <td>",
"        Once/bid/tid",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Lamotrigine",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        12.5-50 mg",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        100-700 mg",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"       <td>",
"        0.15-0.6 mg/kg",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        1-15 mg/kg",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Levetiracetam",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3000 mg",
"       </td>",
"       <td>",
"        10-20 mg/kg",
"       </td>",
"       <td>",
"        40-60 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Some alternatives:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Carbamazepine",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        200-400 mg",
"       </td>",
"       <td>",
"        800-1800 mg",
"       </td>",
"       <td>",
"        10-20 mg/kg",
"       </td>",
"       <td>",
"        10-30 mg/kg",
"       </td>",
"       <td>",
"        Bid/tid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Topiramate",
"       </td>",
"       <td>",
"        25-50 mg",
"       </td>",
"       <td>",
"        200-400 mg",
"       </td>",
"       <td>",
"        1-3 mg/kg",
"       </td>",
"       <td>",
"        5-9 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Zonisamide",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        100-600 mg",
"       </td>",
"       <td>",
"        1-2 mg/kg**",
"       </td>",
"       <td>",
"        6-8 mg/kg**",
"       </td>",
"       <td>",
"        Once/bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Oxcarbazepine",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        300-600 mg",
"       </td>",
"       <td>",
"        900-2400 mg",
"       </td>",
"       <td>",
"        8-10 mg/kg",
"       </td>",
"       <td>",
"        6-51 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Phenytoin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        300-400 mg",
"       </td>",
"       <td>",
"        300-400 mg",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        5 mg/kg",
"       </td>",
"       <td>",
"        4-8 mg/kg",
"       </td>",
"       <td>",
"        Once/bid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Dosage may need to be adjusted for renal or hepatic impairment, or concomitant use of other drugs.",
"     <br>",
"      &bull; Measurement of serum concentrations may be useful to guide therapy. Usual therapeutic serum concentrations are: carbamazepine 6-12 mcg/mL, phenobarbital 15-35 mcg/mL, phenytoin 10-20 mcg/mL, valproate 50-120 mcg/mL. Some patients achieve complete seizure control at lower concentrations, and occasional patients need higher concentrations.",
"      <br>",
"       &Delta; Not FDA-approved unless absence is involved.",
"       <br>",
"        &loz; Once daily for the extended-release formulation (Depakote ER).",
"        <br>",
"         &sect; FDA-approved for adjunctive therapy in adults and children &ge;2 years old with partial seizures, with Lennox-Gastaut syndrome or with primary generalized seizures, and as monotherapy in adults with partial seizures as a substitute for carbamazepine, phenytoin, phenobarbital or valproate.",
"         <br>",
"          &yen; Starting dosage is 25 mg every other day and maintenance dosage is 100 to 400 mg daily when given with valproate.",
"          <br>",
"           &Dagger; Starting dosage is 0.15 mg/kg daily and maintenance dosage is 1 to 5 mg/kg daily when given with valproate.",
"           <br>",
"            &dagger; Not FDA-approved for this indication.",
"            <br>",
"             ** Not FDA-approved for pediatric use.",
"             <br>",
"              &bull;&bull; Adjustments in maintenance dosage above 300 mg/day for adults should usually be made in 25- or 30-mg increments because metabolism becomes saturated.",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drugs for Epilepsy. Treatment guidelines from The Medical Letter 2008; 6(70): 37-46. Copyright &copy;2008 The Medical Letter.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Treatment of partial seizures including secondarily generalized",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Drugs",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total daily adult dosage*",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Total daily pediatric dosage*",
"       </td>",
"       <td class=\"subtitle1\" rowspan=\"2\">",
"        Usual dosing interval",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maintenance",
"       </td>",
"       <td class=\"subtitle2\">",
"        Starting",
"       </td>",
"       <td class=\"subtitle2\">",
"        Maintenance",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Partial, including secondarily generalized",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Drugs of choice:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Carbamazepine",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        200-400 mg",
"       </td>",
"       <td>",
"        800-1800 mg",
"       </td>",
"       <td>",
"        10-20 mg/kg",
"       </td>",
"       <td>",
"        10-30 mg/kg",
"       </td>",
"       <td>",
"        Bid/tid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Lamotrigine",
"       </td>",
"       <td>",
"        12.5-50 mg",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        100-700 mg",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.15-0.6 mg/kg",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        1-15 mg/kg",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Oxcarbazepine",
"       </td>",
"       <td>",
"        300-600 mg",
"       </td>",
"       <td>",
"        900-2400 mg",
"       </td>",
"       <td>",
"        8-10 mg/kg",
"       </td>",
"       <td>",
"        6-51 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Levetiracetam",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3000 mg",
"       </td>",
"       <td>",
"        10-20 mg/kg",
"       </td>",
"       <td>",
"        40-60 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Some alternatives:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Topiramate",
"       </td>",
"       <td>",
"        25-50 mg",
"       </td>",
"       <td>",
"        200-400 mg",
"       </td>",
"       <td>",
"        1-3 mg/kg",
"       </td>",
"       <td>",
"        5-9 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Valproate",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3500 mg",
"       </td>",
"       <td>",
"        10-15 mg/kg",
"       </td>",
"       <td>",
"        15-60 mg/kg",
"       </td>",
"       <td>",
"        Once/bid/tid&yen;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Gabapentin",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        900-1200 mg",
"       </td>",
"       <td>",
"        1800-6400 mg",
"       </td>",
"       <td>",
"        10-15 mg/kg",
"       </td>",
"       <td>",
"        25-40 mg/kg",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        Tid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Zonisamide",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        100-600 mg",
"       </td>",
"       <td>",
"        1-2 mg/kg",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        6-8 mg/kg",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        Once/bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Phenytoin",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        300-400 mg",
"       </td>",
"       <td>",
"        300-400 mg**",
"       </td>",
"       <td>",
"        5 mg/kg",
"       </td>",
"       <td>",
"        4-8 mg/kg",
"       </td>",
"       <td>",
"        Once/bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Pregabalin",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        150 mg",
"       </td>",
"       <td>",
"        150-600 mg",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        -",
"       </td>",
"       <td>",
"        Bid/tid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"7\">",
"        Absence",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Drugs of choice:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Ethosuximide",
"       </td>",
"       <td>",
"        500 mg",
"       </td>",
"       <td>",
"        750-1500 mg",
"       </td>",
"       <td>",
"        10-15 mg/kg",
"       </td>",
"       <td>",
"        20-40 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        <em>",
"         or",
"        </em>",
"        Valproate",
"        <sup>",
"         &bull;",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3500 mg",
"       </td>",
"       <td>",
"        10-15 mg/kg",
"       </td>",
"       <td>",
"        15-60 mg/kg",
"       </td>",
"       <td>",
"        Once/bid/tid",
"        <sup>",
"         &yen;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle3_left\" colspan=\"7\">",
"        Alternatives:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Lamotrigine",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        12.5-50 mg",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        100-700 mg",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        0.15-0.6 mg/kg",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        1-15 mg/kg",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Clonazepam",
"       </td>",
"       <td>",
"        1.5 mg",
"       </td>",
"       <td>",
"        1.5-8 mg",
"       </td>",
"       <td>",
"        0.01-0.03 mg/kg",
"       </td>",
"       <td>",
"        0.05-0.2 mg/kg",
"       </td>",
"       <td>",
"        Bid/tid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Zonisamide",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        100 mg",
"       </td>",
"       <td>",
"        100-600 mg",
"       </td>",
"       <td>",
"        1-2 mg/kg",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        6-8 mg/kg",
"        <sup>",
"         ",
"        </sup>",
"       </td>",
"       <td>",
"        Once/bid",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        Levetiracetam",
"        <sup>",
"         &bull;&bull;",
"        </sup>",
"       </td>",
"       <td>",
"        500-1000 mg",
"       </td>",
"       <td>",
"        1000-3000 mg",
"       </td>",
"       <td>",
"        10-20 mg/kg",
"       </td>",
"       <td>",
"        40-60 mg/kg",
"       </td>",
"       <td>",
"        Bid",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Dosage may need to be adjusted for renal or hepatic impairment, or concomitant use of other drugs.",
"     <br>",
"      &bull; Measurement of serum concentrations may be useful to guide therapy. Usual therapeutic serum concentrations are: carbamazepine 6-12 mcg/mL, phenobarbital 15-35 mcg/mL, phenytoin 10-20 mcg/mL, valproate 50-120 mcg/mL. Some patients achieve complete seizure control at lower concentrations, and occasional patients need higher concentrations.",
"      <br>",
"       &Delta; Starting dosage is 25 mg every other day and maintenance dosage is 100 to 400 mg daily when given with valproate.",
"       <br>",
"        &loz; Starting dosage is 0.15 mg/kg daily and maintenance dosage is 1 to 5 mg/kg daily when given with valproate.",
"        <br>",
"         &sect; Only FDA-approved for adjunctive therapy.",
"         <br>",
"          &yen; Once daily for the extended-release formulation (Depakote ER).",
"          <br>",
"           &Dagger; For children more than 5 years old, 25 to 35 mg/kg/day. For children 3-4 years old, 40 mg/kg/day.",
"           <br>",
"            &dagger; Not FDA-approved for pediatric use.",
"            <br>",
"             ** Adjustments in maintenance dosage above 300 mg/day for adults should usually be made in 25- or 30-mg increments because metabolism becomes saturated.",
"             <br>",
"              &bull;&bull; Not FDA-approved for this indication.",
"             </br>",
"            </br>",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Drugs for Epilepsy. Treatment guidelines from The Medical Letter 2008; 6(70): 37-46. Copyright &copy;2008 The Medical Letter.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f15_42_16047=[""].join("\n");
var outline_f15_42_16047=null;
